Page last updated: 2024-11-04

terfenadine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5405
CHEMBL ID17157
CHEBI ID9453
SCHEMBL ID5152
MeSH IDM0025307
PubMed CID63002
CHEMBL ID1200618
CHEBI ID5051
SCHEMBL ID40914
MeSH IDM0025307

Synonyms (329)

Synonym
AC-15791
MLS001148415
BRD-A06352418-001-03-6
gtpl2608
1-(4-tert-butylphenyl)-4-[4-[hydroxy-di(phenyl)methyl]piperidin-1-yl]butan-1-ol
1-piperidinebutanol, .alpha.-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-
KBIO1_001011
DIVK1C_001011
NCI60_022784
triludan
mdl-9918
teldane
rmi-9918
1-[4-(1,1-dimethylethyl)phenyl]-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butan-1-ol
nsc665802
.alpha.-(4-(1,1-dimethylethyl)phenyl)-4-(hydroxydiphenyl-methyl)-1-piperidine butanol
seldane
nsc-665802
EU-0101213
PRESTWICK_460
cas-50679-08-8
BSPBIO_000216
LOPAC0_001213
cyater
IDI1_001011
BPBIO1_000238
PRESTWICK3_000138
PRESTWICK2_000138
einecs 256-710-8
hsdb 6508
allerplus
terfen
terfenadina [inn-spanish]
alpha-(4-(1,1-dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperidinebutanol
1-(4-tert-butylphenyl)-4-(4-(alpha-hydroxybenzhydryl)piperidino)-butan-1-ol
terdin
teldanex
mdl 9918
1-piperidinebutanol, alpha-(4-(1,1-dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-
aldaban
terfenadinum [inn-latin]
1-(p-tert-butylphenyl)-4-(4'-(alpha-hydroxydiphenylmethyl)-1'-piperidyl)butanol
ternadin
rmi 9918
brn 5857899
alpha-(p-tert-butylphenyl)-4-(hydroxydiphenylmethyl)-1-piperidinebutanol
BIM-0051180.0001
AB00052367
terfenadine
50679-08-8
C07463
terfenadin
(rs)-1-(4-tert-butylphenyl)-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}-butan-1-ol
DB00342
seldane (tn)
D00521
terfenadine (jan/usan/inn)
NCGC00089746-04
MLS000028499 ,
smr000058260
SPBIO_002155
PRESTWICK1_000138
PRESTWICK0_000138
NINDS_001011
OPREA1_343139
NCGC00089746-03
NCGC00089746-02
NCGC00016064-04
T 9652 ,
alpha-(4-[1,1-dimethylethyl]phenyl)-4-[hydroxydiphenylmethyl]-1-piperidinebutanol
HMS2089I14
HMS2093I11
NCGC00016064-08
1-(4-tert-butylphenyl)-4-[4-[hydroxy(diphenyl)methyl]-1-piperidyl]butan-1-ol
L000888
alpha-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1-piperidinebutanol
chebi:9453 ,
CHEMBL17157 ,
nsc-758627
HMS503K03
HMS1568K18
1-(4-tert-butylphenyl)-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butan-1-ol
(+/-)1-(4-tert-butylphenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol
1-(4-tert-butyl-phenyl)-4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butan-1-ol(terfenadine)
1-(4-tert-butylphenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol
1-(4-tert-butyl-phenyl)-4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butan-1-ol
bdbm50017376
teraenadine
NCGC00016064-06
HMS2095K18
HMS3263D08
1-(4-tert-butylphenyl)-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butan-1-ol
A828247
pharmakon1600-01503708
nsc758627
tox21_110296
tox21_110295
dtxsid2023642 ,
dtxcid503642
terfex
CCG-205287
HMS2231N07
S4353
AKOS015962091
NCGC00016064-09
NCGC00016064-03
NCGC00016064-05
terfenadinum
unii-7ba5g9y06q
terfenadine [usan:usp:inn:ban:jan]
nsc 758627
terfenadina
nsc 665802
7ba5g9y06q ,
FT-0630637
LP01213
HMS3373J07
AC-928
SCHEMBL5152
NCGC00016064-12
tox21_110295_1
AB00052367-16
CS-4800
tox21_501213
NCGC00261898-01
1-(4-(tert-butyl)phenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol
T3977
?-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1-piperidinebutanol
.alpha.-(p-tert-butylphenyl)-4-(hydroxydiphenylmethyl)-1-piperidinebutanol
.alpha.-(4-(1,1-dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperidinebutanol
(.+/-.)-terfenadine
1-(4-tert-butylphenyl)-4-(4-[hydroxy(diphenyl)methyl]-1-piperidinyl)-1-butanol #
HY-B1193
AB00052367_18
OPERA_ID_334
AB00052367_17
mfcd00079622
( inverted exclamation marka)-terfenadine
mdl-991
sr-01000000104
SR-01000000104-2
terfenadine, united states pharmacopeia (usp) reference standard
a-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1-piperidinebutanol
terfenadine, european pharmacopoeia (ep) reference standard
SR-01000000104-4
SR-01000000104-7
SBI-0051180.P003
HMS3712K18
1-(4-(tert-butyl)phenyl)-4-(4-(hydroxydiphenylmethyl)-piperidin-1-yl)butan-1-ol
SW196677-3
( inverted exclamation marka)-terfenadine;mdl-991
Q417909
terfenadine,(s)
BRD-A06352418-001-15-0
SDCCGSBI-0051180.P004
NCGC00016064-19
D82079
alpha-[4-(1,1-dmethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1-piperidinebutanol
AS-75636
BT166253
EN300-22527913
terfenadine [inn]
terfenadine [mart.]
terfenadine [usan]
terfenadine [hsdb]
terfenadine [mi]
terfenadine [ep impurity]
terfenadine [jan]
terfenadine [vandf]
terfenadine [ep monograph]
terfenadine [who-dd]
1-piperidinebutanol, .alpha.-(4-(1,1-dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-
altiva
fexofenadine hydrochloride
m-016455-o
allegra flash
allegra od
terfenadine carboxylate hydrochloride
mdl-16455a
fexofenadine hydrochloride, >98% (hplc)
terfenidine
MLS001332493
MLS001332494
BIM-0050472.0001
153439-40-8
D00671
allegra (tn)
fexofenadine hydrochloride (jp17/usp)
NCGC00095906-01
NCGC00092389-01
mdl 16,455a
SPECTRUM1504179
MLS001306422
smr000718798
NCGC00095906-02
F0698
CHEMBL1200618
fexofenadine hcl
A3371
2-(4-{1-hydroxy-4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butyl}-phenyl)-2-methyl-propionic acid; hydrochloride;fexofenadine hcl
dtxcid2028642
dtxsid5048716 ,
tox21_113125
cas-153439-40-8
nsc758678
pharmakon1600-01504179
nsc-758678
S3208
c32h40clno4
NCGC00015453-02
unii-2s068b75zu
children's allegra allergy
children's allegra hives
benzeneacetic acid, 4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethyl-, hydrochloride, (+-)-
allegra hives
carboxyterfenadine hydrochloride
fexofenadine hydrochloride [usan:usp]
nsc 758678
benzeneacetic acid, 4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethyl-, hydrochloride
(+-)-p-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidino)butyl)-alpha-methylhydratropic acid hydrochloride
allegra allergy
2s068b75zu ,
FT-0631183
AB07499
AKOS015907422
CCG-213275
NC00724
2-(4-{1-hydroxy-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl}phenyl)-2-methylpropanoic acid hydrochloride
SCHEMBL40914
NCGC00015453-08
tox21_113125_1
2-(4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid hydrochloride
KS-1057
CS-4483
4-[(4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-alpha,alpha-dimethylbenzeneacetic acid hydrochloride
4-[4-[4-(hydroxydiphenylmethyl)-1-pieridinyl]-1-hydroxybutyl]-alpha,alpha-dimethylbenzeneacetic acid hydrochloride
RRJFVPUCXDGFJB-UHFFFAOYSA-N
4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-alpha,alpha-dimethylbenzeneacetic acid hydrochloride
2-(4-{1-hydroxy-4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butyl}-phenyl)-2-methyl-propionic acid
?,?-dimethyl-4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-benzeneacetic acid hydrochloride
fexofenidine hydrochloride
HY-B0801A
fexofenadine (hydrochloride)
AC-24745
mfcd00865710
2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid;hydrochloride
mdl 16455a
mdl-16455 hydrochloride
terfenidine carboxylate hydrochloride
fexofenadine hydrochloride, united states pharmacopeia (usp) reference standard
fexofenadine hydrochloride [usan]
fexofenadine hydrochloride, european pharmacopoeia (ep) reference standard
fexofenadine hcl, pharmaceutical secondary standard; certified reference material
fexofenadine hydrochloride; 2-[4-[(1rs)-1-hydroxy-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid hydrochloride; allegra; mdl 16455a; telfast; telfast bd
J-505843
CHEBI:5051
SR-01000075889-6
SW199568-2
2-(4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid hcl
EN300-52502
Q27255526
fexofenadine hydrochloride 100 microg/ml in acetonitrile
153439-40-8 (hcl)
fexofenadina cloridrato
chlorhydrate de fexofenadine
clorhidrato de fexofenadina
cloridrato de fexofenadina
fexofenadine impurity standard
fexofenadine hydrochloride- bio-x
BF164454
benzeneacetic acid, 4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-.alpha.,.alpha.-dimethyl-, hydrochloride, (+/-)-
fexofenadine hydrochloride [usp impurity]
fexofenadine hydrochloride [jan]
fexofenadine hydrochloride [who-dd]
fexofenadine hydrochloride [mart.]
fexofenadine hydrochloride [vandf]
fexofenadine hydrochloride [usp monograph]
fexofenadine hydrochloride [mi]
fexofenadine hydrochloride [orange book]
fexofenadine hydrochloride [ep monograph]
fexofenadine hydrochloride component of allegra-d
(+/-)-p-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidino)butyl)-.alpha.-methylhydratropic acid, hydrochloride
fexofenadine hydrochloride [usp-rs]
allegra-d component fexofenadine hydrochloride
Z754918912
exchange select aller ease
good sense aller ease
fexofenadine hydrochloride 60 mg
health mart allergy relief
berkley jensen allergy relief
(+/-)-p-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidino)butyl)-alpha-methylhydratropic acid, hydrochloride
allergy reliefnon-drowsy
equaline aller ease
health mart fexofenadine hydrochloride
curist hives relief
dye free wal fex
allergy 24-hr
2-(4-((1rs)-1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid monohydrochloride
fexofenadine hydrochloride allergy
childrens fexofenadine hydrochlorideallergy
dye free wal fexchildrens allergy
fexofenadine hydrochloride 180 mg
fexofenadine hydrochloride (usp monograph)
childrens fexofenadine hydrochloride
allergy reliefchildren
fexofenadine hydrochloride (ep monograph)
fexofenadine hydrochloride (usan:usp)
fexofenadine hydrochloride (usp-rs)
allegra hives 24hr
childrens fexofenadine hydrochloridehives
12hr allergy relief
crcle fexofenadine hydrochloride
fexofenadine hydrochloride hives
basic care allergy
allergillic
iallergy relief
wal-fex
mucinexallergy
childrens allegra allergy
fexofenadine hydrochloride oral
kirkland signature aller fex
children's fexofenadine hydrochloride hives
sunmark fexofenadine hydrochloride
children's fexofenadine hydrochloride allergy
benzeneacetic acid, 4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethyl-, hydrochloride, (+/-)-
fexofenadine hydrochloride (usp impurity)
fexofenadine hydrochloride (mart.)
dg health aller ease
fex-allergy relief

Research Excerpts

Overview

Terfenadine (TF) is a highly potent histamine H1 receptor antagonist. In clinically effective doses it is free of significant central nervous system side effects. It has recently gained attention due to its anticancer properties.

ExcerptReferenceRelevance
"Terfenadine is a second-generation H1-antihistamine that despite potentially can produce severe side effects it has recently gained attention due to its anticancer properties. "( Inhibitory effect of terfenadine on Kir2.1 and Kir2.3 channels.
Delgado-Ramírez, M; Ferrer, T; Moreno-Galindo, EG; Rodriguez-Leal, FJ; Rodríguez-Menchaca, AA; Sanchez-Chapula, JA, 2021
)
2.38
"Terfenadine is a second generation histamine receptor antagonist which is widely used as a non‑sedating antihistamine to relieve allergic responses. "( Comparative study of the protective effects of terfenadine and amiodarone on barium chloride/aconitine-induced ventricular arrhythmias in rats: a potential role of terfenadine.
Li, S; Liu, B; Su, Y; Xiong, M; Xu, Y, 2014
)
2.1
"Terfenadine (TF) is a highly potent histamine H1 receptor antagonist that in clinically effective doses is free of significant central nervous system side effects. "( Ketoconazole potentiates terfenadine-induced apoptosis in human Hep G2 cells through inhibition of cytochrome p450 3A4 activity.
Chen, CF; Chen, CH; Chen, LC; Ho, YS; Liang, YC; Lin, CH; Lin, JK; Lin, SY; Wang, YJ; Yu, CF, 2002
)
2.06
"Terfenadine is an H1-blocker that may have antiallergic properties. "( Modulation of eicosanoid and histamine release from human dispersed lung cells by terfenadine.
Albat, B; Bloom, M; Bousquet, J; Campbell, AM; Chanez, P; Godard, P; Marty-Ané, C; Michel, FB, 1993
)
1.95
"Terfenadine is a widely used antihistamine."( Torsade de pointes induced by terfenadine in a patient with long QT syndrome.
Kim, SS; Koh, KK; Rim, MS; Yoon, J, 1994
)
1.3
"Terfenadine is an antihistamine that has been reported to be safe for use in human beings and animals. "( Terfenadine toxicosis in dogs.
Greentree, WF; Otto, CM, 1994
)
3.17
"Terfenadine is a selective histamine H1 receptor antagonist which binds preferentially to peripheral receptors in vivo and is devoid of central nervous system depressant activity and thus has an improved adverse effect profile (1). "( Pharmacodynamic bioequivalence: evaluation of different brands of terfenadine hydrochloride.
Gupta, U; Mehta, VL; Tekur, U, 1993
)
1.97
"Terfenadine is a widely prescribed non-sedating antihistamine which undergoes rapid and almost complete first pass biotransformation to an active carboxylic acid metabolite. "( Effect of concomitant administration of cimetidine and ranitidine on the pharmacokinetics and electrocardiographic effects of terfenadine.
Cantilena, LR; Conner, DP; Honig, PK; Mullin, JC; Wortham, DC; Zamani, K, 1993
)
1.93
"Terfenadine is a widely used antihistamine drug with the potential for QTC prolongation."( Investigation of the potential interaction between terfenadine and tedisamil in human liver microsomes.
Bader, A; Borlak, JT; Cameron, GA; Hawksworth, GM; McCully, S, 1998
)
1.27
"Terfenadine is a selective, nonsedative, H(1)-blocker antihistamine used for a variety of allergic conditions. "( Pregnancy outcome after gestational exposure to terfenadine: A multicenter, prospective controlled study.
Addis, A; Bonati, M; Costa, A; Koren, G; Lalkin, A; Lalkin, I; Loebstein, R, 1999
)
2
"Terfenadine is a nonsedating H1-antagonist that when overdosed, used with hepatic compromise, or when given with ketoconazole results in accumulation of parent terfenadine, prolongation of the QT interval, and torsades de pointes in susceptible patients. "( Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.
Cantilena, LR; Conner, DP; Honig, PK; Woosley, RL; Zamani, K, 1992
)
1.96
"Terfenadine is a safe non-sedative H1-receptor antagonist. "( Dose-response relationship between objective measures of histamine-induced weals and dose of terfenadine.
Lush, M; Marks, R; Newcombe, RG; Shall, L, 1991
)
1.94
"Terfenadine is a selective histamine H1-receptor antagonist which, in pharmacodynamic studies, is devoid of central nervous system depressant activity. "( Terfenadine. An updated review of its pharmacological properties and therapeutic efficacy.
Ferrill, M; Goa, KL; McTavish, D, 1990
)
3.16
"Terfenadine is a newly marketed non-sedating antihistamine. "( Accidental terfenadine ingestion in children.
Perez, E; Picciotti, M; Spiller, HA, 1989
)
2.11
"Terfenadine is a unique H1-receptor antagonist devoid of adverse central nervous system (CNS) effects. "( Effect of acute and chronic terfenadine on free and total serum phenytoin concentrations in epileptic patients.
Coniglio, AA; Driscoll, SM; Garnett, WR; Hepler, CD; Karnes, HT; Pellock, JH; Serafin, R; Small, RE; Tsidonis, O,
)
1.87
"Terfenadine is a widely used nonsedating antihistamine currently approved for use at a dosage of 60 mg every 12 hours."( Evaluation of inhibition of wheal response to histamine by multiple doses of terfenadine.
Ryan, WM, 1989
)
1.23
"Terfenadine is a selective H1-histamine receptor antagonist. "( Terfenadine. A review of its pharmacodynamic properties and therapeutic efficacy.
Heel, RC; Sorkin, EM, 1985
)
3.15
"Terfenadine is an antihistamine recently approved for use in the U.S. "( Terfenadine, a nonsedating antihistamine.
Carter, CA; Hayes, JM; Rickman, LA; Skoutakis, VA; Wojciechowski, NJ, 1985
)
3.15
"Terfenadine (Seldane) is a new, highly potent H1 histamine receptor antagonist that in clinically effective doses is free of side effects. "( Terfenadine (Seldane) is a potent and selective histamine H1 receptor antagonist in asthmatic airways.
Holgate, ST; Rafferty, P, 1987
)
3.16
"Terfenadine is a useful therapeutic agent for primary management of chronic idiopathic urticaria."( Double-blind comparison of terfenadine, chlorpheniramine, and placebo in the treatment of chronic idiopathic urticaria.
Bernstein, DI; Buckley, CE; Chu, T; Fox, RW; Grant, JA; Rocklin, RE; Schoenwetter, WF; Spector, SL; Stafford, CT; Stroh, JE, 1988
)
1.29

Effects

Terfenadine has one asymmetric centre in the molecule and is currently used as a racemate.

ExcerptReferenceRelevance
"Terfenadine has been reported to cause cardiac death. "( Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?
Gallacher, DJ; Hermans, AN; Lu, HR, 2012
)
2.34
"Terfenadine has one asymmetric centre in the molecule and is currently used as a racemate."( Terfenadine: a mixture of equipotent antihistamine enantiomers without a clear 'isomeric ballast'.
Timmerman, H; Zhang, MQ, 1993
)
2.45

Actions

ExcerptReferenceRelevance
"Terfenadine did not increase the latency of P300-event-related potentials at the parietal (Pz) or frontal (Fz) scalp electrodes compared with baseline, in contrast to chlorpheniramine and placebo, which did increase P300 latency."( Benefit/risk ratio of the antihistamines (H1-receptor antagonists) terfenadine and chlorpheniramine in children.
Reggin, JD; Roberts, JR; Simons, FE; Simons, KJ, 1994
)
1.25

Treatment

Terfenadine pretreatment resulted in the complete inhibition of both the ipsilateral and contralateral responses to histamine with no effect on methacholine-induced secretions. Pre-treatment with terfen adine resulted in a significantly higher allergen threshold dose than placebo (p less than 0.01), regardless of drug dose.

ExcerptReferenceRelevance
"In terfenadine-treated neurons, AMPA increased [Ca2+](i) by approximately five fold, while AMPA induced no significant increase in [Ca2+](i) in the absence of terfenadine."( RNA synthesis-dependent potentiation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor-mediated toxicity by antihistamine terfenadine in cultured rat cerebellar neurons.
Díaz-Trelles, R; Fernández-Sánchez, MT; Novelli, A, 2003
)
1.04
"In terfenadine-treated cells, the translocation of phosphatidylserine from the inside of plasma membrane to the outside, an early event of the apoptotic process, and chromatin condensation, the morphological characterization of apoptotic cell death, were observed."( Terfenadine induces thymocyte apoptosis via mitochondrial pathway.
Enomoto, R; Kawaguchi, E; Kinoshita, H; Komai, T; Komatsu, H; Konishi, Y; Lee, E; Okazaki, K; Sugahara, C; Yoshida, Y, 2004
)
2.28
"Terfenadine pretreatment resulted in the complete inhibition of both the ipsilateral and contralateral responses to histamine with no effect on methacholine-induced secretions."( Comparison of the secretory response of the nasal mucosa to methacholine and histamine.
Baroody, FM; Naclerio, RM; Wagenmann, M, 1993
)
1.01
"The treatment with terfenadine was continued."( Solar urticaria successfully treated with intravenous immunoglobulins.
Dubertret, L; Frémont, G; Jeanmougin, M; Maksimovic, L; Viguier, M, 2009
)
0.67
"Pre-treatment with terfenadine resulted in a significantly higher allergen threshold dose than placebo (p less than 0.01), regardless of drug dose."( Protective effect of different doses of terfenadine on the conjunctival provocation test.
Buscaglia, S; Canonica, GW; Ciprandi, G; Iudice, A, 1992
)
0.87
"Pretreatment with terfenadine 60 mg orally significantly inhibited the flare response to both the lower dose of antigen and to saline (P less than 0.05)."( The importance of bradykinin and histamine in the skin response to antigen.
Dollery, CT; Fuller, RW; Newman, CM; Pixley, FJ; Warren, JB, 1988
)
0.6

Toxicity

Emmedastine difumarate is more effective than terfenadine in the symptomatic management of seasonal allergic rhinitis. It is particularly active in controlling the main nasal symptoms, such as sneezing and rhinorrhea; it is safe and well tolerated in this therapeutic indication.

ExcerptReferenceRelevance
" Neither terfenadine nor loratadine, another nonsedating antihistamine, potentiated the adverse effects of alcohol on driving performance."( Antihistamines and driving safety.
O'Hanlon, JF, 1988
)
0.69
" Oral LD50 values were approximately 5000 mg/kg in mature mice and rats; intraperitoneal and intravenous values could not be established because of the low solubility of the compound."( Preclinical safety studies with terfenadine.
Gibson, JP; Huffmann, KW; Newberne, JW, 1982
)
0.55
" The primary difference between traditional (first-generation) and nonsedating (second-generation) histamine1-receptor antagonists is the incidence and severity of adverse reactions."( Cardiovascular toxicity of antihistamines.
Smith, SJ, 1994
)
0.29
" Few adverse events were reported during the study; all were mild or moderate and were not significantly different between the two treatment groups."( A comparative study of the efficacy and safety of loratadine syrup and terfenadine suspension in the treatment of 3- to 6-year-old children with seasonal allergic rhinitis.
Klöse, P; Lutsky, BN; Melon, J; Menardo, JL; Molkhou, P; Ronchetti, R; Suonpää, J; Wahn, U; Wessel, F,
)
0.36
" Mild to moderate treatment-related adverse experiences were reported in 7/113 patients (6%) treated with loratadine and 11/119 patients (9%) treated with terfenadine."( Comparative study of the efficacy and safety of loratadine syrup and terfenadine suspension in the treatment of chronic allergic skin diseases in a pediatric population.
Cerio, R; Chieira, ML; deGroot, LJ; Giannetti, A; Gonçalves, HM; Guillot, B; Lutsky, BN; Lynde, CW; Schuller, JL; Vareltzides, A, 1993
)
0.72
"7% for the two adverse events, respectively) than in the T/Ps group (10."( Safety and efficacy of terfenadine/pseudoephedrine versus clemastine/phenylpropanolamine in the treatment of seasonal allergic rhinitis.
Falliers, CJ; Grant, JA; Huster, WJ; McNutt, B; Podleski, WK; Segal, AT; Woehler, TR, 1993
)
0.6
" Both terbinafine and terfenadine were well tolerated when coadministered during this study, as indicated by the low incidence of complaints, abnormalities, and adverse events."( Safe coadministration of terbinafine and terfenadine: a placebo-controlled crossover study of pharmacokinetic and pharmacodynamic interactions in healthy volunteers.
Chang, CT; Cramer, JA; Garreffa, S; Hafkin, B; Hunt, TL; Meligeni, J; Robbins, B, 1996
)
0.87
" The frequency of adverse events was similar among fexofenadine HCl and placebo groups, with no dose-related trends."( Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis.
Ahlbrandt, R; Bernstein, DI; Mason, J; Nathan, RA; Schoenwetter, WF; Storms, W, 1997
)
0.3
"Fexofenadine HCl is both effective and safe for the treatment of ragweed seasonal allergic rhinitis."( Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis.
Ahlbrandt, R; Bernstein, DI; Mason, J; Nathan, RA; Schoenwetter, WF; Storms, W, 1997
)
0.3
"Fexofenadine is safe and efficacious at single doses of 60 mg and 120 mg."( Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit.
Briscoe, MP; Clark, A; Day, JH; Ellis, AK; Mason, J; Smith, JN; Welsh, A, 1997
)
0.3
" In conclusion, fexofenadine HCl is safe and effective in the treatment of fall SAR, with 60 mg bid being the optimal therapeutic dosage."( Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist, in the treatment of fall allergies.
Ahlbrandt, R; Bronsky, EA; Falliers, CJ; Kaiser, HB; Mason, JM,
)
0.13
"The removal of 5 pharmaceuticals from the market in a 12-month period because of unexpected adverse events raised concerns about the adequacy of the drug review process at the US Food and Drug Administration (FDA)."( The safety of newly approved medicines: do recent market removals mean there is a problem?
Friedman, MA; Hass, AE; Lumpkin, MM; Shuren, JE; Thompson, LJ; Woodcock, J, 1999
)
0.3
" Incidence of adverse events was similar between fexofenadine and placebo groups (30."( Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis.
Andrade, C; Casale, TB; Qu, R,
)
0.13
" No serious adverse events were reported in any of the treatment groups."( The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis.
Compton, D; Mason, J; Ricard, N; Stewart, J; Sussman, GL, 1999
)
0.3
" In placebo-controlled trials of seasonal allergic rhinitis (SAR) and chronic idiopathic urticaria (CIU), the type and incidence of adverse events were comparable in fexofenadine and placebo recipients."( The systemic safety of fexofenadine HCl.
Mason, J; Rao, N; Reynolds, R, 1999
)
0.3
" Old (first-generation) H1-receptor antagonists such as chlorpheniramine, diphenhydramine, or triprolidine produce histamine blockade at H1-receptors in the central nervous system (CNS) and frequently cause somnolence or other CNS adverse effects."( H1-receptor antagonists: safety issues.
Estelle, F; Simons, R, 1999
)
0.3
" These three antihistamines have also been shown safe in special populations, including pediatric and elderly patients."( Safety of second generation antihistamines.
Philpot, EE,
)
0.13
" Adverse events occurred with similar incidence in all treatment groups, with no dose-related increases in any event."( Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria.
Mason, J; Nelson, HS; Reynolds, R, 2000
)
0.31
" Adverse events were recorded."( Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis.
Juniper, EF; Van Cauwenberge, P, 2000
)
0.31
" The incidence of adverse events was low and similar across all treatment groups."( Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis.
Juniper, EF; Van Cauwenberge, P, 2000
)
0.31
" Adverse events and onset of symptom relief were also recorded by every patient."( A non-comparative trial of the efficacy and safety of fexofenadine for treatment of perennial allergic rhinitis.
Bunnag, C; Chochaipanichnon, L; Jareoncharsri, P; Kongpatanakul, S; Limprasertsiri, S; Pumhirun, P; Supiyaphun, P; Tunsuriyawong, P, 2000
)
0.31
" The most common adverse event for all regimens was headache, reported in 20 (22%) subjects."( Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study.
Affrime, M; Banfield, C; Batra, V; Clement, R; Gupta, S; Kantesaria, B; Marino, M, 2001
)
0.31
" Adverse events occurred in 20 cases (18."( Multicenter study of the efficacy and safety of fexofenadine 60 mg. twice daily in 108 Thai patients with chronic idiopathic urticaria.
Aunhachoke, K; Charuwichitratana, S; Gherunpong, N; Gritiyarangsan, P; Janjumratsang, P; Jiamton, S; Korkij, W; Krisadapong, J; Kullavanijaya, P; Kulthanan, K; Kuntiranont, M; Sitakalin, C, 2001
)
0.31
" No serious adverse events were reported."( Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis.
Burtin, B; De Vos, C; Donnelly, F; Horak, F; Kavina, A; Stübner, P; Zieglmayer, R, 2001
)
0.31
" Safety was evaluated through adverse event reporting, electrocardiograms, and pre- and posttreatment laboratory panels and physical examinations."( Safety of fexofenadine in children treated for seasonal allergic rhinitis.
Bernstein, DI; Goldsobel, A; Graft, DF; Long, J; Meltzer, EO; Portnoy, J, 2001
)
0.31
" Ten patients (5 on placebo, 5 on fexofenadine) discontinued because of an adverse event; no event that resulted in discontinuation was judged to be caused by study medication."( Safety of fexofenadine in children treated for seasonal allergic rhinitis.
Bernstein, DI; Goldsobel, A; Graft, DF; Long, J; Meltzer, EO; Portnoy, J, 2001
)
0.31
"Fexofenadine, 15, 30, and 60 mg twice daily, was safe and well tolerated in this large pediatric patient population."( Safety of fexofenadine in children treated for seasonal allergic rhinitis.
Bernstein, DI; Goldsobel, A; Graft, DF; Long, J; Meltzer, EO; Portnoy, J, 2001
)
0.31
" There were 40 reports of adverse drug reactions in 27 patients."( Evaluation of the safety of fexofenadine from experience gained in general practice use in England in 1997.
Acharya, NV; Craig-McFeely, PM; Shakir, SA, 2001
)
0.31
"Within the limitations for an observational cohort study, fexofenadine was found to be well tolerated and safe in 16,638 users in general practice in England."( Evaluation of the safety of fexofenadine from experience gained in general practice use in England in 1997.
Acharya, NV; Craig-McFeely, PM; Shakir, SA, 2001
)
0.31
"Fexofenadine-pseudoephedrine was safe and effective in treating a broad range of allergy symptoms, with a rapid onset of action at 45 minutes."( Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit.
Berkowitz, RB; Lutz, C; Meeves, S; Moss, M; Weiler, J; Weiler, K; Woodworth, GG, 2002
)
0.31
" There was no significant difference in adverse events between fexofenadine and placebo, either overall or by causality."( Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis.
Bachert, C; Baena-Cagnani, C; Decosta, P; Finn, AF; Hedlin, G; Kowalski, ML; Meltzer, EO; Potter, P; Rosado Pinto, JE; Ruuth, E; Scheinmann, P; Simons, FE; Wahn, U, 2003
)
0.32
" Patients (and investigators) reported any adverse events during the trial."( Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis--a pooled analysis of three studies.
Bachert, C; Finn, AF; Hedlin, G; Meltzer, EO; Rosado Pinto, JE; Ruuth, E; Scheinmann, P; Wahn, U, 2004
)
0.32
" Safety was assessed on routine laboratory tests and recording vital signs and adverse events (AEs)."( Clinical study of the therapeutic efficacy and safety of emedastine difumarate versus terfenadine in the treatment of seasonal allergic rhinitis.
Assandri, A; Corrado, ME; Hartwig, J; Mion, A; Oldeman, HG; Radicioni, MM, 2004
)
0.55
"The results of study show that emedastine difumarate is more effective than terfenadine in the symptomatic management of seasonal allergic rhinitis and is particularly active in controlling the main nasal symptoms, such as sneezing and rhinorrhea; it is safe and well tolerated in this therapeutic indication, while related AEs are less if compared to those displayed by terfenadine."( Clinical study of the therapeutic efficacy and safety of emedastine difumarate versus terfenadine in the treatment of seasonal allergic rhinitis.
Assandri, A; Corrado, ME; Hartwig, J; Mion, A; Oldeman, HG; Radicioni, MM, 2004
)
0.78
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" and adverse events were recorded in diary cards by the patients in form of scores as well as by the investigator at each visit."( The efficacy and safety of 30 mg fexofenadine HCl bid in pediatric patients with allergic rhinitis.
Direkwattanachai, C; Ngamphaiboon, J; Tiensuwan, M; Vangveeravong, M; Visitsunthorn, N, 2005
)
0.33
" Pretreatment with antihistamines diminishes the incidence of adverse reactions (AR) such as large local and mild systemic reactions but it is suggested that it may mask a development of serious allergic reactions."( [Safety of venom immunotherapy in patients pretreated with antihistamines--a retrospective study].
Bocheńska-Marciniak, M; Kuna, P; Kupczyk, M; Kupryś-Lipińska, I; Tworek, D, 2006
)
0.33
" During the dose increase phase 10 systemic adverse reactions were observed."( [Safety of venom immunotherapy in patients pretreated with antihistamines--a retrospective study].
Bocheńska-Marciniak, M; Kuna, P; Kupczyk, M; Kupryś-Lipińska, I; Tworek, D, 2006
)
0.33
" A vast majority of systemic adverse reactions is of subjective and mild objective nature and appropriate treatment leads to containment of severe reactions."( [Safety of venom immunotherapy in patients pretreated with antihistamines--a retrospective study].
Bocheńska-Marciniak, M; Kuna, P; Kupczyk, M; Kupryś-Lipińska, I; Tworek, D, 2006
)
0.33
" Before the amendment, assessments included physical examination, vital signs reporting (oral temperature, heart rate, and respiratory rate), and adverse event (AE) reporting."( Safety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old.
Hampel, FC; Kittner, B; Lanier, R; Milgrom, H, 2007
)
0.34
"In the combined population, the incidence of treatment-emergent adverse events (TEAEs) was comparable between groups (placebo, 48."( Safety and tolerability of fexofenadine hydrochloride, 15 and 30 mg, twice daily in children aged 6 months to 2 years with allergic rhinitis.
Hampel, FC; Kittner, B; van Bavel, JH, 2007
)
0.34
" Adverse events (AEs); electrocardiograms (ECGs); vital signs; and clinical laboratory tests for hematology, blood chemistry, and urinalysis were analyzed to evaluate safety and tolerability."( Pharmacokinetics, safety and tolerability of an oral suspension of fexofenadine for children with allergic rhinitis.
Grubbe, RE; Kittner, B; Levy, AL; Maloney, MJ; Nayak, AS; Quesada, JT; Segall, N,
)
0.13
" Cell lines have been selected and validated on automated electrophysiology systems to facilitate cost-effective screening for safe and selective compounds at earlier stages in the drug development process."( An ion channel library for drug discovery and safety screening on automated platforms.
Brown, AM; Kuryshev, YA; Liu, Z; Smith, SS; Wible, BA, 2008
)
0.35
" Second-generation antihistamines have become increasingly popular because of their comparable efficacy and lower incidence of adverse effects relative to their first-generation counterparts, and the safety and efficacy of this drug class are established in the adult population."( Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast.
Moeller, ML; Nahata, MC; Phan, H, 2009
)
0.35
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Integration of metabolic function in toxicology models can improve adverse effects prediction in preclinical studies and this system could also be used for chronic studies as well."( Investigation of the effect of hepatic metabolism on off-target cardiotoxicity in a multi-organ human-on-a-chip system.
Bridges, LR; Carmona-Moran, CA; Ekman, G; Elbrecht, DH; Hickman, JJ; Jackson, M; Kumanchik, L; Langer, J; Lavado, A; Long, CJ; Martin, C; McAleer, CW; Narasimhan, NS; Note, R; Oleaga, C; Persaud, K; Riu, A; Roles, J; Rothemund, S; Sasserath, T; Schnepper, MT; Teissier, S; Tran, M; Wang, YI, 2018
)
0.48
" When compared with the first-generation antihistamines, fexofenadine produced significantly lower adverse events frequency (OR = 0."( Antihistamine effects and safety of fexofenadine: a systematic review and Meta-analysis of randomized controlled trials.
Huang, CZ; Jiang, ZH; Luo, Y; Peng, H; Wang, J, 2019
)
0.51

Pharmacokinetics

Study designed to investigate the effects of paroxetine on the pharmacodynamic and pharmacokinetic profile of terfenadine. Atorvastatin coadministration produced an 8% decrease in maximum concentration (Cmax), a 35% increase in area under the concentr.

ExcerptReferenceRelevance
", a randomized, crossover study was undertaken to determine if there were a pharmacokinetic interaction between these two medications."( Pharmacokinetic evaluation of the terfenadine-theophylline interaction.
Fitzsimmons, WE; Luskin, AT; Luskin, SS; MacLeod, CM, 1989
)
0.56
"This article reviews clinical pharmacokinetic data on the H1-receptor antagonists, commonly referred to as the antihistamines."( Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines).
Paton, DM; Webster, DR,
)
0.13
" The serum elimination half-life values of these agents are variable: a few hours for terfenadine and triprolidine; about 9 hours for cetirizine, azatadine, and loratadine; from 20 to 25 hours for hydroxyzine, chlorpheniramine, and brompheniramine; and from 5 to 14 days for astemizole."( The comparative pharmacokinetics of H1-receptor antagonists.
Chung, M; Simons, FE; Simons, KJ; Yeh, J, 1987
)
0.5
" Mean +/- SD active metabolite data for milk and plasma are as follows: Cmax (ng/ml), 41."( Terfenadine pharmacokinetics in breast milk in lactating women.
Abel, SR; Benjamin, S; Hilleman, DE; Lucas, BD; Purdy, CY; Scarim, SK, 1995
)
1.73
" Actual plasma terfenadine levels during terfenadine-ketoconazole coadministration in a clinical pharmacokinetic study were close to those predicted by the model."( In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction.
Duan, SX; Greenblatt, DJ; Harmatz, JS; Shader, RI; von Moltke, LL, 1994
)
0.94
" This assay was used for a pharmacokinetic study in five subjects after administration of a single dose of 60 mg of terfenadine."( A preliminary pharmacokinetic study of the enantiomers of the terfenadine acid metabolite in humans.
Khalil, SK; Surapaneni, S, 1994
)
0.74
" Single-dose terfenadine administration (120 mg) was accompanied by pharmacokinetic profiles and serial determination of the QTc interval for 12 hours."( Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics.
Cantilena, LR; Honig, PK; Hull, R; Smith, JE; Wortham, DC; Zamani, K, 1993
)
0.94
" Pharmacokinetic profiles and morning pre-dose electrocardiograms were obtained whilst the patients were on terfenadine alone and after the addition of cimetidine or rantidine."( Effect of concomitant administration of cimetidine and ranitidine on the pharmacokinetics and electrocardiographic effects of terfenadine.
Cantilena, LR; Conner, DP; Honig, PK; Mullin, JC; Wortham, DC; Zamani, K, 1993
)
0.7
" Pharmacokinetic profiles were obtained while subjects were taking terfenadine alone and after the addition of ketoconazole."( Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences.
Cantilena, LR; Conner, DP; Honig, PK; Mullin, JC; Wortham, DC; Zamani, K,
)
1.81
" We conclude that a pharmacokinetic interaction between terfenadine and fluconazole exists; however, the absence of accumulation of parent terfenadine in plasma suggests that a clinically significant interaction is unlikely."( The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans.
Cantilena, LR; Conner, DP; Honig, PK; Mullin, JC; Worham, DC; Zamani, K, 1993
)
0.75
" The primary end points were QT prolongation on the surface electrocardiogram and the pharmacokinetic parameters: area under the concentration-time curve (AUC), maximum concentration, and time to maximum concentration of terfenadine and its acid metabolite terfenadine carboxylate."( Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram.
Benton, RE; Cantilena, LR; Honig, PK; Woosley, RL; Zamani, K, 1996
)
0.79
"The pharmacokinetic and pharmacodynamic interactions of terbinafine (Lamisil) and terfenadine (Seldane) were assessed in 26 healthy volunteers randomized to receive either terbinafine (250 mg tablet) or its placebo (terbinafine placebo), which were administered in a double-blind manner once daily for 18 days."( Safe coadministration of terbinafine and terfenadine: a placebo-controlled crossover study of pharmacokinetic and pharmacodynamic interactions in healthy volunteers.
Chang, CT; Cramer, JA; Garreffa, S; Hafkin, B; Hunt, TL; Meligeni, J; Robbins, B, 1996
)
0.79
" Data are usually reported on the carboxylic acid metabolite (M1) but there are no published reports of pharmacokinetic parameters for terfenadine itself."( Population pharmacokinetics of terfenadine.
Gaudreault, J; Lalonde, RL; Lessard, D, 1996
)
0.78
" Coadministration of zileuton with terfenadine resulted in a significant increase in the mean AUC and Cmax of terfenadine by approximately 35% and the mean AUC and Cmax of carboxyterfenadine by approximately 15%."( The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine.
Awni, WM; Cao, G; Cavanaugh, JH; Dube, LM; Kasier, J; Leese, P; Locke, CS, 1997
)
0.81
"The relatively small pharmacokinetic effect of zileuton on terfenadine metabolism, with no change in the QTc interval, is unlikely to be of clinical significance."( The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine.
Awni, WM; Cao, G; Cavanaugh, JH; Dube, LM; Kasier, J; Leese, P; Locke, CS, 1997
)
0.77
"The effects of epinastine hydrochloride and terfenadine on electrocardiographic (ECG) parameters in rats were investigated from a pharmacokinetic and pharmacodynamic perspective."( A comparative pharmacokinetic-pharmacodynamic study of the electrocardiographic effects of epinastine and terfenadine in rats.
Iga, T; Kotaki, H; Ohtani, H; Sawada, Y, 1997
)
0.77
" In light of recent reports that the selective serotonin reuptake inhibitor antidepressants may be weak CYP3A4 inhibitors, this study was designed to investigate the effects of paroxetine on the pharmacodynamic and pharmacokinetic profile of terfenadine."( Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men.
Benincosa, LJ; Etheredge, RC; Everitt, DE; Jorkasky, DK; Martin, DE; Zussman, BD, 1997
)
0.71
" Noncompartmental pharmacokinetic data for terfenadine and terfenadine acid metabolite were compared between treatments."( Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine.
Bergstrom, RF; Cerimele, BJ; Goldberg, MJ; Hatcher, BL, 1997
)
0.78
" The area under the concentration-time curve for terfenadine was lower after fluoxetine administration, a statistically significant difference, but the peak concentration of terfenadine was not significantly different."( Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine.
Bergstrom, RF; Cerimele, BJ; Goldberg, MJ; Hatcher, BL, 1997
)
0.78
" Pharmacokinetic investigations have shown the drug to be highly bound to blood proteins, mainly serum albumin, and to have a low brain uptake, explaining its lack of sedative effects."( Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
Carrupt, PA; Jolliet, P; Morin, C; Morin, D; Pagliara, A; Rihoux, JP; Testa, B; Tillement, JP; Urien, S, 1998
)
0.3
" This paper reviews the pharmacokinetic properties of these second-generation agents and is intended to provide comparisons that help explain differences in dosing profiles and drug interactions for members of this class of drugs."( Pharmacokinetic overview of oral second-generation H1 antihistamines.
Estes, KS; González, MA, 1998
)
0.3
" For terfenadine, atorvastatin coadministration produced an 8% decrease in maximum concentration (Cmax), a 35% increase in area under the concentration-time curve extrapolated to infinity (AUC0-infinity), and a 2% decrease in elimination half-life (t1/2)."( Atorvastatin does not produce a clinically significant effect on the pharmacokinetics of terfenadine.
Olson, SC; Smithers, JA; Stern, RH, 1998
)
1.04
"The effect of steady-state venlafaxine administration on the single-dose pharmacokinetic profile of terfenadine, a cytochrome pigment (P450) isoenzyme CYP3A4 substrate, and its active acid metabolite (fexofenadine) was evaluated in an open-label, nonrandomized study."( Effect of venlafaxine on the pharmacokinetics of terfenadine.
Albano, D; Amchin, J; Klockowski, PM; Taylor, KP; Zarycranski, W, 1998
)
0.77
" Plasma concentrations of buspirone were measured up to 18 hr and its pharmacodynamic effects up to 8 hr."( Lack of effect of terfenadine on the pharmacokinetics of the CYP3A4 substrate buspirone.
Kivistö, KT; Lamberg, TS; Neuvonen, PJ, 1999
)
0.64
" After each dose, serial blood samples and ECG measurements were collected to determine sparfloxacin pharmacokinetic and pharmacodynamic variables."( The effect of terfenadine on the cardiac pharmacodynamics of sparfloxacin.
Dorr, MB; Hunt, T; Magner, D; Morganroth, J; Talbot, GH, 1999
)
0.66
"This study was undertaken to assess the effects of coadministration of desloratadine or fexofenadine with azithromycin on pharmacokinetic parameters, tolerability, and electrocardiographic (ECG) findings."( Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study.
Affrime, M; Banfield, C; Batra, V; Clement, R; Gupta, S; Kantesaria, B; Marino, M, 2001
)
0.31
"The results of the pharmacokinetic analysis revealed little change in mean maximum concentration (Cmax) and area under the concentration-time curve (AUC) values for desloratadine with concomitant administration of azithromycin: Cmax ratio, 115% (90% CI, 92-144); AUC, ratio 105% (90% CI, 82-134)."( Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study.
Affrime, M; Banfield, C; Batra, V; Clement, R; Gupta, S; Kantesaria, B; Marino, M, 2001
)
0.31
"05) decreased the oral clearance by 20%, with no change in half-life or renal clearance."( Effect of St John's wort on the pharmacokinetics of fexofenadine.
Hall, SD; Hamman, MA; Huang, SM; Lesko, LJ; Wang, Z, 2002
)
0.31
" Comparison of the pharmacokinetic parameters of omeprazole before and after fexofenadine revealed that there were no differences in peak concentration, time to peak concentration, area under the time concentration curve up to 8 hr, and elimination half-life."( Fexofenadine does not affect omeprazole pharmacokinetics: both are putative P-glycoprotein substrates.
Sugawara, K; Takahata, T; Tateishi, T; Uno, T; Yasui-Furukori, N; Yoshiya, G, 2004
)
0.32
" No changes in any plasma pharmacokinetic parameters of fexofenadine were found during cimetidine treatment."( Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics.
Sugawara, K; Tateishi, T; Uno, T; Yasui-Furukori, N, 2005
)
0.33
"In the placebo phase, pharmacokinetic parameters of fexofenadine showed no statistically significant difference between 2 MDR1 haplotypes; the area under the curve from time 0 to infinity (AUC(0-infinity)) of fexofenadine in the T/T and G/C groups was 5194."( Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism.
Cha, IJ; Choi, YG; Hong, WS; Lee, SS; Nguyen, PM; Shin, JG; Shon, JH; Yoon, YR, 2005
)
0.33
" It is concluded that estimating in vivo receptor occupancy, which takes into account both the affinity of the drug for the receptor and its free plasma concentration, is a far better predictor for human pharmacodynamics and hence antihistamine potency, than considering in vitro affinity and plasmatic half-life only."( Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines.
Baltes, E; Benedetti, MS; Chatelain, P; Gillard, M, 2005
)
0.33
" Elimination half-life and renal clearance in the itraconazole phase were not altered significantly compared with those in the control phase."( Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.
Shimizu, M; Sugawara, K; Tateishi, T; Uno, T, 2006
)
0.33
" The current studies used sandwich-cultured (SC) rat hepatocytes combined with a comprehensive pharmacokinetic modeling approach to investigate the hepatobiliary disposition of terfenadine and fexofenadine, a model drug/metabolite pair."( Hepatobiliary disposition of a drug/metabolite pair: Comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes.
Brouwer, KL; Hoffmaster, KA; Kalvass, JC; Pollack, GM; Turncliff, RZ, 2006
)
0.53
" No significant changes in mean residence time and terminal half-life were observed for all drugs, suggesting a negligible effect of BA on their hepatic/renal elimination."( Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A.
Cousineau, M; Danser, E; Dewire, R; Floden, J; Peng, SX; Ritchie, DM, 2006
)
0.33
" Although the elimination half-life and the renal clearance of fexofenadine remained relatively constant, a single administration of itraconazole with fexofenadine significantly increased mean area under the plasma concentration-time curve (AUC(0-infinity)) of fexofenadine (1701/3554, 4308, and 4107 ng h/ml for control; 50 mg, 100 mg, and 200 mg of itraconazole, respectively)."( Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine.
Shimizu, M; Sugawara, K; Tateishi, T; Uno, T, 2006
)
0.33
" Eight cystic fibrosis patients and 8 healthy volunteers were recruited into a crossover pharmacokinetic study in which participants received 180 mg fexofenadine with or without 1 g probenecid twice a day."( Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine.
Beringer, PM; Burckart, GJ; Hidayat, L; Liu, S; Louie, S; Rao, AP; Shapiro, B, 2008
)
0.35
" The purpose of this study was to assess the pharmacokinetic behavior, safety, and tolerability of a single dose of fexofenadine HCl oral suspension administered to children aged 2-5 years with allergic rhinitis."( Pharmacokinetics, safety and tolerability of an oral suspension of fexofenadine for children with allergic rhinitis.
Grubbe, RE; Kittner, B; Levy, AL; Maloney, MJ; Nayak, AS; Quesada, JT; Segall, N,
)
0.13
" Plasma and urinary fexofenadine concentrations were measured, and pharmacokinetic differences between placebo and quercetin phases were assessed."( Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers.
Kim, KA; Park, JY; Park, PW, 2009
)
0.35
" The area under the time versus concentration curve (AUC) of plasma fexofenadine was increased by 55% by quercetin (2,005."( Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers.
Kim, KA; Park, JY; Park, PW, 2009
)
0.35
"The suitability of fexofenadine as a probe substrate to assess hepatobiliary transport function in humans was evaluated by pharmacokinetic modeling/simulation and in vitro/in situ studies using chemical modulators."( Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function.
Brouwer, KL; Swift, B; Tian, X, 2009
)
0.35
"Simulations based on a pharmacokinetic model developed to describe fexofenadine disposition in humans were conducted to examine the impact of altered hepatobiliary transport on fexofenadine disposition."( Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function.
Brouwer, KL; Swift, B; Tian, X, 2009
)
0.35
" The validated method was applied to a pharmacokinetic study in human volunteers following oral administration of 60 or 120 mg fexofenadine formulations, successfully."( Measurement of fexofenadine concentration in micro-sample human plasma by a rapid and sensitive LC-MS/MS employing protein precipitation: application to a clinical pharmacokinetic study.
Fan, H; Guo, D; Lou, S; Qin, Q; Zhu, Y; Zou, J, 2010
)
0.36
"ESRD can affect the pharmacokinetic disposition of drugs subject to nonrenal clearance."( ESRD impairs nonrenal clearance of fexofenadine but not midazolam.
Frye, RF; Himmelfarb, J; Le, P; Leblond, FA; Naud, J; Nolin, TD; Pichette, V; Sadr, H, 2009
)
0.35
" This article reviews the pharmacokinetic differences between fexofenadine enantiomers in humans and summarizes the previous reports that co-administration of P-glycoprotein inhibitors has altered the stereoselective pharmacokinetics of fexofenadine enantiomers."( Clinical pharmacokinetics of fexofenadine enantiomers.
Miura, M; Uno, T, 2010
)
0.36
" The area under the time versus concentration curve of fexofenadine in the metronidazole phase (2075."( Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers.
Kim, KA; Park, JY, 2010
)
0.36
"A human pharmacokinetic study was performed to assess the ability of a microdose to predict the pharmacokinetics of a therapeutic dose of fexofenadine and to determine its absolute oral bioavailability."( Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability.
Bjerrum, OJ; Garner, C; Gesson, C; Houston, B; Jochemsen, R; Lappin, G; Oosterhuis, B; Rowland, M; Shishikura, Y; Weaver, RJ, 2010
)
0.36
" The pharmacokinetic properties of S-fexofenadine are affected by a single polymorphism of SLCO2B1 in combination with several polymorphisms of ABCB1 C1236T, C3435T, and ABCC2 C-24T."( Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers.
Akamine, Y; Kagaya, H; Miura, M; Sunagawa, S; Uno, T; Yasui-Furukori, N, 2010
)
0.36
" Oral or intravenous (IV) fexofenadine (10 mg/kg) was administered 24 h later and plasma and urine samples collected for pharmacokinetic analysis."( Pharmacokinetics of fexofenadine following LPS administration to rats.
Davey, AK; Gerber, JP; Jaisue, S, 2010
)
0.36
" Neither the genotype nor the apple juice showed significant effects on the pharmacokinetics of midazolam except for a marginally significant decrease in Cmax after administration with apple juice."( The effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans.
Imai, H; Imanaga, J; Kotegawa, T; Ohashi, K; Ohyama, T; Shirasaka, Y; Tamai, I; Tateishi, T; Tsutsumi, K; Yoshizato, T, 2011
)
0.37
"The authors evaluated the contribution of the SLCO2B1 polymorphism to the pharmacokinetics of celiprolol at a microdose (MD) and therapeutic dose (TD) and compared pharmacokinetic proportionality between the 2 dose forms in 30 SLCO2B1 genotype-matched healthy volunteers."( Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose.
Chiyoda, T; Doi, Y; Hirota, T; Ieiri, I; Irie, S; Iwasaki, K; Kimura, M; Maeda, K; Miyagawa, M; Sasaki, T; Sugiyama, Y, 2012
)
0.38
" In this study, fexofenadine, verapamil, risperidone, ondansetron, and imipramine were used as model compounds to investigate the effectiveness of MIM in pharmacokinetic studies."( Development of a novel high-throughput analytical methodology, multiple injection method, for quantitative analysis in drug metabolism and pharmacokinetic studies using liquid chromatography with tandem mass spectrometry.
Ohkawa, T; Tanaka, Y; Yasui, H, 2011
)
0.37
" The P-gp inducer showed a greater effect on the pharmacokinetic parameters of (S)-fexofenadine."( Carbamazepine differentially affects the pharmacokinetics of fexofenadine enantiomers.
Akamine, Y; Kojima, M; Miura, M; Uno, T; Yasui-Furukori, N, 2012
)
0.38
" Safety and pharmacokinetic analyses were performed."( Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects.
Alexander, N; Dahlke, M; Hanna, I; Hariry, S; Jarugula, V; Rebello, S; Vapurcuyan, A; Zhao, S, 2012
)
0.38
" In addition, a physiologically based pharmacokinetic (PBPK) model consisting of 11 compartments (6 tissues +5 sample sites) was applied for mechanistic elucidation and estimation of individual PK parameters."( Effects of verapamil on the pharmacokinetics and hepatobiliary disposition of fexofenadine in pigs.
Bondesson, U; Hedeland, M; Lennernäs, H; Sjögren, E, 2014
)
0.4
" The pharmacokinetic studies proved F23 ability to increase extent of FXD absorption and reduce T(max)."( Phenylalanine-free taste-masked orodispersible tablets of fexofenadine hydrochloride: development, in vitro evaluation and in vivo estimation of the drug pharmacokinetics in healthy human volunteers.
El-Ridi, MS; El-Sherif, NG; Tadros, MI; Yehia, SA, 2015
)
0.42
"A population pharmacokinetic analysis was conducted to characterize the pharmacokinetics of fexofenadine in Japanese pediatric patients (6 months through 16 years) with perennial allergic rhinitis or atopic dermatitis."( Population pharmacokinetic analysis of fexofenadine in Japanese pediatric patients.
Fabre, D; Khier, S; Martinez, JM; Morita, S; Rauch, C, 2014
)
0.4
"The aim of presented study was to assess pharmacokinetic properties of fexofenadine in Taiwanese volunteers."( Pharmacokinetics of fexofenadine in healthy Taiwanese volunteers.
Chen, YA; Hsu, KY, 2014
)
0.4
"In pharmacokinetic evaluation of mice, using serial sampling methods rather than a terminal blood sampling method could reduce the number of animals needed and lead to more reliable data by excluding individual differences."( Using improved serial blood sampling method of mice to study pharmacokinetics and drug-drug interaction.
Nezasa, K; Ogawa, K; Shimizu, R; Takai, N; Tanaka, Y; Watanabe, A; Watari, R; Yamaguchi, Y, 2015
)
0.42
" These results were confirmed by an in vivo pharmacokinetic study of oral administered fexofenadine (10mg/kg) in rats."( Effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine in rats.
Bedada, SK; Neerati, P, 2015
)
0.42
" This method was successfully applied for therapeutic drug monitoring in patients treated with clinical doses of fexofenadine and for pharmacokinetic studies."( HPLC Determination of Fexofenadine in Human Plasma For Therapeutic Drug Monitoring and Pharmacokinetic Studies.
El Bedaiwy, HM; Helmy, SA, 2016
)
0.43
" These results were confirmed by an in vivo pharmacokinetic study of oral administered FEX (10mg/kg) in rats."( Effect of resveratrol on the pharmacokinetics of fexofenadine in rats: Involvement of P-glycoprotein inhibition.
Bedada, SK; Neerati, P; Yellu, NR, 2016
)
0.43
" In comparison with FEX alone, RSV pretreatment significantly increased maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC), while there was no significant change was observed in T1/2 and Tmax of FEX."( Effect of resveratrol on the pharmacokinetics of fexofenadine in rats: Involvement of P-glycoprotein inhibition.
Bedada, SK; Neerati, P; Yellu, NR, 2016
)
0.43
"RSV significantly enhanced the exposure of FEX in rats likely by the inhibition of P-glycoprotein (P-gp) mediated efflux during the intestinal absorption, suggesting that there is a potential pharmacokinetic interaction between RSV and FEX."( Effect of resveratrol on the pharmacokinetics of fexofenadine in rats: Involvement of P-glycoprotein inhibition.
Bedada, SK; Neerati, P; Yellu, NR, 2016
)
0.43
"Whether the combined use of probe drugs for CYP3A4 and P-glycoprotein can clarify the relative contribution of these proteins to pharmacokinetic variability of a dual substrate like tacrolimus has never been assessed."( Fexofenadine, a Putative In Vivo P-glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients.
Annaert, P; Bouillon, T; de Loor, H; Kuypers, D; Vanhove, T, 2017
)
0.46
"In order to better understand the variability of pharmacodynamic and pharmacokinetic profiles of terfenadine between the previous studies as well as to qualitatively and quantitatively examine the proarrhythmic potential of its major active metabolite fexofenadine in comparison with that of terfenadine, we directly compared their electropharmacological effects with halothane-anesthetized dogs (n = 3)."( Comparison of electropharmacological effects between terfenadine and its active derivative fexofenadine using a cross-over study in halothane-anesthetized dogs to analyze variability of pharmacodynamic and pharmacokinetic profiles of terfenadine and torsa
Ando, K; Chiba, K; Goto, A; Hagiwara-Nagasawa, M; Harada, H; Inamura, N; Izumi-Nakaseko, H; Lubna, NJ; Miyamoto, H; Naito, AT; Nakamura, Y; Sugiyama, A; Takagi, K, 2018
)
0.95
" Values for total clearance of compounds from plasma should be one of the most important pharmacokinetic parameters for predictions."( Predicted values for human total clearance of a variety of typical compounds with differently humanized-liver mouse plasma data.
Ito, S; Iwamoto, K; Kamimura, H; Mizunaga, M; Nakayama, K; Negoro, T; Nishiwaki, M; Nomura, Y; Suemizu, H; Yamazaki, H; Yoneda, N, 2020
)
0.56
" This study evaluated a limited sampling strategy using a population pharmacokinetic approach to estimate plasma fexofenadine exposure as an index of P-gp and OATP activities."( Fexofenadine Plasma Concentrations to Estimate Systemic Exposure in Healthy Adults Using a Limited Sampling Strategy with a Population Pharmacokinetic Approach.
Blaquera, CL; Capparelli, EV; Ma, JD; Nikanjam, M; Nolin, TD; Paine, MF; Penzak, SR; Piscitelli, J, 2023
)
0.91
" A population pharmacokinetic model was developed using nonlinear mixed-effects modeling."( Fexofenadine Plasma Concentrations to Estimate Systemic Exposure in Healthy Adults Using a Limited Sampling Strategy with a Population Pharmacokinetic Approach.
Blaquera, CL; Capparelli, EV; Ma, JD; Nikanjam, M; Nolin, TD; Paine, MF; Penzak, SR; Piscitelli, J, 2023
)
0.91

Compound-Compound Interactions

terfenadine 180 mg, flurbiprofen 100 mg, and the drug combination on AMP-induced bronchoconstriction in eight nonatopic asthmatic subjects with a mean age of 53. All of our results confirmed that terfen adine combined with EPI synergistically inhibits the growth and metastatic processes of resistant cells both in vitro and in vivo.

ExcerptReferenceRelevance
" In the present study, we have investigated the effect of oral terfenadine 180 mg, flurbiprofen 100 mg, and the drug combination on AMP-induced bronchoconstriction in eight nonatopic asthmatic subjects with a mean age of 53."( The effect of oral terfenadine alone and in combination with flurbiprofen on the bronchoconstrictor response to inhaled adenosine 5'-monophosphate in nonatopic asthma.
Holgate, ST; Phillips, GD, 1989
)
0.84
"Two studies were performed to measure the effects of acrivastine (BW825C), an antihistamine, in combination with alcohol on the central nervous system."( The effects of acrivastine (BW825C), diphenhydramine and terfenadine in combination with alcohol on human CNS performance.
Cohen, AF; Hamilton, MJ; Peck, AW, 1987
)
0.52
"The utility of primary human hepatocytes in the evaluation of drug-drug interactions is being investigated in our laboratories."( Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: evaluation of model drugs terfenadine and rifampin.
Jurima-Romet, M; Li, AP, 1997
)
0.5
"Many adverse drug-drug interactions are attributable to pharmacokinetic problems and can be understood in terms of alterations of P450-catalyzed reactions."( Role of cytochrome P450 enzymes in drug-drug interactions.
Guengerich, FP, 1997
)
0.3
" A substantial increase was observed in mean Cmax and AUC values for fexofenadine when administered with azithromycin: Cmax, ratio, 169% (90% CI, 120-237); AUC ratio, 167% (90% CI, 122-229)."( Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study.
Affrime, M; Banfield, C; Batra, V; Clement, R; Gupta, S; Kantesaria, B; Marino, M, 2001
)
0.31
" The database included a register of automatic alerts produced every time a predetermined drug combination was detected."( [Risk of drug interactions. Combinations of drugs associated with ventricular arrhythmias].
Aguilar-Chiu, A; Hernández-Garduño, AG; Jerjes-Sánchez, C; Pelaez-Ballestas, I; Viramontes-Madrid, JL,
)
0.13
"In the present study, the inhibitory properties of N-[2-(diisopropylamino)ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]-1,3-thiazole-4-carboxamide monohydrochloride trihydrate (Z-338), a novel gastroprokinetic agent, were investigated and compared with those of cisapride to establish its potential for drug-drug interactions."( Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338.
Furuta, S; Kamada, E; Kawabata, Y; Kurimoto, T; Omata, T; Sugimoto, T; Wu, XC; Yonezawa, K, 2004
)
0.56
" The purpose of the present study is to investigate the possibility that the drug-drug interaction between fexofenadine and probenecid involves the renal basolateral uptake process."( Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid.
Fuse, E; Koepsell, H; Kusuhara, H; Maeda, K; Sugiyama, Y; Tahara, H, 2006
)
0.33
" Collections of individual case safety reports (ICSRs) related to suspected ADR incidents in clinical practice have proven to be very useful in post-marketing surveillance for pairwise drug--ADR associations, but have yet to reach their full potential for drug-drug interaction surveillance."( A statistical methodology for drug-drug interaction surveillance.
Bate, A; Edwards, IR; Norén, GN; Sundberg, R, 2008
)
0.35
"A novel method for the prediction of drug-drug interaction has been established based on the in vitro metabolic stability in the "serum incubation method" using cryopreserved human hepatocytes suspended in 100% human serum."( A novel approach to the prediction of drug-drug interactions in humans based on the serum incubation method.
Chiba, M; Ishii, Y; Shibata, Y; Takahashi, H, 2008
)
0.35
"Cimetidine is known to cause drug-drug interactions (DDIs) with organic cations in the kidney, and a previous clinical study showed that coadministration of cimetidine or probenecid with fexofenadine (FEX) decreased its renal clearance."( The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine.
Horita, S; Inoue, K; Kondo, T; Kusuhara, H; Maeda, K; Matsushima, S; Nakayama, H; Ohta, KY; Sugiyama, Y; Yuasa, H, 2009
)
0.35
" Given that both fluvastatin and fexofenadine can interact with organic anion-transporting polypeptides (OATPs) expressed in intestine and liver, the present results suggest the potential drug interaction between fluvastatin and fexofenadine via the competition for the OATP-mediated cellular transport pathway during intestinal absorption and/or hepatic uptake of drugs."( Pharmacokinetic drug interaction between fexofenadine and fluvastatin mediated by organic anion-transporting polypeptides in rats.
Han, HK; Lee, BJ; Lee, W; Qiang, F, 2009
)
0.35
" Inhibition or induction of P-gp can cause drug-drug interactions and thus influence the effects of P-gp substrate drugs."( 20(S)-ginsenoside Rh2 noncompetitively inhibits P-glycoprotein in vitro and in vivo: a case for herb-drug interactions.
Ai, H; Gu, Y; Hao, G; Li, Y; Peng, Y; Sun, J; Wang, G; Wu, X; Zhang, J; Zhang, X; Zheng, Y; Zhou, F, 2010
)
0.36
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
" Due to the difference in the IC50 values for CYP3A4 and CYP3A5, nonconcordant expression of CYP3A4 and CYP3A5 protein can significantly affect the observed magnitude of CYP3A-mediated drug-drug interactions in humans."( Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions.
Chang, SY; Grubb, MF; Isoherranen, N; Peng, CC; Rodrigues, AD; Shirasaka, Y; Thummel, KE, 2013
)
0.39
" These findings indicate that only fexofenadine is expected to interact with GFJ on OATP2B1 at therapeutic concentrations, in accordance with the clinical observations."( Substrate- and dose-dependent drug interactions with grapefruit juice caused by multiple binding sites on OATP2B1.
Mori, T; Murata, Y; Nakanishi, T; Shirasaka, Y; Tamai, I, 2014
)
0.4
" In addition, using serial sampling methods can be valuable for evaluation of the drug-drug interaction (DDI) potential of drug candidates."( Using improved serial blood sampling method of mice to study pharmacokinetics and drug-drug interaction.
Nezasa, K; Ogawa, K; Shimizu, R; Takai, N; Tanaka, Y; Watanabe, A; Watari, R; Yamaguchi, Y, 2015
)
0.42
" To further validate this cocktail, in this study, we have verified whether probe drugs contained in the latter cause mutual drug-drug interactions."( Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
Bosilkovska, M; Daali, Y; Déglon, J; Desmeules, J; Samer, C; Thomas, A; Walder, B, 2016
)
0.43
" All of our results confirmed that terfenadine combined with EPI synergistically inhibits the growth and metastatic processes of resistant cells both in vitro and in vivo."( Terfenadine combined with epirubicin impedes the chemo-resistant human non-small cell lung cancer both in vitro and in vivo through EMT and Notch reversal.
An, L; Chu, HX; Fan, YH; Feng, F; Li, DD; Ma, HD; Song, Q; Wang, CL; Zhang, Q; Zhao, QC, 2017
)
2.17

Bioavailability

Terfenadine, an antihistaminic drug, has relatively low bioavailability after oral administration due to its limited solubility in water. In particular, the ingestion of grapefruit juice leads to enhanced systemic bioavailability.

ExcerptReferenceRelevance
" Changes in rate of absorption may be due to delayed gastric emptying and more rapid terfenadine solubilization."( Absence of food effects on the pharmacokinetics of terfenadine.
Antony, KK; Eller, MG; McNutt, BE; Okerholm, RA; Walker, BJ; Yuh, L, 1992
)
0.76
" For most of these drugs, the absolute bioavailability is unknown because no intravenous formulations are available for comparative purposes."( The comparative pharmacokinetics of H1-receptor antagonists.
Chung, M; Simons, FE; Simons, KJ; Yeh, J, 1987
)
0.27
"Administration of grapefruit juice concomitantly with terfenadine may lead to an increase in systemic terfenadine bioavailability and result in increases in QT interval."( Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram.
Benton, RE; Cantilena, LR; Honig, PK; Woosley, RL; Zamani, K, 1996
)
0.85
" In addition, first-pass metabolism occurs following oral drug administration and this may be extensive so that bioavailability is low."( Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.
Wilkinson, GR, 1996
)
0.29
" In particular, the ingestion of grapefruit juice leads to enhanced systemic bioavailability of terfenadine and of several important and frequently prescribed other drugs."( [Excessive terfenadine level due to drinking grapefruit juice].
de Wildt, SN; van den Anker, JN, 1997
)
0.9
"Simulated pharmacokinetic (PK) studies were done to determine the effect of intrinsic clearance (CL(INT)) on the probability of meeting bioequivalence criteria for extent (AUC) and rate (Cmax) of drug absorption when the absorption rate and fraction absorbed (F) were formulated either to be equivalent or to differ by 25%."( The role of metabolites in bioequivalency assessment. III. Highly variable drugs with linear kinetics and first-pass effect.
Jackson, AJ, 2000
)
0.31
" We conclude that the cause of the increased oral clearance of fexofenadine is a reduced bioavailability caused by induction of intestinal P-glycoprotein."( The effect of rifampin administration on the disposition of fexofenadine.
Bruce, MA; Haehner-Daniels, BD; Hall, SD; Hamman, MA, 2001
)
0.31
"Terfenadine, an antihistaminic drug, has relatively low bioavailability after oral administration due to its limited solubility in water."( Terfenadine-beta-Cyclodextrin inclusion complex with antihistaminic activity enhancement.
Choi, HG; Han, JH; Kim, CK; Kim, YB; Lee, BJ; Lee, MK; Park, KM; Rhee, JD; Yong, CS, 2001
)
3.2
"Certain foods, such as grapefruit juice, are known to substantially alter the bioavailability of some drugs."( Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine.
Affrime, M; Banfield, C; Gupta, S; Lim, J; Marino, M, 2002
)
0.31
"To assess the effect of consumption of grapefruit juice on the oral bioavailability of two nonsedating antihistamines, fexofenadine and desloratadine."( Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine.
Affrime, M; Banfield, C; Gupta, S; Lim, J; Marino, M, 2002
)
0.31
" In contrast, the bioavailability of desloratadine was unaffected by grapefruit juice."( Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine.
Affrime, M; Banfield, C; Gupta, S; Lim, J; Marino, M, 2002
)
0.31
"The bioavailability of drugs that do not undergo significant intestinal or hepatic metabolism, such as fexofenadine, may be altered when administered with agents that influence drug transport mechanisms."( Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine.
Affrime, M; Banfield, C; Gupta, S; Lim, J; Marino, M, 2002
)
0.31
"Our objective was to investigate the main in vivo transport mechanisms of fexofenadine involved in the intestinal absorption and bioavailability of the drug in humans."( Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine.
Bondesson, U; Hedeland, M; Knutson, L; Lennernäs, H; Petri, N; Tannergren, C, 2003
)
0.32
"In this in vivo perfusion study verapamil increased the bioavailability of fexofenadine."( Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine.
Bondesson, U; Hedeland, M; Knutson, L; Lennernäs, H; Petri, N; Tannergren, C, 2003
)
0.32
" The absolute bioavailability is 50-65% for mizolastine; it is high for levocetirizine as the percentage of the drug eliminated unchanged in the 48 h urine is 77% of the oral dose; the estimation for fexofenadine is at least 33%; no estimation was found for desloratadine."( Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans.
Benedetti, MS; Diquet, B; Molimard, M, 2004
)
0.32
" Clinical studies in humans showed that fruit juices reduced the oral bioavailability of fexofenadine by preferentially inhibiting OATP over P-gp."( Effect of fruit juices on the oral bioavailability of fexofenadine in rats.
Chong, S; Kamath, AV; Yao, M; Zhang, Y, 2005
)
0.33
"This study suggests that verapamil increases fexofenadine exposure probably because of an increase in bioavailability through P-glycoprotein inhibition and that probenecid slightly increases the area under the plasma concentration-time curve of fexofenadine as a result of a pronounced reduction in renal clearance."( Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics.
Sugawara, K; Tateishi, T; Uno, T; Yasui-Furukori, N, 2005
)
0.33
"The purpose of this study was to elucidate the potential clinical relevance and mechanism(s) of action of 2 different volumes of grapefruit juice on the reduction of bioavailability of fexofenadine, a substrate of organic anion transporting polypeptides."( Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides.
Bailey, DG; Dresser, GK; Kim, RB, 2005
)
0.33
"Grapefruit juice at a commonly consumed volume diminished the oral bioavailability of fexofenadine sufficiently to be pertinent clinically, likely by direct inhibition of uptake by intestinal organic anion transporting polypeptide A (OATP-A; new nomenclature, OATP1A2)."( Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides.
Bailey, DG; Dresser, GK; Kim, RB, 2005
)
0.33
" Comparing the pharmacokinetics after intravenous and oral administration indicated that the bioavailability of fexofenadine was at most 2% in mice."( P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion.
Fuse, E; Kusuhara, H; Sugiyama, Y; Tahara, H, 2005
)
0.33
" Consistent with this finding, in vivo studies showed that ketoconazole did not affect the Fa Fg for fexofenadine, a pharmacokinetic parameter that reflects absorption and bioavailability in the small intestine."( The advantages of the Ussing chamber in drug absorption studies.
Gotoh, Y; Kamada, N; Momose, D, 2005
)
0.33
" The apparent absorption rate constant (ka) of [(14)C]bepotastine in the small intestine was greatly increased by cyclosporin A and verapamil, especially in the distal portion, and the site-specific absorption of [(14)C]bepotastine disappeared."( Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate.
Fukuda, H; Kamikozawa, Y; Ohashi, R; Sugiura, M; Tamai, I; Yabuuchi, H, 2006
)
0.33
" The fexofenadine AUC(infinity) was increased by lopinavir/ritonavir, likely due to increased bioavailability secondary to P-glycoprotein inhibition."( Time-dependent interaction between lopinavir/ritonavir and fexofenadine.
Bourbeau, M; Cameron, DW; Campbell, P; Chauhan, BM; Foster, BC; Seguin, I; van Heeswijk, RP, 2006
)
0.33
"To support the pharmacokinetic and bioavailability study of a once-daily fexofenadine/pseudoephedrine combination, a high-performance liquid chromatography/positive ion electrospray tandem mass spectrometry (HPLC/ESI-MS/MS) method for the simultaneous quantification of fexofenadine and pseudoephedrine was developed and validated with 500 microL human plasma using mosapride as an internal standard (IS)."( Simultaneous quantification of fexofenadine and pseudoephedrine in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: method development, validation and application to a clinical study.
Kandikere, VN; Komarneni, P; Maurya, S; Mudigonda, K; Nirogi, RV; Shukla, M, 2006
)
0.33
" The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetic, bioavailability or bioequivalence studies."( Quantification of fexofenadine in human plasma by liquid chromatography coupled to electrospray tandem mass spectrometry using mosapride as internal standard.
Kandikere, VN; Komarneni, P; Maurya, S; Mudigonda, K; Nirogi, RV; Shukla, M, 2007
)
0.34
"We showed previously that grapefruit and orange juices inhibited human enteric organic anion-transporting polypeptide (OATP)1A2 in vitro and lowered oral fexofenadine bioavailability clinically."( Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice.
Bailey, DG; Dresser, GK; Kim, RB; Leake, BF, 2007
)
0.34
" The absolute oral bioavailability of fexofenadine in humans is not known because of a lack of studies of intravenous administration of this agent."( Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic fexofenadine in humans.
Chen, C, 2007
)
0.6
" Although itraconazole co-administration is known to increase the bioavailability of a racemic mixture of fexofenadine, little is known about the stereoselective inhibition of P-gp activity by itraconazole."( The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers.
Miura, M; Suzuki, T; Tateishi, T; Uno, T, 2008
)
0.35
" No major cytochrome P450 inhibition has been reported with desloratadine, fexofenadine and levocetirizine, and the bioavailability of desloratadine is minimally affected by drugs interfering with transporter molecules."( Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.
Devillier, P; Faisy, C; Roche, N, 2008
)
0.35
" bioavailability in preclinical species and humans."( Involvement of intestinal uptake transporters in the absorption of azithromycin and clarithromycin in the rat.
Davis, CB; Dawson, PA; Garver, E; Han, C; Hugger, ED; Rao, A; Shearn, SP, 2008
)
0.35
"51 to 0); and increased bioavailability (from 37 to 95%)."( Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.
Bedynek, PS; Hoffer, C; Kharasch, ED; Walker, A; Whittington, D, 2008
)
0.35
" Whole-body MALDI-IMS data showed that the poor oral bioavailability of terfenadine was largely due to high first-pass metabolism in the intestines and the liver before the compound reached systemic circulation."( Visualization of first-pass drug metabolism of terfenadine by MALDI-imaging mass spectrometry.
Chen, J; Crossman, L; Hsieh, Y; Knemeyer, I; Korfmacher, WA, 2008
)
0.84
" Consequently, the bioavailability of oral fluvastatin was significantly lower (p<0."( Pharmacokinetic drug interaction between fexofenadine and fluvastatin mediated by organic anion-transporting polypeptides in rats.
Han, HK; Lee, BJ; Lee, W; Qiang, F, 2009
)
0.35
" The mean bioavailability (F(ev)) of fexofenadine was decreased by 16."( Long-term effects of Panax ginseng on disposition of fexofenadine in rats in vivo.
Cao, Z; Jie, J; Li, W; Zhang, R; Zhou, Y, 2009
)
0.35
" Since the quality of final drug product is affected by the source of ingredients, type and amount of excipients and manufacturing process, bioequivalence studies are used to determine the bioavailability and characterize the pharmacokinetics of the new formulation relative to a reference formulation."( Bioequivalence of fexofenadine tablet formulations assessed in healthy Iranian volunteers.
Barghi, L; Islambulchilar, Z; Jalilian, H; Valizadeh, H; Zakeri-Milani, P, 2009
)
0.35
" Moreover, the bioavailability of fexofenadine x HCl after nasal administration of the microsphere formulation to rabbits was increased up to about 48% while that of the control solution was only about 3%."( Preparation and evaluation of spray-dried hyaluronic acid microspheres for intranasal delivery of fexofenadine hydrochloride.
Cho, HJ; Choi, MK; Chung, SJ; Huh, Y; Kim, DD; Kim, JS; Oh, E; Shim, CK; Yoon, IS, 2010
)
0.36
" The bioavailability of fexofenadine was increased by approximately 2-folds via the concomitant use of piperine."( Effect of piperine, a major component of black pepper, on the intestinal absorption of fexofenadine and its implication on food-drug interaction.
Han, HK; Jin, MJ, 2010
)
0.36
"To enhance the solubility and bioavailability of poorly absorbable fexofenadine, microemulsion system composed of oil, surfactant and co-surfactant was developed for intranasal delivery."( Preparation and evaluation of fexofenadine microemulsions for intranasal delivery.
Balakrishnan, P; Cho, HJ; Chung, SJ; Kim, DD; Kim, H; Kim, YS; Piao, HM; Shim, CK, 2010
)
0.36
"P-Glycoprotein accounts for multidrug resistance in chemotherapy patients and contributes to reduced oral bioavailability and distribution of drugs in the brain."( A quantitative structure-activity relationship for the modulation effects of flavonoids on p-glycoprotein-mediated transport.
Ho, HO; Kao, YH; Lin, YK; Liou, YB; Sheu, MT, 2010
)
0.36
" In conclusion, LPS treatment increased the bioavailability of fexofenadine but did not affect other pharmacokinetic parameters."( Pharmacokinetics of fexofenadine following LPS administration to rats.
Davey, AK; Gerber, JP; Jaisue, S, 2010
)
0.36
" Although the relative bioavailability of colonic administration of diclofenac, metformin and cevimeline compared to oral administration was similar regardless of the drug doses in the colon, colonic absorption of diltiazem varied according to the doses."( The relationship between the drug concentration profiles in plasma and the drug doses in the colon.
Hosoi, Y; Kanamaru, T; Konno, T; Nakagami, H; Tajiri, S; Yada, S; Yoshida, K, 2010
)
0.36
"A new type of interaction in which fruit juices diminish oral drug bioavailability through inhibition of uptake transport is the focus of this review."( Fruit juice inhibition of uptake transport: a new type of food-drug interaction.
Bailey, DG, 2010
)
0.36
"The oral bioavailability of some drugs is markedly lower in cynomolgus monkeys than in humans."( Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans.
Komuro, S; Mizuki, Y; Nishimuta, H; Sato, K; Yabuki, M, 2011
)
0.37
"Fexofenadine is a nonsedative antihistamine that exhibits good oral bioavailability despite its zwitterionic chemical structure and efflux by P-gp."( Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters.
Knight, BM; Ming, X; Thakker, DR, 2011
)
0.37
" In this work, novel FEX loaded water in oil microemulsion (w/o) was designed to improve bioavailability and compared with Fexofen(®) syrup in in vitro and in vivo studies."( Improvement of effect of water-in-oil microemulsion as an oral delivery system for fexofenadine: in vitro and in vivo studies.
Alvarez, IG; Gundogdu, E; Karasulu, E, 2011
)
0.37
" In conclusion, intranasal administration of chitosan coated liposome appeared to be effective to enhance the bioavailability as well as prolonged exposure of fexofenadine in rats."( Enhanced systemic exposure of fexofenadine via the intranasal administration of chitosan-coated liposome.
Han, HK; Lee, BJ; Qiang, F; Shin, HJ, 2012
)
0.38
" When FEX was administered at 3 h after the administration of CsA, the hepatic availability (F(h)) and the fraction absorbed in the intestine as an unchanged form (F(a)·F(g)) of FEX were increased, resulting in increased bioavailability (=F(a)·F(g)·F(h))."( Long-lasting inhibition of the intestinal absorption of fexofenadine by cyclosporin A in rats.
Fukuda, K; Horie, T; Shitara, Y; Suzuki, K, 2012
)
0.38
"The contribution of intestinal first-pass hydrolysis to oral bioavailability was evaluated in rats using a model prodrug of fexofenadine (FXD), which has poor oral bioavailability."( Effect of intestinal first-pass hydrolysis on the oral bioavailability of an ester prodrug of fexofenadine.
Adachi, Y; Imai, T; Ninomiya, S; Nogata, R; Ohura, K; Soejima, T, 2012
)
0.38
"  Ritonavir dramatically increases the bioavailability of a variety of concurrently administered drugs by inhibition of metabolic enzymes and drug transporters."( Analysis of the pharmacokinetic boosting effects of ritonavir on oral bioavailability of drugs in mice.
Banba, H; Takayama, K; Takeda-Morishita, M; Tomaru, A, 2013
)
0.39
" This experimental system is useful for clarifying the cause of low bioavailability of various drugs."( In vivo assessment of the impact of efflux transporter on oral drug absorption using portal vein-cannulated rats.
Hashimoto, T; Konno, Y; Matsuda, Y; Nagai, M; Satsukawa, M; Taguchi, T; Yamashita, S, 2013
)
0.39
" To increase oral bioavailability of carboxylic acid 9, two different prodrug approaches were applied."( Synthesis and pharmacological properties of a new hydrophilic and orally bioavailable 5-HT4 antagonist.
Andressen, KW; Brudeli, B; Klaveness, J; Levy, FO; Moltzau, LR; Nguyen, CH; Nilsen, NO, 2013
)
0.39
"Fexofenadine hydrochloride (FXD) is a slightly soluble, bitter-tasting, drug having an oral bioavailability of 35%."( Phenylalanine-free taste-masked orodispersible tablets of fexofenadine hydrochloride: development, in vitro evaluation and in vivo estimation of the drug pharmacokinetics in healthy human volunteers.
El-Ridi, MS; El-Sherif, NG; Tadros, MI; Yehia, SA, 2015
)
0.42
"OATP2B1-mediated grapefruit juice (GFJ)-drug interactions are substrate-dependent; for example, GFJ ingestion significantly reduces bioavailability of fexofenadine, but not pravastatin."( Substrate- and dose-dependent drug interactions with grapefruit juice caused by multiple binding sites on OATP2B1.
Mori, T; Murata, Y; Nakanishi, T; Shirasaka, Y; Tamai, I, 2014
)
0.4
"Diosmin is a natural flavone glycoside, a potent P-glycoprotein (P-gp) inhibitor in cultured cells and have the potential to alter the bioavailability of P-gp substrate drugs."( Effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine in rats.
Bedada, SK; Neerati, P, 2015
)
0.42
"Diosmin significantly enhanced the oral bioavailability of fexofenadine by the inhibition of P-gp mediated drug efflux during the intestinal absorption."( Effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine in rats.
Bedada, SK; Neerati, P, 2015
)
0.42
"5 mg/kg dose) showed that the relative bioavailability of drug from P407/C934P gel was 11."( Carbopol-incorporated thermoreversible gel for intranasal drug delivery.
Balakrishnan, P; Cho, HJ; Hahn, TW; Ko, HJ; Park, EK; Song, CK; Song, KW, 2015
)
0.42
" The intestinal absorption rate for each drug was acquired by deconvolution, using historical intravenous data as reference, and used with the intestinal surface area and the dose remaining in the lumen to estimate the Peff."( Human in vivo regional intestinal permeability: quantitation using site-specific drug absorption data.
Dahlgren, D; Lennernäs, H; Roos, C; Sjögren, E, 2015
)
0.42
" FXD contains a carboxyl group and is poorly absorbed because of low membrane permeability and efflux by P-glycoprotein (P-gp)."( Design of Fexofenadine Prodrugs Based on Tissue-Specific Esterase Activity and Their Dissimilar Recognition by P-Glycoprotein.
Imai, T; Kotani, S; Nakada, Y; Ohura, K, 2015
)
0.42
"Attempts to formulate acyclovir to improve its bioavailability and reduce the frequency of dosing from the present q4h have not materialized."( The Interesting Case of Acyclovir Delivered Using Chitosan in Humans: Is it a Drug Issue or Formulation Issue?
Srinivas, NR, 2016
)
0.43
" Similarly absorption rate constant (Ka), fraction absorbed (Fab) and effective permeability (Peff) of FEX were increased significantly in ileum of RSV and VER pretreated groups when compared to FEX alone group."( Effect of resveratrol on the pharmacokinetics of fexofenadine in rats: Involvement of P-glycoprotein inhibition.
Bedada, SK; Neerati, P; Yellu, NR, 2016
)
0.43
"The results suggest that altered pharmacokinetics and enhanced bioavailability of FEX might be attributed to PIP-mediated inhibition of P-gp drug efflux."( The influence of piperine on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers.
Bedada, SK; Boga, PK, 2017
)
0.46
"Capsaicin is the main pungent principle present in chili peppers has been found to possess P-glycoprotein (P-gp) inhibition activity in vitro, which may have the potential to modulate bioavailability of P-gp substrates."( Capsaicin pretreatment enhanced the bioavailability of fexofenadine in rats by P-glycoprotein modulation: in vitro, in situ and in vivo evaluation.
Appani, R; Bedada, SK; Boga, PK, 2017
)
0.46
"Capsaicin pretreatment significantly enhanced the intestinal absorption and bioavailability of fexofenadine in rats likely by inhibition of P-gp mediated cellular efflux, suggesting that the combined use of capsaicin with P-gp substrates may require close monitoring for potential drug interactions."( Capsaicin pretreatment enhanced the bioavailability of fexofenadine in rats by P-glycoprotein modulation: in vitro, in situ and in vivo evaluation.
Appani, R; Bedada, SK; Boga, PK, 2017
)
0.46
" Oral area under the plasma concentration-time curve (AUC) and bioavailability of well known BCRP (sulfasalazine and rosuvastatin), P-glycoprotein (fexofenadine, aliskiren, and talinolol), and CYP3A (midazolam) substrates were investigated in the presence and absence of inhibitors."( Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys.
Abe, K; Ando, O; Imaoka, T; Karibe, T, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" In drug discovery research, using human IECs to evaluate membrane permeability and metabolic stability can offer very useful information when exploring for drug candidate compounds that have good bioavailability and when trying to predict the fraction absorbed and intestinal availability in humans."( Generation of intestinal organoids derived from human pluripotent stem cells for drug testing.
Kawachi, T; Kume, S; Miwa, H; Takahashi, K; Yoshida, S, 2020
)
0.56
"Alogliptin (ALG), an inhibitor of dipeptidylpeptidase-4, is used in the management of type 2 diabetes mellitus, and has a high absorption rate (>60-71%), despite its low lipophilicity (logP=-1."( Intestinal Absorption of Alogliptin Is Mediated by a Fruit-Juice-Sensitive Transporter.
Abe, M; Ishii, M; Kikuchi, T; Morimoto, K; Ogihara, T; Oikawa, E; Sasaki, M; Tomita, M, 2021
)
0.62
"The aim of this work was to probe cubosomes for enhanced intestinal absorption and oral bioavailability of poorly absorbable fexofenadine HCl (FEX-HCl)."( Cubosomes for Enhancing Intestinal Absorption of Fexofenadine Hydrochloride: In situ and in vivo Investigation.
Ashmawy, SM; El Maghraby, GM; El Nashar, NF; Sultan, AA, 2022
)
0.72
"An early prediction of solubility in physiological media (PBS, SGF and SIF) is useful to predict qualitatively bioavailability and absorption of lead candidates."( Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
Bharate, SS; Vishwakarma, RA, 2015
)
0.42
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Desorption electrospray ionization (DESI) mass spectrometry (MS) imaging was used to image locusts dosed with the antihistamine drug terfenadine. The effectiveness of chronic dosing with temelastine (SK&F 93944) 75 mg twice daily compared with placebo was assessed using non-invasive objective assessment techniques.

ExcerptRelevanceReference
"In a three-way, double-blind, crossover study the onset of action and effects at the end of the dosing interval of 10 mg/day astemizole, 10 mg/day loratadine and 120 mg/day terfenadine forte given for 3 days to six atopic volunteers were assessed using the Vienna challenge chamber (VCC)."( Onset and duration of the effects of three antihistamines in current use--astemizole, loratadine and terfenadine forte--studied during prolonged, controlled allergen challenges in volunteers.
Berger, U; Horak, F; Jäger, S, 1992
)
0.69
" Recommended dosage of loratadine (CAS 79794-75-5) is 10 mg once daily, whereas terfenadine (CAS 50679-08-8) until recently has been recommended as 60 mg twice daily."( Comparison of loratadine and terfenadine in allergic seasonal rhinoconjunctivitis with emphasis on nasal stuffiness and peak flow.
Hindberg Rasmussen, W; Høi, L; Lorentzen, KA; Nüchel Petersen, L; Olsen, OT; Svendsen, UG, 1992
)
0.8
" A definite dose-response relationship was demonstrated between the weal and flare areas and the three active treatments."( Dose-response relationship between objective measures of histamine-induced weals and dose of terfenadine.
Lush, M; Marks, R; Newcombe, RG; Shall, L, 1991
)
0.5
" Bedtime dosing of hydroxyzine was investigated as a dosing strategy to minimize reaction time degradation and adverse subjective symptoms previously documented for hydroxyzine in divided doses."( Objective antihistamine side effects are mitigated by evening dosing of hydroxyzine.
Apaliski, SJ; Goetz, DW; Jacobson, JM; Martin, ME; Repperger, DW, 1991
)
0.28
" At the dosage used, cetirizine therapy appears to be no more effective than terfenadine."( A comparison of cetirizine and terfenadine in the management of solar urticaria.
Bilsland, D; Ferguson, J, 1991
)
0.8
" The itch responses provoked by wool fibres were significantly stronger in AD patients than in controls, whereas the histamine-induced dose-response curves for itch did not differ significantly between the two groups, who discriminated equally well between weak and strong histamine stimuli."( Itch and atopic dermatitis: clinical and experimental studies.
Wahlgren, CF, 1991
)
0.28
" When compounds were administered intravenously, at a dosage (1 mg/kg) which fully abolished responses to intravenous histamine, the observed rank order for inhibition of PAF-induced hyperreactivity was: ketotifen greater than cetirizine greater than acrivastine greater than KB-2413 greater than oxatomide greater than azelastine greater than terfenadine = astemizole = clemastine = mepyramine = loratadine = saline."( Histamine(H1) antagonists and airway hyperreactivity in the guinea-pig.
Chapman, ID; Hoshiko, K; Morley, J, 1991
)
0.45
" Analysis of individual results demonstrated a shift toward the right of the dose-response curves to histamine with SK&F 104353 compared to that with placebo in three subjects, whereas the active compound did not exhibit any protective effect against histamine in the remaining nine subjects."( Effects of SK&F 104353, a leukotriene receptor antagonist, on the bronchial responses to histamine in subjects with asthma: a comparative study with terfenadine.
Dinh Xuan, AT; Lockhart, A; Marsac, J; Regnard, J; Rey, J; Similowski, T, 1990
)
0.48
" Further, astemizole has the longest time to relief of symptoms in this class; histamine wheal inhibition is not apparent until the second day of 10 mg dosing and does not peak for 9 to 12 days."( Pharmacology of antihistamines.
Woodward, JK, 1990
)
0.28
" In conclusion, epinastine is one of the most effective peripherally acting H1 antagonist which lacks significant CNS side effects and is suitable as a once daily dosage regimen."( Antihistaminic activity and side effect profile of epinastine and terfenadine in healthy volunteers.
Adamus, WS; Kuthan, H; Schilling, JC, 1990
)
0.52
" Eye discomfort lessened but not to the level experienced by those dosed from the beginning of the season."( Profile of ragweed hay fever symptom control with terfenadine started before or after symptoms are established.
Brooks, CD; Francom, SF; Karl, KJ, 1990
)
0.53
" It is concluded that 10 mg loratadine, administered once daily, controls the symptoms of rhinitis more effectively than 120 mg terfenadine given once daily in the last few hours of the 24 h dosing period."( Comparative efficacy of once daily loratadine versus terfenadine in the treatment of allergic rhinitis.
Banov, CH,
)
0.59
" This was conducted, first as a dose-response study and, second, as a time-course study."( Inhibition of hypertonic saline-induced bronchoconstriction by terfenadine and flurbiprofen. Evidence for the predominant role of histamine.
Finnerty, JP; Holgate, ST; Wilmot, C, 1989
)
0.52
"The objective of this double-blind study, which is part of a multicenter study, was to determine whether terfenadine (120 mg once daily) has similar efficacy and tolerability to the standard dosage of 60 mg twice daily in the treatment of chronic urticaria."( Comparison of efficacy and tolerability of terfenadine administered once daily versus twice daily in patients with chronic idiopathic urticaria.
Köhler, ME; Paul, E; Reinel, D; Ulrich, R, 1989
)
0.75
"The objective of these three double-blind multi-centre studies was to determine whether terfenadine 120 mg once daily has similar efficacy and tolerability as the standard dosage of 60 mg twice daily in the treatment of chronic urticaria."( Terfenadine once daily in chronic urticaria. A multi-centre double-blind comparison of terfenadine once daily versus twice daily.
, 1989
)
1.94
" These effects on exercise-induced bronchospasm followed a dose-response curve; 180 mg had the most significant effect."( Terfenadine blockade of exercise-induced bronchospasm.
Altman, LC; Bierman, CW; Furukawa, CT; Pierson, WE; Shapiro, GG, 1989
)
1.72
" Terfenadine is a widely used nonsedating antihistamine currently approved for use at a dosage of 60 mg every 12 hours."( Evaluation of inhibition of wheal response to histamine by multiple doses of terfenadine.
Ryan, WM, 1989
)
1.42
" Terfenadine, 120 mg once daily, is as effective as the currently approved dosage of 60 mg twice daily in the treatment of seasonal allergic rhinitis, and terfenadine, 120 mg once daily, has the added convenience of allowing the patient once a day dosing."( Once versus twice daily dosing of terfenadine in the treatment of seasonal allergic rhinitis: US and European studies.
Biedermann, AA; Chu, TJ; Goldsobel, AB; Wolfe, JD; Yamate, M, 1989
)
1.47
" With the used study design and dosage slight superiority of Astemizole over Terfenadine could be observed."( [Comparison of astemizole and terfenadine in the treatment of chronic urticaria. A randomized double-blind study of 40 patients].
Bödeker, RH; Paul, E, 1985
)
0.79
" The lack of CNS depression and anticholinergic effects, and the long duration of action that allows twice-a-day dosing make terfenadine an attractive alternative to other antihistamines."( Terfenadine, a nonsedating antihistamine.
Carter, CA; Hayes, JM; Rickman, LA; Skoutakis, VA; Wojciechowski, NJ, 1985
)
1.92
"The dose-response effect of nonsedating H1 histamine-receptor antagonist, terfenadine, administered orally in single doses, was studied on methacholine-induced bronchoconstriction in nine patients with extrinsic bronchial asthma in a double-blind, placebo-controlled, crossover trial."( Effect of terfenadine on methacholine-induced bronchoconstriction in asthma.
Patel, KR, 1987
)
0.91
" Initially the histamine dose-response curves of four subjects were found to be shifted 10-fold to the right by terfenadine 60 mg, given orally."( Effect of an oral H1-receptor antagonist, terfenadine, on antigen-induced asthma.
Chan, TB; Eiser, NM; Shelton, DM, 1986
)
0.75
" The effectiveness of chronic dosing with temelastine (SK&F 93944) 75 mg twice daily and terfenadine 60 mg twice daily compared with placebo in inhibiting the weal and flare response to intradermal histamine was assessed using non-invasive objective assessment techniques."( Non-invasive instrumental techniques to detect terfenadine and temelastine induced suppression of histamine weals in man.
Marks, R; Shall, L, 1987
)
0.75
" For H1-receptor antagonists with long half-life values, steady state may not be reached for several days (chlorpheniramine and brompheniramine) or several weeks (astemizole), and significant accumulation of drug occurs if the dosing interval is more frequent than every half-life."( The comparative pharmacokinetics of H1-receptor antagonists.
Chung, M; Simons, FE; Simons, KJ; Yeh, J, 1987
)
0.27
"012) when the areas under the dose-response curves were compared."( Effect of terfenadine on the bronchoconstriction induced by ultrasonically nebulized distilled water.
Bewtra, AK; Hopp, RJ; Nair, NM; Townley, RG, 1988
)
0.68
" The cumulative results indicate that the nonsedative antihistamine terfenadine, given orally at a dosage of 60 mg twice daily, is effective in the treatment of seasonal allergic rhinitis in both adults and children."( The use of antihistamines for the treatment of airway disease.
Meltzer, EO, 1988
)
0.51
"In this multicentre, double-blind, randomized, parallel group study, 315 patients with allergic or vasomotor rhinitis were treated on a twice daily dosing schedule with either a 60 mg terfenadine-120 mg pseudoephedrine hydrochloride combination or 120 mg pseudoephedrine hydrochloride (extended release) for 2 weeks."( A comparative tolerance study of terfenadine-pseudoephedrine combination tablets and pseudoephedrine tablets in patients with allergic or vasomotor rhinitis.
Ayars, GH; Bernstein, IL; Kemp, JP; Podleski, WK; Prenner, BM; Salzmann, JK; Schoenwetter, WF; Stroh, JE,
)
0.6
" These maximal effects were observed 3 h after atropine dosing for salivary secretion and 1 h for heart rate."( Evaluation of the antimuscarinic activity of atropine, terfenadine and mequitazine in healthy volunteers.
Advenier, C; Beaumont, D; Brion, N, 1988
)
0.52
" A combination of the two drugs both in "standard" and modified dosage resulted in the greatest reduction in the wheal and flare."( Effect of terfenadine and ranitidine on histamine and suxamethonium wheals.
Bödeker, RH; Paul, E; Pfeffer, M, 1988
)
0.68
" None of the terfenadein dosage schedules up to 200 mg tid caused sedation significantly different from that of placebo."( Clinical investigation of terfenadine, a non-sedating antihistamine.
Brandon, ML; Weiner, M, 1980
)
0.56
" In contrast, administration of terfenadine in therapeutic dosage does not result in the occupation of cerebral H1-receptors in the living mouse, as observed for most H1-antihistamines."( Relationship between occupation of cerebral H1-receptors and sedative properties of antihistamines. Assessment in the case of terfenadine.
Llorens, C; Quach, TT; Rose, C; Schwartz, JC, 1982
)
0.75
" None of the terfenadine dosage schedules up to 200 mg 3 times a day caused sedation significantly different from that of placebo or efficacy greater than that seen with 20 mg 3 times a day."( Clinical studies of terfenadine in seasonal allergic rhinitis.
Brandon, ML; Weiner, M, 1982
)
0.96
" With sustained-release antihistamines, early-evening dosage may provide sufficient activity, without sedation, the next day."( Antihistamines and sedation.
Nicholson, AN, 1983
)
0.27
"Comparison of plasma level data obtained from a dose-response study to that of a 14C material balance study indicates that 99."( Pharmacokinetics and biotransformation studies of terfenadine in man.
Garteiz, DA; Hook, RH; Okerholm, RA; Walker, BJ, 1982
)
0.52
" Eight patients with alcohol-induced asthma received terfenadine (60 mg, twice on the test day) or placebo, with the last dosing 2 h before the test in a double-blind, randomized, cross-over manner."( Inhibitory effect of terfenadine, a selective H1 histamine antagonist, on alcoholic beverage-induced bronchoconstriction in asthmatic patients.
Fujimura, M; Matsuda, T; Myou, S; Nishi, K; Ohka, T, 1995
)
0.86
" Assessments were made prior to dosing and at one, three, and five hours after dosing; a 7-hour post-drug assessment was included in the second trial."( Characterization of daytime sleepiness and psychomotor performance following H1 receptor antagonists.
Canestrari, DA; Miller, RD; Riker, DK; Witek, TJ; Yang, JY, 1995
)
0.29
"05) and slower choice reaction times were noted one and three hours after dosing (P < ."( Characterization of daytime sleepiness and psychomotor performance following H1 receptor antagonists.
Canestrari, DA; Miller, RD; Riker, DK; Witek, TJ; Yang, JY, 1995
)
0.29
" Terfenadine, at concentrations achievable at standard dosing regimens, has anti-inflammatory properties in vitro."( Effect of terfenadine on human eosinophil and neutrophil chemotactic response and generation of superoxide.
Eda, R; Hopp, RJ; Townley, RG, 1994
)
1.6
" The lessons learned from the experiences with these drugs hold implications for the future development of agents that prolong the QT interval and suggest the need for dose-response relation data and metabolic evaluations to define the subpopulations at particular risk."( Is QT interval prolongation harmful? A regulatory perspective.
Botstein, P, 1993
)
0.29
" Dosage restriction and awareness of the clinical conditions and drug interactions capable of inhibiting the metabolism of terfenadine are essential for prevention of this serious reaction."( Mechanism of the cardiotoxic actions of terfenadine.
Chen, Y; Freiman, JP; Gillis, RA; Woosley, RL,
)
0.61
" Evaluation criteria were: (a) clinical: signs and symptoms (recorded daily in a diary card by patients); (b) cytological: inflammatory cell count (neutrophils, eosinophils, metachromatic cells) from nasal lavage at T0 and T7; (c) immunocytochemical: ICAM-1/CD54 expression on nasal epithelial cells at T0 and T7; and (d) mediators dosage (ECP-MPO) on nasal lavage at T0 and T7."( Terfenadine exerts antiallergic activity reducing ICAM-1 expression on nasal epithelial cells in patients with pollen allergy.
Canonica, GW; Ciprandi, G; Del Giacco, GS; Pronzato, C; Ricca, V; Varese, P, 1995
)
1.73
" Histamine tests were performed on 10 occasions up to +24 h after dosing using an intradermal injection of histamine 2 micrograms with concommittant contralateral injection of a saline control."( Comparative wheal and flare study of mizolastine vs terfenadine, cetirizine, loratadine and placebo in healthy volunteers.
Cabanis, MJ; Caplain, H; Chaufour, S; Rosenzweig, P; Thebault, JJ; Ulliac, N, 1995
)
0.54
"To investigate the single dose-response effects of grapefruit juice on terfenadine disposition and electrocardiographic measurements."( Grapefruit juice-terfenadine single-dose interaction: magnitude, mechanism, and relevance.
Arnold, MO; Bailey, DG; Bend, JR; Rau, SE; Spence, JD; Tran, LT, 1997
)
0.87
" Epinastine slightly increased the heart rate, but did not affect any of the other ECG parameters even at a plasma concentration of 400 ng mL-1, which is more than 10 times the maximum concentration attained after an ordinary dosage regimen in man."( A comparative pharmacokinetic-pharmacodynamic study of the electrocardiographic effects of epinastine and terfenadine in rats.
Iga, T; Kotaki, H; Ohtani, H; Sawada, Y, 1997
)
0.51
" This report describes the first case of TDP in a healthy patient taking the recommended therapeutic dosage of terfenadine."( Torsades de pointes with terfenadine ingestion.
June, RA; Nasr, I, 1997
)
0.81
" Marked sedation occurred in three of the first 10 subjects treated with topical doxepin, necessitating a reduction in dosage for the remaining six subjects."( The effects of topical doxepin on responses to histamine, substance P and prostaglandin E2 in human skin.
Archer, CB; Kennedy, CT; Sabroe, RA, 1997
)
0.3
"To investigate the clinical efficacy and safety of fexofenadine HCl in the treatment of ragweed seasonal allergic rhinitis and to characterize the dose-response relationship of fexofenadine HCl at dosages of 60, 120, and 240 mg bid."( Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis.
Ahlbrandt, R; Bernstein, DI; Mason, J; Nathan, RA; Schoenwetter, WF; Storms, W, 1997
)
0.3
" Patients were randomized to receive fexofenadine HCl (60, 120, or 240 mg bid) or placebo at 12-hour dosing intervals (7:00 AM and 7:00 PM)."( Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis.
Ahlbrandt, R; Bernstein, DI; Mason, J; Nathan, RA; Schoenwetter, WF; Storms, W, 1997
)
0.3
" Fexofenadine HCl at each dosage provided significant improvement in total symptom score (P < or = ."( Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis.
Ahlbrandt, R; Bernstein, DI; Mason, J; Nathan, RA; Schoenwetter, WF; Storms, W, 1997
)
0.3
" Because there was no additional efficacy at higher dosages, 60 mg bid appears to be the optimal therapeutic dosage for these patients."( Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis.
Ahlbrandt, R; Bernstein, DI; Mason, J; Nathan, RA; Schoenwetter, WF; Storms, W, 1997
)
0.3
" On the final day of coadministration, the rate-corrected QT interval (QTc) was unaltered compared with terfenadine dosed alone; maximum QTc values (mean [SEM]) were 404 (4) and 405 (5) msec, respectively."( Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men.
Benincosa, LJ; Etheredge, RC; Everitt, DE; Jorkasky, DK; Martin, DE; Zussman, BD, 1997
)
0.75
"It was concluded that fexofenadine has no effect on performance after being taken in the recommended dosage of 60 mg twice daily."( Fexofenadine's effects, alone and with alcohol, on actual driving and psychomotor performance.
O'Hanlon, JF; Vermeeren, A, 1998
)
0.3
" Their longer duration of action also enables a more patient-friendly dosing regimen which increases patient compliance."( Pharmacokinetic overview of oral second-generation H1 antihistamines.
Estes, KS; González, MA, 1998
)
0.3
" Blood samples were drawn before terfenadine dosing and at various intervals for 48 hours after dosing to measure plasma concentrations of terfenadine and its acid metabolite."( Effect of venlafaxine on the pharmacokinetics of terfenadine.
Albano, D; Amchin, J; Klockowski, PM; Taylor, KP; Zarycranski, W, 1998
)
0.84
" In addition, fexofenadine hydrochloride showed significant antihistaminic activity and dose-proportional pharmacokinetics over a wide dosing range."( Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers.
Russell, T; Stoltz, M; Weir, S, 1998
)
0.3
" Unlike other reported ion-pair techniques, the suggested methods have the advantage of being applicable for the determination of the three drugs in their pharmaceutical dosage forms without prior extraction."( Determination of astemizole, terfenadine and flunarizine hydrochloride by ternary complex formation with eosin and lead(II).
Abdel-Fattah, L; Bebawy, LI; Kelani, K, 1999
)
0.59
" Twelve-lead electrocardiographic data were collected once before and after dosing or serially throughout these studies."( Cardiovascular safety of fexofenadine HCl.
Ahlbrandt, R; Mason, J; Pratt, CM; Reynolds, R; Russell, T, 1999
)
0.3
"Fexofenadine HCl (Allegra, Telfast) is approved in the US for twice-daily dosing in the treatment of seasonal allergic rhinitis (SAR)."( Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis.
Andrade, C; Casale, TB; Qu, R,
)
0.13
") after dosing to steady-state (6."( Cardiovascular safety of fexofenadine HCl.
Ahlbrandt, R; Brown, AM; Mason, J; Pratt, C; Rampe, D; Reynolds, R; Russell, T, 1999
)
0.3
"Fexofenadine HCl (Allegra, Telfast) is approved in the US for twice-daily dosing for treatment of seasonal allergic rhinitis."( Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis.
Casale, TB; Meltzer, EO; Nathan, RA; Thompson, AK, 1999
)
0.3
" In addition, assessment was made immediately before dosing in the morning for the previous 30 minutes."( Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis.
Bousquet, J; Howarth, PH; Reynolds, R; Roi, L; Stern, MA, 1999
)
0.3
" Efficacy was maintained for the entire dosing interval (ie, for 24 hours)."( Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis.
Bousquet, J; Howarth, PH; Reynolds, R; Roi, L; Stern, MA, 1999
)
0.3
"The terfenadine-pseudoephedrine dosage form discussed here is the sustained-release core tablet composed of outer (fast-release) and inner (sustained-release) layers."( Development of terfenadine-pseudoephedrine double-layer tablet dissolution-equivalent to core tablet.
Choi, HG; Kim, CK; Yong, C, 2000
)
1.22
" Based on this fact, a spectrophotometric method was developed for the determination of terfenadine in dosage forms."( Use of mixed anhydrides for the determination of terfenadine in dosage forms and spiked human plasma.
Al-Majed, AA; Al-Zehouri, J; Belal, F, 2000
)
0.78
" Fexofenadine given in the conventional dosage can prevent recurrences and represents a successful treatment measure when dealing with this peculiar form of solar urticaria."( Fixed solar urticaria to visible light successfully treated with fexofenadine.
Bazex, J; Journé, F; Loche, E; Marguery, MC; Schwarze, HP, 2001
)
0.31
" QTc prolongation (mean value over the dosing interval) was the pharmacodynamic parameter measured."( Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation.
Abernethy, DR; Barbey, JT; Brown, KS; Feirrera, I; Ford, N; Franc, J; Salazar, DE, 2001
)
0.66
" In the present study, we investigated the dose-response relationship of different antihistamines on the performance in a reaction-time task that has been developed for rats."( Dissociable effects of histamine H1 antagonists on reaction-time performance in rats.
Blokland, A; Ramaekers, J; Scholtissen, B; Vermeeren, A,
)
0.13
"Subjects evaluated at a referral medical center were placed on traditional dosing of fexofenadine at 60 mg, twice daily, or placebo in a double-blind, crossover fashion for 1 week before the nasal challenge."( Evaluation of cytokines in nasal secretions after nasal antigen challenge: lack of influence of antihistamines.
Bensch, GW; Borish, LC; Nelson, HS, 2002
)
0.31
" Before dosing and at 1, 3, 6, 9, and 24 hours after the first antihistamine dose as well as at 168, 192, and 216 hours after the first dose (ie, 12, 36, and 60 hours after the seventh and last consecutive daily H(1)-antihistamine dose), we measured fexofenadine, loratadine, or chlorpheniramine concentrations in plasma and in skin tissue samples obtained through use of punch biopsies, along with suppression of histamine-induced skin wheals and flares."( Clinical pharmacology of H1-antihistamines in the skin.
Gu, X; Silver, NA; Simons, FE; Simons, KJ, 2002
)
0.31
" In conclusion, this study shows that, at the end of the conventional dosing interval, ebastine 10 mg and cetirizine 10 mg once daily in repeated doses suppressed the histamine wheal more effectively than did loratadine 10 mg once daily or fexofenadine 60 mg twice daily."( Inhibition of the histamine wheal by ebastine compared with cetirizine, fexofenadine and loratadine at steady state.
Boyce, M; Carey, W; Luria, X; Warrington, S, 2002
)
0.31
") to be more effective overall than the regimen containing the highest fexo-fenadine dosage (with nedocromil as rescue only)."( Supplementation of fexofenadine therapy with nedocromil sodium 2% ophthalmic solution to treat ocular symptoms of seasonal allergic conjunctivitis.
Alexander, M; Allegro, S; Hicks, A; Patel, P, 2003
)
0.32
"Supplementation of oral fexofenadine therapy with nedocromil sodium 2% ophthalmic solution relieves ocular symptoms of seasonal allergic rhinoconjunctivitis, allowing control of rhinal symptoms with half the recommended dosage of fexofenadine."( Supplementation of fexofenadine therapy with nedocromil sodium 2% ophthalmic solution to treat ocular symptoms of seasonal allergic conjunctivitis.
Alexander, M; Allegro, S; Hicks, A; Patel, P, 2003
)
0.32
" Onset of flare suppression occurred 2 hours after dosing with fexofenadine and 4 hours after dosing with loratadine."( Relative potency of fexofenadine HCl 180 mg, loratadine 10 mg, and placebo using a skin test model of wheal-and-flare suppression.
Christian, CD; Crisalida, T; Economides, A; Georges, GC; Hale, M; Kaliner, MA; Liao, Y; Meeves, SG; White, MV; Woodworth, TH, 2003
)
0.32
"The anti-inflammatory effects of repeated dosing with mediator antagonists as add-on therapy to that with inhaled corticosteroids (ICSs) in patients with asthma remain to be fully established."( Repeated dosing effects of mediator antagonists in inhaled corticosteroid-treated atopic asthmatic patients.
Haggart, K; Jackson, CM; Lee, DK; Lipworth, BJ, 2004
)
0.32
"We elected to evaluate the effects of repeated dosing with fexofenadine (FEX) and montelukast (ML) at clinically recommended doses in ICS-treated asthmatic patients using adenosine monophosphate (AMP) bronchial challenge as the primary outcome."( Repeated dosing effects of mediator antagonists in inhaled corticosteroid-treated atopic asthmatic patients.
Haggart, K; Jackson, CM; Lee, DK; Lipworth, BJ, 2004
)
0.32
"Repeated dosing with FEX and ML as add-on therapy improved AMP PC(20) and other surrogate inflammatory markers along with asthma diary outcomes in ICS-treated atopic asthmatic patients."( Repeated dosing effects of mediator antagonists in inhaled corticosteroid-treated atopic asthmatic patients.
Haggart, K; Jackson, CM; Lee, DK; Lipworth, BJ, 2004
)
0.32
" Although widely used in the treatment of allergic diseases, fexofenadine is not listed in any pharmacopeia, and there are few methods in the literature for its quantitation in pharmaceutical dosage forms."( Development and validation of a liquid chromatographic method for fexofenadine hydrochloride in capsules.
Breier, AR; Menegola, J; Paim, CS; Schapoval, EE; Steppe, M,
)
0.13
" The trials were designed as crossover studies in 18 subjects comprising various potential dosing regimens with and without weight stratification."( The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride.
Jensen, BK; Kittner, B; Krishna, R; Krishnaswami, S; Sankoh, AJ, 2004
)
0.32
" A dosing regimen was identified in which fexofenadine disposition was not affected by alfentanil."( Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination.
Hoffer, C; Kharasch, ED; Sheffels, P; Walker, A, 2005
)
0.33
"Pharmacokinetic parameters AUC0-infinity1 and Cmax1 following a single-dose (Day 1, dose 1), Cmax7, AUC0-24(7) at steady-state and Cmin7 measured at the end of the dosing interval (Day 9, dose 7) revealed bioequivalence between FEX 180 mg/PSE 240 mg combination tablet and the individual components taken concurrently."( Single-dose and steady-state bioequivalence of fexofenadine and pseudoephedrine combination tablets compared with individual formulations in healthy adults.
Agrawala, P; Haribhakti, R; Howard, DR; Kittner, B, 2005
)
0.33
"To evaluate the efficacy and safety of once-daily dosing of fexofenadine hydrochloride, 180 mg, on CIU."( Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study.
Georges, G; Kaplan, AP; Liao, Y; Meeves, S; Spector, SL; Varghese, ST, 2005
)
0.33
" The best dissolution conditions tested, for the products in each respective pharmaceutical dosage form were applied to evaluate the dissolution profiles."( Development and validation of dissolution tests for fexofenadine hydrochloride capsules and coated tablets.
Breier, AR; Paim, CS; Schapoval, EE; Steppe, M, 2005
)
0.33
"A single dose of fexofenadine hydrochloride (60 mg as solution) was applied under fasting conditions, either alone or directly after a solution of erythromycin lactobionate (corresponding to a dose of 250 mg erythromycin), to the jejunum, ileum and colon in 6 healthy volunteers (3 male and 3 female) using a regional intubation dosing technology (Bioperm AB, Lund, Sweden)."( Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers.
Bondesson, U; Borga, O; Hedeland, M; Lennernas, H; Nyberg, L; Petri, N, 2006
)
0.33
"00105) and 10-day dosing (102 +/- 40 L/h, P = ."( The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.
Gorski, JC; Hall, SD; Hamman, MA; Lemma, GL; Wang, Z; Zaheer, NA, 2006
)
0.33
" In addition, small tablet size and once-daily dosing may provide patients with increased convenience and improve adherence."( Once-daily immediate-release fexofenadine and sustained-release pseudoephedrine combination: a new treatment option for allergic rhinitis.
Mansfield, LE, 2006
)
0.33
" She subsequently received maintenance dosing in the outpatient clinic weekly for 4 weeks and bimonthly for 8 weeks, and she continues monthly maintenance VIT."( Ultrarush venom desensitization after systemic reactions during conventional venom immunotherapy.
Chegini, S; Hamilos, DL; Oren, E, 2006
)
0.33
"A simple RP-HPLC method using a PDA detector was developed and validated for the analysis and dissolution studies of fexofenadine hydrochloride (FEX) in dosage forms."( Simple and reliable HPLC analysis of fexofenadine hydrochloride in tablets and its application to dissolution studies.
Oliveira, DC; Rolim, CM; Weigch, A, 2007
)
0.34
"The objective of the current study was to develop a simple, accurate, precise and rapid reversed-phase HPLC method and subsequent validation using ICH suggested approach for the determination of antihistaminic-decongestant pharmaceutical dosage forms containing binary mixtures of pseudoephedrine hydrochloride (PSE) with fexofenadine hydrochloride (FEX) or cetirizine dihydrochloride (CET)."( Development and validation of a rapid RP-HPLC method for the determination of cetirizine or fexofenadine with pseudoephedrine in binary pharmaceutical dosage forms.
Karakuş, S; Küçükgüzel, I; Küçükgüzel, SG, 2008
)
0.35
" No significant change in latency for REM sleep or percentage REM sleep after dosing with fexofenadine was observed."( The effects of fexofenadine at steady-state on sleep architecture: a study using polysomnography in healthy Korean volunteers.
Ahn, JH; Kim, JE; Kim, MJ; Kim, SD; Lee, HW; Moon, SO; Park, DJ; Yoon, YR, 2008
)
0.35
" Ketoconazole strongly inhibited CYP3A4-mediated terfenadine metabolism in vitro, and the method predicted 6- to 37-fold increase of terfenadine AUC by the concomitant dosing of ketoconazole, which reasonably well agreed with the observed 13- to 59-fold increase of AUC in clinical studies."( A novel approach to the prediction of drug-drug interactions in humans based on the serum incubation method.
Chiba, M; Ishii, Y; Shibata, Y; Takahashi, H, 2008
)
0.6
" In a randomized, two-phase, crossover design, verapamil was dosed 80 mg three times daily (with total daily doses of 240 mg) for 6 days, and on day 6, a single 120-mg dose of fexofenadine was administered along with an 80-mg dose of verapamil."( Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil.
Hokama, N; Miura, M; Sakugawa, T; Suzuki, T; Tateishi, T; Uno, T, 2009
)
0.35
" In the treatment phase, carbamazepine was dosed 100 mg three times daily (for a total daily dose of 300 mg) for 7 days, and on Day 7, a single 60-mg dose of fexofenadine was coadministered with a 100-mg dose of carbamazepine."( Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics.
Akamine, Y; Kaneko, S; Uno, T; Yamada, S; Yasui-Furukori, N, 2009
)
0.35
" Alternative dosage forms such as liquids or oral disintegrating tablets are available for most agents, allowing ease of administration to most young children and infants; however, limited data are available regarding use in infants for most agents, except desloratadine, cetirizine and montelukast."( Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast.
Moeller, ML; Nahata, MC; Phan, H, 2009
)
0.35
" Thus, the proposed method is suitable for the simultaneous analysis of active ingredients in tablet dosage forms and human serum."( Simultaneous determination of gliquidone, fexofenadine, buclizine, and levocetirizine in dosage formulation and human serum by RP-HPLC.
Arayne, MS; Mirza, AZ; Siddiqui, FA; Sultana, N,
)
0.13
" These results suggested the feasibility that thermosensitive gels could be used as an effective dosage form to enhance the nasal absorption of FXD HCl."( Poloxamer/cyclodextrin/chitosan-based thermoreversible gel for intranasal delivery of fexofenadine hydrochloride.
Balakrishnan, P; Cho, HJ; Chung, SJ; Hong, SS; Jang, TY; Kim, DD; Kim, KS; Park, EK; Shim, CK; Song, KW, 2011
)
0.37
"After the dosing of an extended-release (ER) formulation, compounds may exist in solutions at various concentrations in the colon because the drugs are released at various speeds from the ER dosage form."( The relationship between the drug concentration profiles in plasma and the drug doses in the colon.
Hosoi, Y; Kanamaru, T; Konno, T; Nakagami, H; Tajiri, S; Yada, S; Yoshida, K, 2010
)
0.36
" A dosage of 1 nM tended to shorten action potential duration (APD60) (-30 ± 30."( Drug-induced QTC prolongation dangerously underestimates proarrhythmic potential: lessons from terfenadine.
De Clerck, F; Dujardin, K; Dumotier, B; Hoffmann, P; Hondeghem, LM, 2011
)
0.59
" Three drugs (celiprolol, fexofenadine, and atenolol) were orally administered as a cassette dosing following the MD (totally 97."( Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose.
Chiyoda, T; Doi, Y; Hirota, T; Ieiri, I; Irie, S; Iwasaki, K; Kimura, M; Maeda, K; Miyagawa, M; Sasaki, T; Sugiyama, Y, 2012
)
0.38
" Micro/small dosing is useful for examining the mechanism of drug interactions without safety concern."( Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs.
Ando, Y; Deguchi, M; Hirota, T; Ieiri, I; Irie, S; Izumi, N; Kanda, E; Kimura, M; Kotani, N; Kusuhara, H; Maeda, K; Matsuguma, K; Matsuki, S; Morishita, M; Okuzono, T; Sugiyama, Y; Tsunemitsu, S; Yamane, N, 2013
)
0.39
" A rapid, simple, selective and precise densitometric method was developed and validated for simultaneous estimation of six synthetic binary mixtures and their pharmaceutical dosage forms."( Thin layer chromatography-densitometric determination of some non-sedating antihistamines in combination with pseudoephedrine or acetaminophen in synthetic mixtures and in pharmaceutical formulations.
Atia, NN; El-Gizawy, SM; El-Kommos, ME; Hosny, NM, 2014
)
0.4
"05), but also increased the cumulative dosage of aconitine required to induce various arrhythmias (all P<0."( Comparative study of the protective effects of terfenadine and amiodarone on barium chloride/aconitine-induced ventricular arrhythmias in rats: a potential role of terfenadine.
Li, S; Liu, B; Su, Y; Xiong, M; Xu, Y, 2014
)
0.66
"Desorption electrospray ionization (DESI) mass spectrometry (MS) imaging was used to image locusts dosed with the antihistamine drug terfenadine."( Distribution of terfenadine and its metabolites in locusts studied by desorption electrospray ionization mass spectrometry imaging.
Hansen, SH; Janfelt, C; Olsen, LR, 2015
)
0.97
" Co-administration of diosmin with fexofenadine can reduce the dosage and results in reduced side effects of fexofenadine."( Effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine in rats.
Bedada, SK; Neerati, P, 2015
)
0.42
" These findings suggested that developed thermoreversible gels could be used as promising dosage forms to improve intranasal drug absorption."( Carbopol-incorporated thermoreversible gel for intranasal drug delivery.
Balakrishnan, P; Cho, HJ; Hahn, TW; Ko, HJ; Park, EK; Song, CK; Song, KW, 2015
)
0.42
"Attempts to formulate acyclovir to improve its bioavailability and reduce the frequency of dosing from the present q4h have not materialized."( The Interesting Case of Acyclovir Delivered Using Chitosan in Humans: Is it a Drug Issue or Formulation Issue?
Srinivas, NR, 2016
)
0.43
" If one examines the pharmacokinetic disposition of acyclovir, it is clear that renal elimination is so rapid necessitating frequent dosing of acyclovir."( The Interesting Case of Acyclovir Delivered Using Chitosan in Humans: Is it a Drug Issue or Formulation Issue?
Srinivas, NR, 2016
)
0.43
" Male rats were dosed orally with garlic (120 mg/kg), ginkgo (17 mg/kg), St."( Effect of Garlic, Gingko, and St. John's Wort Extracts on the Pharmacokinetics of Fexofenadine: A Mechanistic Study.
Gerber, JP; Milne, RW; Turkanovic, J; Ward, MB, 2017
)
0.46
" In cases of failure, treatment was switched to omalizumab at doses of < 300 mg/month with incremental dosage increases as necessary (monthly dose range, 150-600 mg/month)."( Real-life experience in the treatment of solar urticaria: retrospective cohort study.
Enk, CD; Hodak, E; Lapidoth, M; Levi, A; Mazor, S; Snast, I; Uvaidov, V, 2019
)
0.51
" QTc prolongation was observed in the marmosets dosed with sotalol, astemizole, flecainide, quinidine, verapamil and terfenadine."( Telemetered common marmosets is useful for the assessment of electrocardiogram parameters changes induced by multiple cardiac ion channel inhibitors.
Hinoi, E; Miyawaki, I; Tsubouchi, T; Watanabe, K; Yamada, T, 2019
)
0.72
" This article exemplifies the reported analytical methods like electrometric methods, ultraviolet spectroscopy, mass spectroscopy, thin layer chromatography, high performance liquid chromatography, high performance thin layer chromatography and tandem spectroscopy for determination of fexofenadine HCl and montelukast sodium in dosage form and in biological matrices."( A Review of Different Analytical Techniques for Fexofenadine Hydrochloride and Montelukast Sodium in Different Matrices.
Kumar, V; Nalini, CN, 2021
)
0.62
"Drug dosing is challenging in patients with end-stage renal disease."( Chronic Inhibition of CYP3A is Temporarily Reduced by Each Hemodialysis Session in Patients With End-Stage Renal Disease.
Åsberg, A; Christensen, H; Egeland, EJ; Robertsen, I; Witczak, BJ; Zaré, HK, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diarylmethaneAny compound containing two aryl groups connected by a single C atom.
diarylmethaneAny compound containing two aryl groups connected by a single C atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Terfenadine H1-Antihistamine Action87

Protein Targets (131)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency28.18385.623417.292931.6228AID2323
endonuclease IVEscherichia coliPotency1.25890.707912.432431.6228AID1708
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency26.83253.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency12.38450.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency26.83250.173734.304761.8120AID1346859
ATAD5 protein, partialHomo sapiens (human)Potency26.35580.004110.890331.5287AID493106; AID493107; AID504466; AID504467
USP1 protein, partialHomo sapiens (human)Potency38.94480.031637.5844354.8130AID504865
SMAD family member 3Homo sapiens (human)Potency26.83250.173734.304761.8120AID1346859
TDP1 proteinHomo sapiens (human)Potency3.67880.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency11.23710.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency5.05610.180013.557439.8107AID1460; AID1468
ThrombopoietinHomo sapiens (human)Potency2.51190.02517.304831.6228AID917; AID918
AR proteinHomo sapiens (human)Potency19.40160.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743054; AID743063
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency11.88320.013326.981070.7614AID1346978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency0.00070.011212.4002100.0000AID1030
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency33.49150.000657.913322,387.1992AID1259377
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency23.29460.001022.650876.6163AID1224838; AID1224839; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.73770.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency19.39900.000214.376460.0339AID720691; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency9.04440.003041.611522,387.1992AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency4.36590.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency19.86930.001530.607315,848.9004AID1224819; AID1224820; AID1224821; AID1224823; AID1224841; AID1224842; AID1224848; AID1224849; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency11.88230.375827.485161.6524AID743217
estrogen nuclear receptor alphaHomo sapiens (human)Potency26.07970.000229.305416,493.5996AID1259244; AID743075; AID743077; AID743080; AID743091
cytochrome P450 2D6Homo sapiens (human)Potency0.27540.00108.379861.1304AID1645840
67.9K proteinVaccinia virusPotency11.90470.00018.4406100.0000AID720579; AID720580
glucocerebrosidaseHomo sapiens (human)Potency31.62280.01268.156944.6684AID2101
ParkinHomo sapiens (human)Potency29.09290.819914.830644.6684AID720573
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency9.03130.001024.504861.6448AID743212; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency26.66000.001019.414170.9645AID743094; AID743140; AID743191
arylsulfatase AHomo sapiens (human)Potency37.93301.069113.955137.9330AID720538
caspase-3Homo sapiens (human)Potency11.88320.013326.981070.7614AID1346978
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency30.25770.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency24.70120.016525.307841.3999AID504836; AID602332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency29.84930.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency18.15710.001628.015177.1139AID1224843; AID1224895; AID1259385; AID1259395
activating transcription factor 6Homo sapiens (human)Potency27.90280.143427.612159.8106AID1159516; AID1159519
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency24.490119.739145.978464.9432AID1159509; AID1159518
Histone H2A.xCricetulus griseus (Chinese hamster)Potency21.97410.039147.5451146.8240AID1224845; AID1224896
Caspase-7Cricetulus griseus (Chinese hamster)Potency13.33320.006723.496068.5896AID1346980
Bloom syndrome protein isoform 1Homo sapiens (human)Potency44.66840.540617.639296.1227AID2364; AID2528
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency56.23410.036619.637650.1187AID1466; AID2242
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency91.99970.01262.451825.0177AID485313
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency84.921423.934123.934123.9341AID1967
D(1A) dopamine receptorHomo sapiens (human)Potency10.82670.02245.944922.3872AID488982; AID488983
atrial natriuretic peptide receptor 1 precursorHomo sapiens (human)Potency37.93300.134610.395030.1313AID1347049
chromobox protein homolog 1Homo sapiens (human)Potency39.81070.006026.168889.1251AID488953
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency0.32460.01789.637444.6684AID588834
caspase-3Cricetulus griseus (Chinese hamster)Potency13.33320.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency5.09340.000323.4451159.6830AID743065; AID743067
histone deacetylase 9 isoform 3Homo sapiens (human)Potency3.75780.037617.082361.1927AID1259364
heat shock protein beta-1Homo sapiens (human)Potency33.48890.042027.378961.6448AID743210; AID743228
huntingtin isoform 2Homo sapiens (human)Potency17.91110.000618.41981,122.0200AID1688
ras-related protein Rab-9AHomo sapiens (human)Potency58.04790.00022.621531.4954AID485297
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency16.90710.00378.618923.2809AID2660; AID2666; AID2667; AID2668
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency16.50610.000627.21521,122.0200AID743202; AID743219
DNA polymerase eta isoform 1Homo sapiens (human)Potency22.38720.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency17.78280.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency20.89550.00798.23321,122.0200AID2546
gemininHomo sapiens (human)Potency11.55290.004611.374133.4983AID463097; AID624296
DNA polymerase kappa isoform 1Homo sapiens (human)Potency21.19230.031622.3146100.0000AID588579
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency40.53340.005612.367736.1254AID624032
M-phase phosphoprotein 8Homo sapiens (human)Potency56.23410.177824.735279.4328AID488949
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency9.58170.00106.000935.4813AID943; AID944
lamin isoform A-delta10Homo sapiens (human)Potency8.42440.891312.067628.1838AID1459; AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency12.58930.015812.3113615.5000AID1461
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency33.49150.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency0.01330.00339.158239.8107AID1347407
Cellular tumor antigen p53Homo sapiens (human)Potency32.58100.002319.595674.0614AID651631; AID720552
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency56.23413.548118.039535.4813AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency56.23413.548118.039535.4813AID1466
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency33.49150.001551.739315,848.9004AID1259244
D(1A) dopamine receptorSus scrofa (pig)Potency18.49270.00378.108123.2809AID2667
Ataxin-2Homo sapiens (human)Potency14.12540.011912.222168.7989AID588378
Chain A, HADH2 proteinHomo sapiens (human)Potency3.16230.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency3.16230.025120.237639.8107AID886
thioredoxin reductaseRattus norvegicus (Norway rat)Potency89.12510.100020.879379.4328AID588453
15-lipoxygenase, partialHomo sapiens (human)Potency19.95260.012610.691788.5700AID887
TDP1 proteinHomo sapiens (human)Potency2.90930.000811.382244.6684AID686979
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency7.94210.001022.650876.6163AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency33.49150.003041.611522,387.1992AID1159552
estrogen nuclear receptor alphaHomo sapiens (human)Potency15.08900.000229.305416,493.5996AID743069
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency31.61550.000627.21521,122.0200AID743219
gemininHomo sapiens (human)Potency1.83560.004611.374133.4983AID624297
lamin isoform A-delta10Homo sapiens (human)Potency0.25120.891312.067628.1838AID1487
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency6.30960.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
XBP1Homo sapiens (human)IC50 (µMol)5.14000.16005.404910.0000AID504313
ubiquitin-conjugating enzyme E2 NHomo sapiens (human)IC50 (µMol)20.00000.873010.721978.4000AID493155
DNA damage-inducible transcript 3 proteinMus musculus (house mouse)IC50 (µMol)4.12000.16003.995910.0000AID504322
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)IC50 (µMol)0.93000.00032.63119.0000AID1207776
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)IC50 (µMol)1.23100.00011.00768.7800AID625218
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)Ki0.64500.00000.887110.0000AID625218
Bile salt export pumpHomo sapiens (human)IC50 (µMol)75.23500.11007.190310.0000AID1449628; AID1473738
Epidermal growth factor receptorHomo sapiens (human)IC50 (µMol)3.56600.00000.536910.0000AID625184
Tyrosine-protein kinase FynHomo sapiens (human)IC50 (µMol)6.12300.00021.67898.6800AID625185
ATP-dependent translocase ABCB1Mus musculus (house mouse)IC50 (µMol)2.00000.06404.012610.0000AID150754; AID681128
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)1.92800.00041.877310.0000AID625207
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)Ki1.91200.00322.28879.3160AID625207
ATP-dependent translocase ABCB1Homo sapiens (human)IC50 (µMol)1.81670.00022.318510.0000AID150752; AID150755; AID681122; AID681126; AID681127; AID681131
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)0.32000.00011.753610.0000AID54923
DNA gyrase subunit BStaphylococcus aureusIC50 (µMol)190.00000.00401.50207.7000AID1164962
Muscarinic acetylcholine receptor M1Homo sapiens (human)IC50 (µMol)2.90000.00001.403910.0000AID140895
Transcriptional activator protein LuxRAliivibrio fischeriIC50 (µMol)92.00001.36003.25337.0000AID493958
D(2) dopamine receptorHomo sapiens (human)IC50 (µMol)6.16700.00000.74728.0000AID625253
D(2) dopamine receptorHomo sapiens (human)Ki2.05600.00000.651810.0000AID625253
Dipeptidyl peptidase 4Rattus norvegicus (Norway rat)IC50 (µMol)0.35000.00231.21555.0000AID393556
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)2.34000.00021.874210.0000AID35986
Alpha-2C adrenergic receptorHomo sapiens (human)IC50 (µMol)3.74800.00001.47257.8980AID625203
Alpha-2C adrenergic receptorHomo sapiens (human)Ki0.54500.00030.483410.0000AID625203
DRattus norvegicus (Norway rat)IC50 (µMol)0.12880.00030.50267.7625AID243189
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.12880.00031.09147.7625AID243189
DNA gyrase subunit AStaphylococcus aureusIC50 (µMol)190.00000.00401.98397.7000AID1164962
ATP-dependent translocase ABCB1Mus musculus (house mouse)IC50 (µMol)23.00000.20004.713010.0000AID150753; AID681119
Substance-K receptorHomo sapiens (human)IC50 (µMol)2.67700.00013.12109.5530AID625227
Substance-K receptorHomo sapiens (human)Ki0.89200.00011.92429.7930AID625227
D(1A) dopamine receptorHomo sapiens (human)IC50 (µMol)2.67300.00031.84739.2250AID625252
D(1A) dopamine receptorHomo sapiens (human)Ki1.33700.00010.836310.0000AID625252
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.12880.00031.09147.7625AID243189
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.12880.00031.06917.7625AID243189
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)2.34000.00021.270410.0000AID35986
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)1.92800.00081.541620.0000AID625207
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki1.91200.00031.465610.0000AID625207
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)IC50 (µMol)0.12880.00070.97749.7000AID243189
Alpha-1D adrenergic receptorHomo sapiens (human)IC50 (µMol)2.34000.00020.75688.8970AID35986
5-hydroxytryptamine receptor 2AHomo sapiens (human)IC50 (µMol)0.25500.00010.88018.8500AID625192
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki0.07300.00000.385510.0000AID625192
5-hydroxytryptamine receptor 2CHomo sapiens (human)IC50 (µMol)1.23100.00011.03029.0000AID625218
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki0.64500.00010.954910.0000AID625218
Histamine H1 receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.09400.00151.307210.0000AID86582
Alpha-1A adrenergic receptorHomo sapiens (human)IC50 (µMol)2.34000.00020.56145.4000AID35986
Histamine H1 receptorHomo sapiens (human)IC50 (µMol)0.01150.00000.44365.1768AID1202708; AID625269
Histamine H1 receptorHomo sapiens (human)Ki0.03350.00000.511010.0000AID448777; AID625269; AID87692
Alpha-1B adrenergic receptorHomo sapiens (human)IC50 (µMol)2.34000.00020.65268.3300AID35986
D(3) dopamine receptorHomo sapiens (human)IC50 (µMol)1.50300.00011.01788.7960AID625254
D(3) dopamine receptorHomo sapiens (human)Ki0.51100.00000.602010.0000AID625254
5-hydroxytryptamine receptor 2BHomo sapiens (human)IC50 (µMol)0.04800.00011.18738.9125AID625217
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki0.03000.00030.769310.0000AID625217
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)2.34000.00001.819410.0000AID35986
5-hydroxytryptamine receptor 6Homo sapiens (human)IC50 (µMol)1.30600.00170.83815.4200AID625221
5-hydroxytryptamine receptor 6Homo sapiens (human)Ki0.60600.00020.522910.0000AID625221
Cytochrome P450 2J2Homo sapiens (human)IC50 (µMol)8.10000.01202.53129.4700AID264035
C-C chemokine receptor type 5Homo sapiens (human)IC50 (µMol)1.10300.00020.25679.0000AID625239
C-C chemokine receptor type 5Homo sapiens (human)Ki0.85200.00210.23060.8520AID625239
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)IC50 (µMol)0.93000.00032.59559.0000AID1207776
Sodium-dependent dopamine transporter Homo sapiens (human)IC50 (µMol)0.25500.00071.841946.0000AID625256
Sodium-dependent dopamine transporter Homo sapiens (human)Ki0.20300.00021.11158.0280AID625256
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)2.45440.00091.901410.0000AID1164981; AID1207233; AID1483327; AID1572115; AID161281; AID161283; AID161284; AID1649553; AID240820; AID243151; AID243189; AID276169; AID393554; AID393556; AID393558; AID393559; AID397743; AID408340; AID420668; AID448775; AID448776; AID576612; AID661410; AID82355
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)Ki0.15130.00211.840710.0000AID1202709; AID1832389; AID238610
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)IC50 (µMol)0.93000.00032.63119.0000AID1207776
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)IC50 (µMol)1.12500.00032.25459.6000AID1207708; AID1207776
Sodium channel protein type 5 subunit alphaHomo sapiens (human)IC50 (µMol)0.97100.00033.64849.2000AID1207174
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (688)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
detection of light stimulus involved in visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
MAPK cascadeEpidermal growth factor receptorHomo sapiens (human)
ossificationEpidermal growth factor receptorHomo sapiens (human)
embryonic placenta developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein phosphorylationEpidermal growth factor receptorHomo sapiens (human)
hair follicle developmentEpidermal growth factor receptorHomo sapiens (human)
translationEpidermal growth factor receptorHomo sapiens (human)
signal transductionEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
activation of phospholipase C activityEpidermal growth factor receptorHomo sapiens (human)
salivary gland morphogenesisEpidermal growth factor receptorHomo sapiens (human)
midgut developmentEpidermal growth factor receptorHomo sapiens (human)
learning or memoryEpidermal growth factor receptorHomo sapiens (human)
circadian rhythmEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
diterpenoid metabolic processEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
cerebral cortex cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell growthEpidermal growth factor receptorHomo sapiens (human)
lung developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of superoxide anion generationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
response to cobalaminEpidermal growth factor receptorHomo sapiens (human)
response to hydroxyisoflavoneEpidermal growth factor receptorHomo sapiens (human)
cellular response to reactive oxygen speciesEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
ERBB2-EGFR signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of protein catabolic processEpidermal growth factor receptorHomo sapiens (human)
vasodilationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphorylationEpidermal growth factor receptorHomo sapiens (human)
ovulation cycleEpidermal growth factor receptorHomo sapiens (human)
hydrogen peroxide metabolic processEpidermal growth factor receptorHomo sapiens (human)
negative regulation of apoptotic processEpidermal growth factor receptorHomo sapiens (human)
positive regulation of MAP kinase activityEpidermal growth factor receptorHomo sapiens (human)
tongue developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA repairEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA replicationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of bone resorptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of vasoconstrictionEpidermal growth factor receptorHomo sapiens (human)
negative regulation of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEpidermal growth factor receptorHomo sapiens (human)
regulation of JNK cascadeEpidermal growth factor receptorHomo sapiens (human)
symbiont entry into host cellEpidermal growth factor receptorHomo sapiens (human)
protein autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
astrocyte activationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEpidermal growth factor receptorHomo sapiens (human)
digestive tract morphogenesisEpidermal growth factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationEpidermal growth factor receptorHomo sapiens (human)
neuron projection morphogenesisEpidermal growth factor receptorHomo sapiens (human)
epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
protein insertion into membraneEpidermal growth factor receptorHomo sapiens (human)
response to calcium ionEpidermal growth factor receptorHomo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicEpidermal growth factor receptorHomo sapiens (human)
positive regulation of glial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
morphogenesis of an epithelial foldEpidermal growth factor receptorHomo sapiens (human)
eyelid development in camera-type eyeEpidermal growth factor receptorHomo sapiens (human)
response to UV-AEpidermal growth factor receptorHomo sapiens (human)
positive regulation of mucus secretionEpidermal growth factor receptorHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
cellular response to amino acid stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to mechanical stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to cadmium ionEpidermal growth factor receptorHomo sapiens (human)
cellular response to epidermal growth factor stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to estradiol stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to xenobiotic stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to dexamethasone stimulusEpidermal growth factor receptorHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
liver regenerationEpidermal growth factor receptorHomo sapiens (human)
cell-cell adhesionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein kinase C activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of prolactin secretionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of miRNA transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein localization to plasma membraneEpidermal growth factor receptorHomo sapiens (human)
negative regulation of cardiocyte differentiationEpidermal growth factor receptorHomo sapiens (human)
neurogenesisEpidermal growth factor receptorHomo sapiens (human)
multicellular organism developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of kinase activityEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
response to singlet oxygenTyrosine-protein kinase FynHomo sapiens (human)
neuron migrationTyrosine-protein kinase FynHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase FynHomo sapiens (human)
heart processTyrosine-protein kinase FynHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
calcium ion transportTyrosine-protein kinase FynHomo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
axon guidanceTyrosine-protein kinase FynHomo sapiens (human)
learningTyrosine-protein kinase FynHomo sapiens (human)
feeding behaviorTyrosine-protein kinase FynHomo sapiens (human)
regulation of cell shapeTyrosine-protein kinase FynHomo sapiens (human)
gene expressionTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of gene expressionTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of hydrogen peroxide biosynthetic processTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of neuron projection developmentTyrosine-protein kinase FynHomo sapiens (human)
protein ubiquitinationTyrosine-protein kinase FynHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
protein catabolic processTyrosine-protein kinase FynHomo sapiens (human)
forebrain developmentTyrosine-protein kinase FynHomo sapiens (human)
T cell costimulationTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of protein ubiquitinationTyrosine-protein kinase FynHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase FynHomo sapiens (human)
cellular response to platelet-derived growth factor stimulusTyrosine-protein kinase FynHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of protein catabolic processTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinTyrosine-protein kinase FynHomo sapiens (human)
response to ethanolTyrosine-protein kinase FynHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
ephrin receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
dendrite morphogenesisTyrosine-protein kinase FynHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
activated T cell proliferationTyrosine-protein kinase FynHomo sapiens (human)
modulation of chemical synaptic transmissionTyrosine-protein kinase FynHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
leukocyte migrationTyrosine-protein kinase FynHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTyrosine-protein kinase FynHomo sapiens (human)
cellular response to hydrogen peroxideTyrosine-protein kinase FynHomo sapiens (human)
cellular response to transforming growth factor beta stimulusTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein targeting to membraneTyrosine-protein kinase FynHomo sapiens (human)
dendritic spine maintenanceTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein localization to nucleusTyrosine-protein kinase FynHomo sapiens (human)
regulation of glutamate receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of dendritic spine maintenanceTyrosine-protein kinase FynHomo sapiens (human)
response to amyloid-betaTyrosine-protein kinase FynHomo sapiens (human)
cellular response to amyloid-betaTyrosine-protein kinase FynHomo sapiens (human)
cellular response to L-glutamateTyrosine-protein kinase FynHomo sapiens (human)
cellular response to glycineTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein localization to membraneTyrosine-protein kinase FynHomo sapiens (human)
regulation of calcium ion import across plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activityTyrosine-protein kinase FynHomo sapiens (human)
innate immune responseTyrosine-protein kinase FynHomo sapiens (human)
cell differentiationTyrosine-protein kinase FynHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
positive regulation of monoatomic ion transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
neuromuscular synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M1Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M1Homo sapiens (human)
cognitionMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of postsynaptic membrane potentialMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of glial cell proliferationMuscarinic acetylcholine receptor M1Homo sapiens (human)
positive regulation of intracellular protein transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
muscle contractionSubstance-K receptorHomo sapiens (human)
tachykinin receptor signaling pathwaySubstance-K receptorHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionSubstance-K receptorHomo sapiens (human)
intestine smooth muscle contractionSubstance-K receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionSubstance-K receptorHomo sapiens (human)
operant conditioningSubstance-K receptorHomo sapiens (human)
positive regulation of vascular permeabilitySubstance-K receptorHomo sapiens (human)
positive regulation of monoatomic ion transportSubstance-K receptorHomo sapiens (human)
positive regulation of smooth muscle contractionSubstance-K receptorHomo sapiens (human)
response to electrical stimulusSubstance-K receptorHomo sapiens (human)
prolactin secretionSubstance-K receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionSubstance-K receptorHomo sapiens (human)
positive regulation of flagellated sperm motilitySubstance-K receptorHomo sapiens (human)
temperature homeostasisD(1A) dopamine receptorHomo sapiens (human)
conditioned taste aversionD(1A) dopamine receptorHomo sapiens (human)
behavioral fear responseD(1A) dopamine receptorHomo sapiens (human)
regulation of protein phosphorylationD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1A) dopamine receptorHomo sapiens (human)
response to amphetamineD(1A) dopamine receptorHomo sapiens (human)
protein import into nucleusD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
synapse assemblyD(1A) dopamine receptorHomo sapiens (human)
memoryD(1A) dopamine receptorHomo sapiens (human)
mating behaviorD(1A) dopamine receptorHomo sapiens (human)
grooming behaviorD(1A) dopamine receptorHomo sapiens (human)
adult walking behaviorD(1A) dopamine receptorHomo sapiens (human)
visual learningD(1A) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(1A) dopamine receptorHomo sapiens (human)
astrocyte developmentD(1A) dopamine receptorHomo sapiens (human)
dopamine transportD(1A) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1A) dopamine receptorHomo sapiens (human)
neuronal action potentialD(1A) dopamine receptorHomo sapiens (human)
dentate gyrus developmentD(1A) dopamine receptorHomo sapiens (human)
striatum developmentD(1A) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of cell migrationD(1A) dopamine receptorHomo sapiens (human)
peristalsisD(1A) dopamine receptorHomo sapiens (human)
operant conditioningD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
vasodilationD(1A) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
maternal behaviorD(1A) dopamine receptorHomo sapiens (human)
positive regulation of potassium ion transportD(1A) dopamine receptorHomo sapiens (human)
glucose importD(1A) dopamine receptorHomo sapiens (human)
habituationD(1A) dopamine receptorHomo sapiens (human)
sensitizationD(1A) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(1A) dopamine receptorHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(1A) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic potentiationD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1A) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1A) dopamine receptorHomo sapiens (human)
modification of postsynaptic structureD(1A) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of neuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-1D adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1D adrenergic receptorHomo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
apoptotic processAlpha-1A adrenergic receptorHomo sapiens (human)
smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
activation of phospholipase C activityAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1A adrenergic receptorHomo sapiens (human)
adult heart developmentAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of cell population proliferationAlpha-1A adrenergic receptorHomo sapiens (human)
response to xenobiotic stimulusAlpha-1A adrenergic receptorHomo sapiens (human)
response to hormoneAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of autophagyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of action potentialAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
calcium ion transport into cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
cell growth involved in cardiac muscle cell developmentAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase C signalingAlpha-1A adrenergic receptorHomo sapiens (human)
pilomotor reflexAlpha-1A adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
inflammatory responseHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
memoryHistamine H1 receptorHomo sapiens (human)
visual learningHistamine H1 receptorHomo sapiens (human)
regulation of vascular permeabilityHistamine H1 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H1 receptorHomo sapiens (human)
regulation of synaptic plasticityHistamine H1 receptorHomo sapiens (human)
cellular response to histamineHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H1 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-1B adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of cardiac muscle contractionAlpha-1B adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1B adrenergic receptorHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
cerebral cortex cell migration5-hydroxytryptamine receptor 6Homo sapiens (human)
positive regulation of TOR signaling5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 6Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 6Homo sapiens (human)
fatty acid metabolic processCytochrome P450 2J2Homo sapiens (human)
icosanoid metabolic processCytochrome P450 2J2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2J2Homo sapiens (human)
regulation of heart contractionCytochrome P450 2J2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2J2Homo sapiens (human)
linoleic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
organic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
MAPK cascadeC-C chemokine receptor type 5Homo sapiens (human)
dendritic cell chemotaxisC-C chemokine receptor type 5Homo sapiens (human)
calcium ion transportC-C chemokine receptor type 5Homo sapiens (human)
chemotaxisC-C chemokine receptor type 5Homo sapiens (human)
cellular defense responseC-C chemokine receptor type 5Homo sapiens (human)
cell surface receptor signaling pathwayC-C chemokine receptor type 5Homo sapiens (human)
G protein-coupled receptor signaling pathwayC-C chemokine receptor type 5Homo sapiens (human)
cell-cell signalingC-C chemokine receptor type 5Homo sapiens (human)
release of sequestered calcium ion into cytosol by sarcoplasmic reticulumC-C chemokine receptor type 5Homo sapiens (human)
calcium-mediated signalingC-C chemokine receptor type 5Homo sapiens (human)
signalingC-C chemokine receptor type 5Homo sapiens (human)
symbiont entry into host cellC-C chemokine receptor type 5Homo sapiens (human)
chemokine-mediated signaling pathwayC-C chemokine receptor type 5Homo sapiens (human)
response to cholesterolC-C chemokine receptor type 5Homo sapiens (human)
cellular response to lipopolysaccharideC-C chemokine receptor type 5Homo sapiens (human)
negative regulation of macrophage apoptotic processC-C chemokine receptor type 5Homo sapiens (human)
inflammatory responseC-C chemokine receptor type 5Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-C chemokine receptor type 5Homo sapiens (human)
immune responseC-C chemokine receptor type 5Homo sapiens (human)
cell chemotaxisC-C chemokine receptor type 5Homo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
sensory perception of soundVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion importVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transporter activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
skeletal system developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
extraocular skeletal muscle developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
striated muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
endoplasmic reticulum organizationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
myoblast fusionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
neuromuscular junction developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle adaptationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle fiber developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
release of sequestered calcium ion into cytosolVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cellular response to caffeineVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
immune system developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
heart developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
embryonic forelimb morphogenesisVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
camera-type eye developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transport into cytosolVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of ventricular cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rateSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac conduction system developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac ventricle developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
brainstem developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
response to denervation involved in regulation of muscle adaptationSodium channel protein type 5 subunit alphaHomo sapiens (human)
telencephalon developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cerebellum developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
odontogenesis of dentin-containing toothSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of epithelial cell proliferationSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cellular response to calcium ionSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of cardiac muscle cell contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
ventricular cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during Purkinje myocyte cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell to bundle of His cell communicationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of heart rate by cardiac conductionSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (195)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
virus receptor activityEpidermal growth factor receptorHomo sapiens (human)
chromatin bindingEpidermal growth factor receptorHomo sapiens (human)
double-stranded DNA bindingEpidermal growth factor receptorHomo sapiens (human)
MAP kinase kinase kinase activityEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane signaling receptor activityEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
integrin bindingEpidermal growth factor receptorHomo sapiens (human)
protein bindingEpidermal growth factor receptorHomo sapiens (human)
calmodulin bindingEpidermal growth factor receptorHomo sapiens (human)
ATP bindingEpidermal growth factor receptorHomo sapiens (human)
enzyme bindingEpidermal growth factor receptorHomo sapiens (human)
kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein phosphatase bindingEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
ubiquitin protein ligase bindingEpidermal growth factor receptorHomo sapiens (human)
identical protein bindingEpidermal growth factor receptorHomo sapiens (human)
cadherin bindingEpidermal growth factor receptorHomo sapiens (human)
actin filament bindingEpidermal growth factor receptorHomo sapiens (human)
ATPase bindingEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor bindingEpidermal growth factor receptorHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase FynHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase FynHomo sapiens (human)
protein bindingTyrosine-protein kinase FynHomo sapiens (human)
ATP bindingTyrosine-protein kinase FynHomo sapiens (human)
phospholipase activator activityTyrosine-protein kinase FynHomo sapiens (human)
enzyme bindingTyrosine-protein kinase FynHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
identical protein bindingTyrosine-protein kinase FynHomo sapiens (human)
alpha-tubulin bindingTyrosine-protein kinase FynHomo sapiens (human)
phospholipase bindingTyrosine-protein kinase FynHomo sapiens (human)
transmembrane transporter bindingTyrosine-protein kinase FynHomo sapiens (human)
metal ion bindingTyrosine-protein kinase FynHomo sapiens (human)
ephrin receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
tau protein bindingTyrosine-protein kinase FynHomo sapiens (human)
tau-protein kinase activityTyrosine-protein kinase FynHomo sapiens (human)
growth factor receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
scaffold protein bindingTyrosine-protein kinase FynHomo sapiens (human)
disordered domain specific bindingTyrosine-protein kinase FynHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Mus musculus (house mouse)
tachykinin receptor activitySubstance-K receptorHomo sapiens (human)
protein bindingSubstance-K receptorHomo sapiens (human)
substance K receptor activitySubstance-K receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1A) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1A) dopamine receptorHomo sapiens (human)
protein bindingD(1A) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine bindingD(1A) dopamine receptorHomo sapiens (human)
arrestin family protein bindingD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1A) dopamine receptorHomo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
identical protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1D adrenergic receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1A adrenergic receptorHomo sapiens (human)
histamine receptor activityHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H1 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H1 receptorHomo sapiens (human)
protein bindingAlpha-1B adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1B adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1B adrenergic receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
histamine receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 6Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
monooxygenase activityCytochrome P450 2J2Homo sapiens (human)
iron ion bindingCytochrome P450 2J2Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
isomerase activityCytochrome P450 2J2Homo sapiens (human)
linoleic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
hydroperoxy icosatetraenoate isomerase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 5,6-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
heme bindingCytochrome P450 2J2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2J2Homo sapiens (human)
virus receptor activityC-C chemokine receptor type 5Homo sapiens (human)
actin bindingC-C chemokine receptor type 5Homo sapiens (human)
phosphatidylinositol phospholipase C activityC-C chemokine receptor type 5Homo sapiens (human)
chemokine receptor activityC-C chemokine receptor type 5Homo sapiens (human)
protein bindingC-C chemokine receptor type 5Homo sapiens (human)
coreceptor activityC-C chemokine receptor type 5Homo sapiens (human)
C-C chemokine receptor activityC-C chemokine receptor type 5Homo sapiens (human)
C-C chemokine bindingC-C chemokine receptor type 5Homo sapiens (human)
identical protein bindingC-C chemokine receptor type 5Homo sapiens (human)
chemokine (C-C motif) ligand 5 bindingC-C chemokine receptor type 5Homo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
ankyrin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
small molecule bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
molecular function activator activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 5 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
calmodulin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
fibroblast growth factor bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
enzyme bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein kinase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein domain specific bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ankyrin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ubiquitin protein ligase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
nitric-oxide synthase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in Purkinje myocyte action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
scaffold protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (109)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
photoreceptor outer segmentVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
ruffle membraneEpidermal growth factor receptorHomo sapiens (human)
Golgi membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceEpidermal growth factor receptorHomo sapiens (human)
nucleusEpidermal growth factor receptorHomo sapiens (human)
cytoplasmEpidermal growth factor receptorHomo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
endoplasmic reticulum membraneEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
focal adhesionEpidermal growth factor receptorHomo sapiens (human)
cell surfaceEpidermal growth factor receptorHomo sapiens (human)
endosome membraneEpidermal growth factor receptorHomo sapiens (human)
membraneEpidermal growth factor receptorHomo sapiens (human)
basolateral plasma membraneEpidermal growth factor receptorHomo sapiens (human)
apical plasma membraneEpidermal growth factor receptorHomo sapiens (human)
cell junctionEpidermal growth factor receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneEpidermal growth factor receptorHomo sapiens (human)
early endosome membraneEpidermal growth factor receptorHomo sapiens (human)
nuclear membraneEpidermal growth factor receptorHomo sapiens (human)
membrane raftEpidermal growth factor receptorHomo sapiens (human)
perinuclear region of cytoplasmEpidermal growth factor receptorHomo sapiens (human)
multivesicular body, internal vesicle lumenEpidermal growth factor receptorHomo sapiens (human)
intracellular vesicleEpidermal growth factor receptorHomo sapiens (human)
protein-containing complexEpidermal growth factor receptorHomo sapiens (human)
receptor complexEpidermal growth factor receptorHomo sapiens (human)
Shc-EGFR complexEpidermal growth factor receptorHomo sapiens (human)
basal plasma membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
membrane raftTyrosine-protein kinase FynHomo sapiens (human)
dendriteTyrosine-protein kinase FynHomo sapiens (human)
nucleusTyrosine-protein kinase FynHomo sapiens (human)
mitochondrionTyrosine-protein kinase FynHomo sapiens (human)
endosomeTyrosine-protein kinase FynHomo sapiens (human)
cytosolTyrosine-protein kinase FynHomo sapiens (human)
actin filamentTyrosine-protein kinase FynHomo sapiens (human)
plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
postsynaptic densityTyrosine-protein kinase FynHomo sapiens (human)
dendriteTyrosine-protein kinase FynHomo sapiens (human)
perikaryonTyrosine-protein kinase FynHomo sapiens (human)
cell bodyTyrosine-protein kinase FynHomo sapiens (human)
membrane raftTyrosine-protein kinase FynHomo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein kinase FynHomo sapiens (human)
perinuclear endoplasmic reticulumTyrosine-protein kinase FynHomo sapiens (human)
glial cell projectionTyrosine-protein kinase FynHomo sapiens (human)
Schaffer collateral - CA1 synapseTyrosine-protein kinase FynHomo sapiens (human)
plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M1Homo sapiens (human)
Schaffer collateral - CA1 synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic density membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
plasma membraneATP-dependent translocase ABCB1Mus musculus (house mouse)
plasma membraneSubstance-K receptorHomo sapiens (human)
sperm flagellumSubstance-K receptorHomo sapiens (human)
sperm headSubstance-K receptorHomo sapiens (human)
sperm midpieceSubstance-K receptorHomo sapiens (human)
sperm midpieceSubstance-K receptorHomo sapiens (human)
plasma membraneSubstance-K receptorHomo sapiens (human)
nucleusD(1A) dopamine receptorHomo sapiens (human)
endoplasmic reticulum membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
ciliumD(1A) dopamine receptorHomo sapiens (human)
presynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
dendritic spineD(1A) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
ciliary membraneD(1A) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1A) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(1A) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
nucleusAlpha-1A adrenergic receptorHomo sapiens (human)
nucleoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
caveolaAlpha-1A adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
cytosolHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
synapseHistamine H1 receptorHomo sapiens (human)
dendriteHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
nucleusAlpha-1B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
caveolaAlpha-1B adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
cilium5-hydroxytryptamine receptor 6Homo sapiens (human)
synapse5-hydroxytryptamine receptor 6Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2J2Homo sapiens (human)
extracellular exosomeCytochrome P450 2J2Homo sapiens (human)
cytoplasmCytochrome P450 2J2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2J2Homo sapiens (human)
cell surfaceC-C chemokine receptor type 5Homo sapiens (human)
endosomeC-C chemokine receptor type 5Homo sapiens (human)
plasma membraneC-C chemokine receptor type 5Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 5Homo sapiens (human)
cell surfaceC-C chemokine receptor type 5Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 5Homo sapiens (human)
cytoplasmC-C chemokine receptor type 5Homo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
sarcoplasmic reticulumVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
T-tubuleVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
I bandVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic densityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
dendriteVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic density membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleolusSodium channel protein type 5 subunit alphaHomo sapiens (human)
endoplasmic reticulumSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
cell surfaceSodium channel protein type 5 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 5 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
lateral plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 5 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 5 subunit alphaHomo sapiens (human)
sarcolemmaSodium channel protein type 5 subunit alphaHomo sapiens (human)
perinuclear region of cytoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (372)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1617350Inhibition of recombinant human CYP2J2 expressed in baculovirus infected insect cells co-expressing NADPH-CYP reductase and cytochrome b5 assessed as reduction in CYP2J2-mediated EPA epoxidation by measuring sum of EEQ and DiHETEs level at 1 to 50 uM usin2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
Development of Robust 17(
AID701300Apparent permeability across MDCK cells expressing human MDR12012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structural modifications that alter the P-glycoprotein efflux properties of compounds.
AID681127TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID781330pKa (acid-base dissociation constant) as determined by potentiometric titration2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1470755Inhibition of Trypanosoma cruzi trans-sialidase at 1 mM using N-acetyllactosamine as substrate in presence of 3'-sialyllactose measured after 15 mins by HPAEC-PAD relative to control2017European journal of medicinal chemistry, May-26, Volume: 132An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method.
AID1164976Antimicrobial activity against Acinetobacter baumannii 983709 incubated for 16 hrs by CLSI based method2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
AID448779Cardiovascular toxicity in iv dosed Hartley guinea pig QTc prolongation after 30 mins by ECG2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1164978Antimicrobial activity against Escherichia coli 8314 incubated for 16 hrs by CLSI based method2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID161283Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.12003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID673435Half life in human liver microsomes at 1 uM2012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variants.
AID1127843Cytotoxicity against human M14 cells assessed as cell viability after 4 hrs using bis-AAF-R110 as substrate by ApoTox-Glo triplex assay2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Novel pyrrolidine diketopiperazines selectively inhibit melanoma cells via induction of late-onset apoptosis.
AID1164965Inhibition of Staphylococcus aureus RnpA2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
AID448777Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.
AID76319Oral antiallergy activity in the guinea pig anaphylaxis (GPA) model, at a pretreatment time of 1 h1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Synthesis and antiallergy activity of 4-(diarylhydroxymethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds.
AID1164969Antimicrobial activity against methicillin-resistant Staphylococcus aureus USA300 NRS384 incubated for 16 hrs by CLSI based method2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
AID161284Inhibitory activity against Potassium channel HERG2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1164967Antimicrobial activity against ciprofloxacin-resistant Staphylococcus aureus CRC61 incubated for 16 hrs by CLSI based method2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
AID448776Inhibition of human ERG in L929 cells at 10 uM by whole cell patch-clamp assay2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID448778Antihistamine activity in iv dosed Hartley guinea pig assessed as inhibition of histamine-induced bronchoconstriction pretreated before histamine challenge2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.
AID679733TP_TRANSPORTER: increase in Doxorubicin intracellular accumulation (Doxorubicin: 0-20 uM, Terfenadine: 5 uM) in MCF-7/ADR cells1993Biochemical pharmacology, Jan-26, Volume: 45, Issue:2
Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1640018Luciferase/luciferin-expressing antifolate-resistant parasites were used to infect a culture of HepG2 cells that were pre-incubated with compounds. Infected hepatocytes emit light due to the luciferase reaction. Assay results are presented as the percent 2018Science (New York, N.Y.), 12-07, Volume: 362, Issue:6419
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.
AID1548642Metabolic stability in human liver microsomes assessed as intrinsic clearance at 1.426 uM incubated for 60 mins by LC-MS/MS analysis2020Journal of medicinal chemistry, 05-14, Volume: 63, Issue:9
First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform-Specific Aspartate.
AID76321Oral antiallergy activity in the guinea pig anaphylaxis (GPA) model, at a pretreatment time of 24 h; NT=Not tested1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Synthesis and antiallergy activity of 4-(diarylhydroxymethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds.
AID78864Compound was evaluated for inhibition of contraction in guinea pig ileum induced by leukotriene D4 (LTD4); Not active1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
(Piperidinylalkoxy)chromones: novel antihistamines with additional antagonistic activity against leukotriene D4.
AID16029Pharmacokinetic parameter :drug bound to plasma was reported1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
AID680523TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 5 uM, Terfenadine: 10 uM) in Caco-2 cells1999Pharmaceutical research, Mar, Volume: 16, Issue:3
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
AID1548639Metabolic stability in human liver microsomes assessed as compound remaining in presence of NADPH at 1.426 uM incubated for 60 mins by LC-MS/MS analysis2020Journal of medicinal chemistry, 05-14, Volume: 63, Issue:9
First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform-Specific Aspartate.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID393556Inhibition of human ERG Y652A mutant expressed in HEK293 cells by whole cell patch clamp method2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach.
AID704094Cardiotoxicity against Sprague-Dawley rat Langendorff perfused heart assessed as QT time interval at 30 uM by electrophysiological analysis (Rvb = 68.51 2.73 ms)2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling.
AID1127845Cytotoxicity against human M14 cells assessed as cell viability after 4 hrs using GF-AFC as substrate by ApoTox-Glo triplex assay2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Novel pyrrolidine diketopiperazines selectively inhibit melanoma cells via induction of late-onset apoptosis.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1470761Trypanocidal activity against bloodstream form of Trypanosoma cruzi NINOA infected in NIH mouse assessed as reduction in parasitemia at 100 mg/kg, po measured at 6 hrs post dose by microscopic method2017European journal of medicinal chemistry, May-26, Volume: 132An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method.
AID1194349Cardiotoxic inhibition of ERG channel in Zebrafish assessed as change in atrio ventricular beats ratio at 20 uM after 4 hrs2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID1470753Trypanocidal activity against trypomastigote stage of Trypanosoma cruzi NINOA infected in NIH mouse blood assessed as parasite lysis at 50 ug/ml after 24 hrs by optical microscopic method relative to control2017European journal of medicinal chemistry, May-26, Volume: 132An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method.
AID1207174Inhibition of sodium current measured using whole-cell patch clamp experiments in HEK-293 cells stably transfected with hNaV1.5 cDNA2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID678835TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing LLC-PK1 cells1999Pharmaceutical research, Mar, Volume: 16, Issue:3
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
AID1207708Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID1164973Antimicrobial activity against Enterococcus faecium 824-05 incubated for 16 hrs by CLSI based method2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1750323Half life in human liver microsomes at 1 uM measured up to 60 mins in presence of NADPH by HPLC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID393555Inhibition of human ERG td[wt:Y652A] mutant expressed in HEK293 cells by whole cell patch clamp method2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach.
AID1649553Inhibition of human ERG expressed in HEK293 cells measured after 30 mins by FluxOR dye based FLIPR TETRA assay2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
AID393557Inhibition of human ERG td[wt:F656A] mutant expressed in HEK293 cells by whole cell patch clamp method2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach.
AID150754Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID1164968Antimicrobial activity against ciprofloxacin-resistant Staphylococcus aureus CRC118 incubated for 16 hrs by CLSI based method2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
AID1164977Antimicrobial activity against Klebsiella pneumoniae CKP4 incubated for 16 hrs by CLSI based method2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
AID681122TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID264035Inhibition of human recombinant CYP2J2 expressed in baculovirus-infected Sf9 insect cells2006Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10
Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID161281Inhibition of human Potassium channel HERG expressed in mammalian cells2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1305711Half life in mouse liver microsomes at 0.1 uM2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Coumarin carboxylic acids as monocarboxylate transporter 1 inhibitors: In vitro and in vivo studies as potential anticancer agents.
AID420669Lipophilicity, log D at pH 7.02009European journal of medicinal chemistry, May, Volume: 44, Issue:5
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID24863pA2 value is determined compared to standard H1-antagonists1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
New antihistamines: substituted piperazine and piperidine derivatives as novel H1-antagonists.
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID393554Inhibition of wild-type human ERG expressed in HEK293 cells by whole cell patch clamp method2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach.
AID420668Inhibition of human ERG in MCF7 cells2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID1207233Inhibition of hERG K channel2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID1207264Effective free therapeutic plasma concentration (EFTPC): the concentration of unbound compund in the blood plasma at therapeutic dose (mean of range)2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID1470754Trypanocidal activity against trypomastigote stage of Trypanosoma cruzi NINOA infected in NIH mouse blood after 24 hrs by optical microscopic method2017European journal of medicinal chemistry, May-26, Volume: 132An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method.
AID250135Inhibition of compound against MES-SA/DX5 cell line was determined using P-glycoprotein assay2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR.
AID1202708Inhibition of histamine H1 receptor (unknown origin)2015Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6
CNS drug design: balancing physicochemical properties for optimal brain exposure.
AID448775Inhibition of human ERG in L929 cells by whole cell patch-clamp assay2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.
AID86735Dissociation constant was determined against H1 receptor of guinea pig lung membranes using radioligand binding assays.1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
(Piperidinylalkoxy)chromones: novel antihistamines with additional antagonistic activity against leukotriene D4.
AID1164971Antimicrobial activity against vancomycin intermediate-resistant Staphylococcus aureus Mu50 incubated for 16 hrs by CLSI based method2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1470763Solubility of the compound in water2017European journal of medicinal chemistry, May-26, Volume: 132An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method.
AID1207706Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID624623Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID397743Inhibition of human ERG channel2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID234883Potency relative to 7-[3-(4-Benzhydryl-piperidine-1-yl)-propyl]-1,3-dimethyl-3,7-dihydro-purine-2,6-dione1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
New antihistamines: substituted piperazine and piperidine derivatives as novel H1-antagonists.
AID485979Inhibition of CETP in rabbit serum at 10 uM after 1 hr by fluorescent cholesteryl esters transfer assay2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration.
AID1164981Displacement of [3H]astemizole from human ERG expressed in HEK293 cells by scintillation counting method2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
AID681119TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1470758Trypanocidal activity against bloodstream form of Trypanosoma cruzi INC-5 infected in NIH mouse assessed as reduction in parasitemia at 100 mg/kg, po measured at 6 hrs post dose by microscopic method2017European journal of medicinal chemistry, May-26, Volume: 132An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method.
AID681128TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID1209990Inhibition of CYP2J2-mediated astemizole O-demethylation in human liver microsomes after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1703748Intrinsic clearance in human liver microsomes at 0.1 uM in presence of NADPH measured upto 60 mins by LC/MS/MS analysis2020European journal of medicinal chemistry, Sep-15, Volume: 202Evaluation of N-phenyl-2-aminothiazoles for treatment of multi-drug resistant and intracellular Staphylococcus aureus infections.
AID1207776Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits2013Scientific reports, , Volume: 3MICE models: superior to the HERG model in predicting Torsade de Pointes.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID276169Inhibition of human ERG potassium channel in HEK293 cells by patch clamp assay2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Inhibitory effect of carboxylic acid group on hERG binding.
AID1207707Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID243422log (1/Km) value for human liver microsome cytochrome P450 3A42005Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
AID1164979Antimicrobial activity against tolC and imp(-) containing Escherichia coli incubated for 16 hrs by CLSI based method2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID704093Cardiotoxicity against Sprague-Dawley rat Langendorff perfused heart assessed as QT time interval at 10 uM by electrophysiological analysis (Rvb = 68.51 2.73 ms)2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling.
AID1305710Half life in human liver microsomes at 0.1 uM2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Coumarin carboxylic acids as monocarboxylate transporter 1 inhibitors: In vitro and in vivo studies as potential anticancer agents.
AID76323Oral antiallergy activity in the guinea pig anaphylaxis (GPA) model of, at a pretreatment time of 6 h1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Synthesis and antiallergy activity of 4-(diarylhydroxymethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds.
AID1164964Inhibition of Staphylococcus aureus RNAse J22014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID82355K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.12002Journal of medicinal chemistry, Aug-29, Volume: 45, Issue:18
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
AID453203Lipophilicity, log D of the compound2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
AID150752Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID680085TP_TRANSPORTER: inhibition of Azidopine photoaffinity labelling (Azidopine: 0.2 uM, Terfenadine: 100 uM) in membranes from KB/V20C cells1993Biochemical pharmacology, Jan-26, Volume: 45, Issue:2
Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells.
AID625294Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in O'Brien data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID493961Induction of of LuxR-dependent quorum sensing in Vibrio fischeri assessed as induction of bioluminescence intensity up to 200 uM2010Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15
LuxR-dependent quorum sensing: computer aided discovery of new inhibitors structurally unrelated to N-acylhomoserine lactones.
AID311932Inhibition of ASM in human H4 cells assessed as residual activity at 10 uM2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1207709Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID122891Compound was evaluated for IL 4 production inhibition from mice splenocytes stimulated by anti-CD3 mAb1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
New N-(pyridin-4-yl)-(indol-3-yl)acetamides and propanamides as antiallergic agents.
AID393559Inhibition of human ERG S624A mutant expressed in HEK293 cells by whole cell patch clamp method2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1832389Binding affinity to human ERG assessed as inhibition constant2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of Novel Acetamide-Based Heme Oxygenase-1 Inhibitors with Potent
AID1640019Luciferase/luciferin-expressing antifolate-resistant parasites were used to infect a culture of HepG2 cells that were pre-incubated with compounds. Infected hepatocytes emit light due to the luciferase reaction. Assay results are presented as the percent 2018Science (New York, N.Y.), 12-07, Volume: 362, Issue:6419
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1164980Antimicrobial activity against Staphylococcus aureus U1 incubated for 16 hrs by CLSI based method2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
AID681126TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID19468Partition coefficient (logP)2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1202709Inhibition of human ERG channel2015Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6
CNS drug design: balancing physicochemical properties for optimal brain exposure.
AID1127842Induction of apoptosis human M14 cells assessed as caspase activity after 4 to 24 hrs using DEVD peptide as substrate by ApoTox-Glo triplex assay2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Novel pyrrolidine diketopiperazines selectively inhibit melanoma cells via induction of late-onset apoptosis.
AID150756Inhibition of P-gp was determined using rhodamine-assay in human CaCo-2 cells2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID681120TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in Caco-2 cells2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID122892Compound was evaluated for IL 5 production inhibitio from mice splenocytes stimulated by anti-CD3 mAb1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
New N-(pyridin-4-yl)-(indol-3-yl)acetamides and propanamides as antiallergic agents.
AID150751Inhibition of P-glycoprotein using ATPase in MDR1 membranes2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1382494Intrinsic clearance in human liver microsomes at 0.1 uM preincubated for 5 mins followed by NDAPH addition measured up to 60 mins by HPLC-MS/MS analysis2018European journal of medicinal chemistry, Mar-25, Volume: 148Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA).
AID240820Inhibitory concentration against IKr potassium channel2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
AID1470751Trypanocidal activity against trypomastigote stage of Trypanosoma cruzi INC-5 infected in NIH mouse blood assessed as parasite lysis at 50 ug/ml after 24 hrs by optical microscopic method relative to control2017European journal of medicinal chemistry, May-26, Volume: 132An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method.
AID150753Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID188956Oral antiallergy activity in the passive foot anaphylaxis (PFA) model of rat, at a dose of 10 (mg/kg); not significantly different from negative control group1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Synthesis and antiallergy activity of 4-(diarylhydroxymethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1470752Trypanocidal activity against trypomastigote stage of Trypanosoma cruzi INC-5 infected in NIH mouse blood after 24 hrs by optical microscopic method2017European journal of medicinal chemistry, May-26, Volume: 132An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method.
AID1548641Metabolic stability in human liver microsomes assessed as half life at 1.426 uM incubated for 60 mins by LC-MS/MS analysis2020Journal of medicinal chemistry, 05-14, Volume: 63, Issue:9
First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform-Specific Aspartate.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1164961Antimicrobial activity against Staphylococcus aureus UAMS1 incubated for 16 hrs by CLSI based method2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
AID624629Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID408340Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Support vector machines classification of hERG liabilities based on atom types.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1290697Drug metabolism in human liver microsomes assessed as cytochrome P450-mediated compound oxidation by measuring drug recovery after 1 hr by HPLC analysis2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy.
AID1164970Antimicrobial activity against methicillin-resistant Staphylococcus aureus USA300-0114 incubated for 16 hrs by CLSI based method2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
AID139398Tested for effect on central nervous system in mice at 100 mg/kg peroral dose barbiturate-sleeping time (BST)1994Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17
[(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine derivatives as dual antagonists of PAF and histamine.
AID493958Inhibition of LuxR-dependent quorum sensing in Vibrio fischeri assessed as reduction of 3-oxo-C6-HSL-induced bioluminescence intensity2010Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15
LuxR-dependent quorum sensing: computer aided discovery of new inhibitors structurally unrelated to N-acylhomoserine lactones.
AID54923Inhibition of human cytochrome P450 3A42003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID243189Inhibition of partially open human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel)2005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
A two-state homology model of the hERG K+ channel: application to ligand binding.
AID624628Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID150755Inhibition of P-glycoprotein using calcein-AM assay transfected in porcine PBCEC2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID87692Binding affinity towards histamine H1 receptor2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID624626Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID393558Inhibition of human ERG F656A mutant expressed in HEK293 cells by whole cell patch clamp method2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach.
AID311935Partition coefficient, log P of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1209987Inhibition of CYP2J2 in human liver microsomes using 7 probe cocktail containing phenacetin, paclitaxel, diclofenac, S-mephenytoin, dextromethorphan, astemizole and midazolam after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1222791Oral clearance in human2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Which metabolites circulate?
AID1572115Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by manual patch clamp assay2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.
AID765484Half life in human liver microsomes at 1 uM by LC-MS analysis2013European journal of medicinal chemistry, Sep, Volume: 67N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines: a novel class of antitumor agents targeting the colchicine site on tubulin.
AID1470757Trypanocidal activity against bloodstream form of Trypanosoma cruzi INC-5 infected in NIH mouse assessed as reduction in parasitemia at 100 mg/kg, po measured at 2 to 4 hrs post dose by microscopic method2017European journal of medicinal chemistry, May-26, Volume: 132An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method.
AID681131TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID661410Inhibition of human Erg expressed in HEK293 cells assessed as rubidium efflux after 4 hrs by atomic absorbance spectrometric analysis2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Discovery of a novel melanin concentrating hormone receptor 1 (MCHR1) antagonist with reduced hERG inhibition.
AID587815Metabolic stability of the compound in human liver microsome assessed as compound remaining2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
Potent farnesyltransferase inhibitors with 1,4-diazepane scaffolds as novel destabilizing microtubule agents in hormone-resistant prostate cancer.
AID503311Antiproliferative activity against human PC3 cells at 10 uM after 120 hrs by MTT assay relative to DMSO2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID624622Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID35986Compound is evaluated for in vitro receptor binding affinity against Alpha-1 adrenergic receptor1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
New antihistamines: substituted piperazine and piperidine derivatives as novel H1-antagonists.
AID1075746Half life in human liver microsomes at 1 uM by LC-MS analysis2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.
AID243151Inhibitory concentration against potassium channel HERG2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1470760Trypanocidal activity against bloodstream form of Trypanosoma cruzi NINOA infected in NIH mouse assessed as reduction in parasitemia at 100 mg/kg, po measured at 2 to 4 hrs post dose by microscopic method2017European journal of medicinal chemistry, May-26, Volume: 132An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method.
AID1382495Half life in human liver microsomes at 0.1 uM preincubated for 5 mins followed by NDAPH addition measured up to 60 mins by HPLC-MS/MS analysis2018European journal of medicinal chemistry, Mar-25, Volume: 148Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA).
AID701301Efflux ratio of permeability in MDCK cells expressing human MDR12012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structural modifications that alter the P-glycoprotein efflux properties of compounds.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID268084Metabolic stability in rat liver microsomes2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Dipeptidyl nitriles as human dipeptidyl peptidase I inhibitors.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID140564Tested for effect on central nervous system in mice at 100 mg/kg peroral dose for spontaneous motor activity (SMA) expressed as percentage relative to control1994Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17
[(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine derivatives as dual antagonists of PAF and histamine.
AID1285114Half life in human liver microsomes at 0.1 uM up to 60 mins by HPLC-MS/MS analysis2016European journal of medicinal chemistry, Apr-13, Volume: 112Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validation.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1194348Cardiotoxic inhibition of ERG channel in Zebrafish assessed as change in heart rate of ventricles at 20 uM after 4 hrs2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.
AID1164963Inhibition of Staphylococcus aureus topoisomerase 4 assessed as reduction in decatenation of kDNA at 100 to 500 uM by gel electrophoresis method2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
AID1164974Antimicrobial activity against Enterococcus faecalis OG1RF incubated for 16 hrs by CLSI based method2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
AID781329pKa (acid-base dissociation constant) as determined by other workers2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1207202Inhibition of calcium current (ICaL) measured using whole-cell patch clamp experiments in isolated guinea pig ventricular myocytes2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID754101Inhibition of human ERG expressed in HEK293 cells at 50 nM by whole-cell patch-clamp technique relative to control2013European journal of medicinal chemistry, Jun, Volume: 64Synthesis and pharmacological properties of a new hydrophilic and orally bioavailable 5-HT4 antagonist.
AID24562Pharmacokinetic parameter :half life in humans was reported1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
AID673434Intrinsic clearance in human liver microsomes at 1 uM2012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variants.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID86589Inhibitory activity against Tritiated [3H]- mepyramine binding to histamine H1 receptor in guinea pig cerebral cortex1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Synthesis and antiallergy activity of 4-(diarylhydroxymethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds.
AID1548640Metabolic stability in human liver microsomes assessed as compound remaining in PBS buffer at pH 7.4 at 1.426 uM incubated for 60 mins by LC-MS/MS analysis2020Journal of medicinal chemistry, 05-14, Volume: 63, Issue:9
First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform-Specific Aspartate.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1750324Intrinsic clearance in human liver microsomes at 1 uM measured up to 60 mins in presence of NADPH by HPLC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity.
AID1202710Apparent permeability of the compound2015Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6
CNS drug design: balancing physicochemical properties for optimal brain exposure.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID453204Permeability in human skin after 48 hrs by Franz cell permeability assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1222793Dissociation constant, pKa of the compound2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Which metabolites circulate?
AID311934Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1483327Inhibition of human ERG expressed in HEK293 cells by patch clamp method2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID22246Pharmacokinetic parameter :volume apparent of distribution was reported1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
AID1164962Inhibition of Staphylococcus aureus DNA gyrase assessed as reduction in enzyme-catalyzed supercoiling of relaxed circular pBR322 DNA by agarose gel electrophoresis2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
AID17268Dissociation constant (KD) of the compound1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
New antihistamines: substituted piperazine and piperidine derivatives as novel H1-antagonists.
AID238610Inhibition of [3H]astemizole binding to Potassium channel HERG2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.
AID1164975Antimicrobial activity against Mycobacterium tuberculosis mc2 6020 incubated for 16 hrs by alamar blue assay2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
AID1164972Antimicrobial activity against vancomycin-resistant Staphylococcus aureus VRSA1 incubated for 16 hrs by CLSI based method2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
AID1703749Half life in human liver microsomes at 0.1 uM in presence of NADPH by LC/MS/MS analysis2020European journal of medicinal chemistry, Sep-15, Volume: 202Evaluation of N-phenyl-2-aminothiazoles for treatment of multi-drug resistant and intracellular Staphylococcus aureus infections.
AID86582Compound is evaluated for in vitro receptor binding affinity against H1 receptor1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
New antihistamines: substituted piperazine and piperidine derivatives as novel H1-antagonists.
AID1194347Cardiotoxic inhibition of ERG channel in Zebrafish assessed as change in heart rate of atria at 20 uM after 4 hrs2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.
AID140895Compound is evaluated for in vitro receptor binding affinity against Muscarinic acetylcholine receptor M11995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
New antihistamines: substituted piperazine and piperidine derivatives as novel H1-antagonists.
AID79197Compound was evaluated for antihistaminic activity against isolated guinea pig ileum.1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
(Piperidinylalkoxy)chromones: novel antihistamines with additional antagonistic activity against leukotriene D4.
AID302758Solubility by shake flask method2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Poorly soluble marketed drugs display solvation limited solubility.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1346732Human Kv10.1 (Voltage-gated potassium channels)2004Molecular pharmacology, May, Volume: 65, Issue:5
Molecular determinants for high-affinity block of human EAG potassium channels by antiarrhythmic agents.
AID1345190Human CYP2J2 (CYP2 family)2006Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10
Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2.
AID1346751Human Kv11.1 (Voltage-gated potassium channels)1997FEBS letters, Nov-03, Volume: 417, Issue:1
A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.
AID1346037Human H1 receptor (Histamine receptors)2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1193495Thermodynamic equilibrium solubility, log S of the compound in simulated intestinal fluid at pH 6.8 at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1193493Thermodynamic equilibrium solubility, log S of the compound in PBS at pH 7.4 at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1193494Thermodynamic equilibrium solubility, log S of the compound in simulated gastric fluid at pH 1.2 at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1193499Thermodynamic equilibrium solubility, log S of the compound simulated intestinal fluid at pH 6.8 at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1193496Thermodynamic equilibrium solubility, log S of the compound in water at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1193500Thermodynamic equilibrium solubility, log S of the compound2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1193497Thermodynamic equilibrium solubility, log S of the compound PBS at pH 7.4 at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1193492Thermodynamic equilibrium solubility, log S of the compound in water at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1193498Thermodynamic equilibrium solubility, log S of the compound simulated gastric fluid at pH 1.2 at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,621)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990239 (14.74)18.7374
1990's524 (32.33)18.2507
2000's462 (28.50)29.6817
2010's330 (20.36)24.3611
2020's66 (4.07)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 61.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index61.94 (24.57)
Research Supply Index7.75 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index108.30 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (61.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials568 (32.44%)5.53%
Trials0 (0.00%)5.53%
Reviews120 (6.85%)6.00%
Reviews0 (0.00%)6.00%
Case Studies109 (6.23%)4.05%
Case Studies0 (0.00%)4.05%
Observational1 (0.06%)0.25%
Observational0 (0.00%)0.25%
Other953 (54.43%)84.16%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 1 Double-blind (3rd Party Open), Randomized, Placebo-controlled Study To Investigate The Safety And Toleration Of Multiple Oral Doses Of Pf-03654764 In Combination With Fexofenadine In Healthy Subjects [NCT01298505]Phase 136 participants (Actual)Interventional2010-06-04Terminated(stopped due to This study was stopped due to lack of evidence for clinical efficacy.)
A Randomized, Double Blind, Parallel Group Study for Assessing the Efficacy and Safety of a Twice-daily Fexofenadine HCl 60 mg - Pseudoephedrine HCl 60 mg Combination or Fexofenadine HCl 60 mg - Pseudoephedrine HCl 120 mg Combination Versus Allegra® 60 mg [NCT01306721]Phase 3520 participants (Actual)Interventional2011-02-28Completed
A Randomized, Double Blind, Placebo Controlled, Four Way Crossover Study To Determine The Effects Of PF-03654764 +/- Allegra (Fexofenadine) On Symptoms Of Allergic Rhinitis In Subjects Exposed To Ragweed Pollen In An Environmental Exposure Unit. [NCT01033396]Phase 264 participants (Actual)Interventional2010-01-31Completed
A Randomized, Double Blind, Double Dummy, Placebo Controlled, Four Way Crossover Study To Determine The Effects Of An H3 Receptor Antagonist (PF-03654746) On Congestion Following A Nasal Allergen Challenge In Subjects With Seasonal Allergic Rhinitis. [NCT00562120]Phase 221 participants (Actual)Interventional2007-12-31Completed
A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis [NCT00502775]Phase 4680 participants (Actual)Interventional2007-08-31Completed
Effect of Antihistamines on Ureteral Stent-Related Symptoms: Randomized Controlled Trial [NCT04726345]Phase 278 participants (Anticipated)Interventional2021-06-29Recruiting
A Pilot Randomized Double Blind Study to Assess the Safety and Efficacy of 1% Ibuprofen/ 1%Fexofenadine Topical Cream for the Treatment of Dark Circles Under the Eyes [NCT01172522]Phase 230 participants (Actual)Interventional2010-09-30Completed
A Double-Blind, Parallel, Randomized, Placebo Controlled Trial to Evaluate Onset of Action of Loratadine and Fexofenadine in Subjects With Seasonal Allergic Rhinitis in a Pollen Challenge Chamber [NCT01469234]Phase 4255 participants (Actual)Interventional2011-10-31Completed
The Effect of Sodium Lauryl Sulfate on the Oral Absorption of Fexofenadine in Humans [NCT04534153]Early Phase 112 participants (Anticipated)Interventional2023-01-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00502775 (12) [back to overview]Mean Change From Baseline at Day 15 for Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ)
NCT00502775 (12) [back to overview]Mean Change From Baseline in 24 Hour Reflective Total Nasal Symptom Score (24 Hour rTNSS)
NCT00502775 (12) [back to overview]Mean Change From Baseline in 24 Hour Reflective Total Ocular Symptoms Score (rTOSS)
NCT00502775 (12) [back to overview]Mean Change From Baseline in Daytime Reflective Total Nasal Symptom Score (D-rTNSS)
NCT00502775 (12) [back to overview]Mean Change From Baseline in Daytime Reflective Total Ocular Symptom Score (D-rTOSS)
NCT00502775 (12) [back to overview]Mean Change From Baseline in Evening Peak Nasal Inspiratory Flow (PNIF)
NCT00502775 (12) [back to overview]Mean Change From Baseline in Morning Peak Nasal Inspiratory Flow (PNIF)
NCT00502775 (12) [back to overview]Mean Change From Baseline in Nighttime Reflective Total Nasal Symptom Score (N-rTNSS)
NCT00502775 (12) [back to overview]Mean Change From Baseline in Nighttime Reflective Total Ocular Symptom Score (N-rTOSS)
NCT00502775 (12) [back to overview]Mean Change From Baseline in Pre-Dose Instantaneous Total Nasal Symptom Score (iTNSS)
NCT00502775 (12) [back to overview]Mean Change From Baseline in Pre-Dose Instantaneous Total Ocular Symptom Score (iTOSS)
NCT00502775 (12) [back to overview]Mean Change From Baseline in the Nighttime Symptom Score (NSS)
NCT00562120 (7) [back to overview]Minimum Cross-Sectional Area (Amin) Maximum Fall Measured Using Acoustic Rhinometry
NCT00562120 (7) [back to overview]Minimum Cross-Sectional Area (Amin) Proportion Measured Using Acoustic Rhinometry
NCT00562120 (7) [back to overview]Nasal Volume Maximum Fall Measured Using Acoustic Rhinometry
NCT00562120 (7) [back to overview]Nasal Volume Proportion Measured Using Acoustic Rhinometry
NCT00562120 (7) [back to overview]Serum PF-03654746 Concentration
NCT00562120 (7) [back to overview]Nasal Symptom Scores: Nasal Congestion, Nasal Itching, Rhinorrhea
NCT00562120 (7) [back to overview]Nasal Symptom Scores: Sneezing
NCT01172522 (1) [back to overview]Number of Participants Who Showed Improvement in Under Eye Swelling and Dark Circles Relative to Baseline Per Intervention
NCT01469234 (8) [back to overview]Mean Individual Symptom Score for Itchy Nose by Post-Treatment Evaluation Time Point
NCT01469234 (8) [back to overview]Mean Individual Symptom Score for Runny Nose by Post-Treatment Evaluation Time Point
NCT01469234 (8) [back to overview]Mean Individual Symptom Scores for Itchy Eyes by Post-Treatment Evaluation Time Point
NCT01469234 (8) [back to overview]Mean Individual Symptom Scores for Itchy Mouth/Throat/Ears by Post-Treatment Evaluation Time Point
NCT01469234 (8) [back to overview]Mean Individual Symptom Scores for Nasal Congestion by Post-Treatment Evaluation Time Point
NCT01469234 (8) [back to overview]Mean Individual Symptom Scores for Sneezing by Post-Treatment Evaluation Time Point
NCT01469234 (8) [back to overview]Mean Individual Symptom Scores for Watery Eyes by Post-Treatment Evaluation Time Point
NCT01469234 (8) [back to overview]Mean Major Symptom Complex (MSC) Score by Post-Treatment Evaluation Time Point (From 180 Minutes to 300 Minutes)

Mean Change From Baseline at Day 15 for Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ)

Subjects completed the 16-item Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ)to assess nocturnal rhinitis-related quality of life. The NRQLQ measures the functional problems most troublesome to patients with nocturnal allergy symptoms. Each question scored from 0-6 with higher scores indicating more nocturnal impairment. (NCT00502775)
Timeframe: Baseline, Day 15 or if Early Withdrawal Day

InterventionScore on a Scale (Mean)
Placebo-1.4
Fluticasone Furoate 110mcg-2.0
Fexofenadine 180 mg-1.4

[back to top]

Mean Change From Baseline in 24 Hour Reflective Total Nasal Symptom Score (24 Hour rTNSS)

Subjects assessed four nasal symptoms (rhinorrhea, nasal congestion, nasal itching, and sneezing). The sum of the four nasal symptoms comprised the total nasal symptom score (TNSS).Reflective rating represented symptoms over preceding 12 hours. Scores: 0=symptoms not present, 1=mild severity, 2=moderate severity, 3=severe. (NCT00502775)
Timeframe: Baseline and Weeks 1-2

InterventionScore on a Scale (Mean)
Placebo-2.8
Fluticasone Furoate 110mcg-4.1
Fexofenadine 180 mg-2.8

[back to top]

Mean Change From Baseline in 24 Hour Reflective Total Ocular Symptoms Score (rTOSS)

Subjects assessed three ocular symptoms (itching/ burning eyes, tearing/watering eyes, and eye redness). The sum of the 3 ocular symptoms comprised the total ocular symptom score (TOSS). Reflective rating represented symptoms over preceding 12 hours. Scores: 0=symptoms not present, 1=mild severity, 2=moderate severity, 3=severe. (NCT00502775)
Timeframe: Baseline and Weeks 1-2

InterventionScore on a Scale (Mean)
Placebo-2.3
Fluticasone Furoate 110mcg-2.7
Fexofenadine 180 mg-2.2

[back to top]

Mean Change From Baseline in Daytime Reflective Total Nasal Symptom Score (D-rTNSS)

Subjects assessed four nasal symptoms (rhinorrhea, nasal congestion, nasal itching, and sneezing). The sum of the four nasal symptoms comprised the total nasal symptom score (TNSS). Reflective rating represented symptoms over preceding 12 hours. Scores: 0=symptoms not present, 1=mild severity, 2=moderate severity, 3=severe. (NCT00502775)
Timeframe: Baseline and Weeks 1-2

InterventionScore on a Scale (Mean)
Placebo-3.0
Fluticasone Furoate 110mcg-4.2
Fexofenadine 180 mg-2.9

[back to top]

Mean Change From Baseline in Daytime Reflective Total Ocular Symptom Score (D-rTOSS)

Subjects assessed three ocular symptoms (itching/ burning eyes, tearing/watering eyes, and eye redness). The sum of the 3 ocular symptoms comprised the total ocular symptom score (TOSS). Reflective rating represented symptoms over preceding 12 hours. Scores: 0=symptoms not present, 1=mild severity, 2=moderate severity, 3=severe. (NCT00502775)
Timeframe: Baseline and Weeks 1-2

InterventionScore on a Scale (Mean)
Placebo-2.5
Fluticasone Furoate 110mcg-2.9
Fexofenadine 180 mg-2.4

[back to top]

Mean Change From Baseline in Evening Peak Nasal Inspiratory Flow (PNIF)

Subjects used a portable hand-held inspiratory flow meter to measure and record PNIF in the evening. Three measurements were taken and the highest measurement was recorded in the electronic diary. A positive change signifies improved nasal air flow. (NCT00502775)
Timeframe: Baseline and Weeks 1-2

InterventionScore on a Scale (Mean)
Placebo2.3
Fluticasone Furoate 110mcg9.7
Fexofenadine 180 mg0.3

[back to top]

Mean Change From Baseline in Morning Peak Nasal Inspiratory Flow (PNIF)

Subjects used a portable hand-held inspiratory flow meter to measure and record PNIF in the morning prior to taking the study medication. Three measurements were taken and the highest measurement was recorded in the electronic diary. A positive change signifies improved nasal air flow. (NCT00502775)
Timeframe: Baseline and Weeks 1-2

InterventionScore on a Scale (Mean)
Placebo4.8
Fluticasone Furoate 110mcg13.0
Fexofenadine 180 mg2.2

[back to top]

Mean Change From Baseline in Nighttime Reflective Total Nasal Symptom Score (N-rTNSS)

Subjects assessed four nasal symptoms (rhinorrhea, nasal congestion, nasal itching, and sneezing). The sum of the four nasal symptoms comprised the total nasal symptom score (TNSS). Reflective rating represented symptoms over preceding 12 hours. Scores: 0=symptoms not present, 1=mild severity, 2=moderate severity, 3=severe. (NCT00502775)
Timeframe: Baseline and Weeks 1-2

InterventionScore on a Scale (Mean)
Placebo-2.9
Fluticasone Furoate 110mcg-4.1
Fexofenadine 180 mg-2.9

[back to top]

Mean Change From Baseline in Nighttime Reflective Total Ocular Symptom Score (N-rTOSS)

Subjects assessed three ocular symptoms (itching/ burning eyes, tearing/watering eyes, and eye redness). The sum of the 3 ocular symptoms comprised the total ocular symptom score (TOSS). Reflective rating represented symptoms over preceding 12 hours. Scores: 0=symptoms not present, 1=mild severity, 2=moderate severity, 3=severe. (NCT00502775)
Timeframe: Baseline and Weeks 1-2

InterventionScore on a Scale (Mean)
Placebo-2.3
Fluticasone Furoate 110mcg-2.7
Fexofenadine 180 mg-2.2

[back to top]

Mean Change From Baseline in Pre-Dose Instantaneous Total Nasal Symptom Score (iTNSS)

Subjects assessed four nasal symptoms (rhinorrhea, nasal congestion, nasal itching, and sneezing). The sum of the four nasal symptoms comprised the total nasal symptom score (TNSS).Instantaneous rating represented symptoms at the time of the assessment. Scores: 0=symptoms not present, 1=mild severity, 2=moderate severity, 3=severe. (NCT00502775)
Timeframe: Baseline and Weeks 1-2

InterventionScore on a Scale (Mean)
Placebo-2.8
Fluticasone Furoate 110mcg-4.1
Fexofenadine 180 mg-2.7

[back to top]

Mean Change From Baseline in Pre-Dose Instantaneous Total Ocular Symptom Score (iTOSS)

Subjects assessed three ocular symptoms (itching/ burning eyes, tearing/watering eyes, and eye redness). The sum of the four ocular symptoms comprised the total nasal symptom score (TOSS).Instantaneous rating represented symptoms at the time of the assessment. Scores: 0=symptoms not present, 1=mild severity, 2=moderate severity, 3=severe. (NCT00502775)
Timeframe: Baseline and Weeks 1-2

InterventionScore on a Scale (Mean)
Placebo-2.2
Fluticasone Furoate 110mcg-2.7
Fexofenadine 180 mg-2.2

[back to top]

Mean Change From Baseline in the Nighttime Symptom Score (NSS)

Questions include: 1. Nasal congestion on awakening (Score: 0=none, 1=mild, 2=moderate, 3=severe); 2. Difficulty going to sleep (Score: 0=not at all, 1=little, 2=moderately, 3=very); 3. Nighttime awakenings (Score: 0=not at all, 1=once, 2=more than once, 3=felt like awake all night). The sum of the ratings for the three items comprises the NSS. (NCT00502775)
Timeframe: Baseline and Weeks 1-2

InterventionScore on a Scale (Mean)
Placebo-2.3
Fluticasone Furoate 110mcg-3.1
Fexofenadine 180 mg-2.2

[back to top]

Minimum Cross-Sectional Area (Amin) Maximum Fall Measured Using Acoustic Rhinometry

Acoustic rhinometry: a technique intended for assessment of the geometry of the nasal cavity and nasopharynx and for evaluating nasal obstruction. At each time point, there were 2 acoustic rhinometry measurements taken, one for each nostril. The mean of the left and right nostril measurements was taken as the measurement at each time point. Minimum Cross-Sectional Area (Amin) at Baseline was defined as mean of the 3, 'post-diluent, pre-allergen challenge' measures for each intervention period at 2 hrs 10 min, 2 hrs 25 min and 2 hrs 40 min post PF-03654746/placebo dose. Amin 'post-allergen challenge' measures were recorded at 2 hrs 55 min, 3 hrs 10 min and 3 hrs 25 min post PF-03654746/placebo dose for each intervention period. The maximum fall in Amin was calculated as baseline measure minus smallest 'post-allergen challenge' Amin measurement of the 3 measures. (NCT00562120)
Timeframe: 2 hrs 10 min, 2 hrs 25 min, 2 hrs 40 min post dose (Baseline); 2 hrs 55 min, 3 hrs 10 min, 3 hrs 25 min post dose on Day 1 of each intervention period

Interventionsquare centimeter (cm^2) (Mean)
PF-03654746 10 mg0.155
PF-03654746 1 mg0.157
Allegra-D0.204
Placebo0.190

[back to top]

Minimum Cross-Sectional Area (Amin) Proportion Measured Using Acoustic Rhinometry

Acoustic rhinometry: a technique intended for assessment of the geometry of nasal cavity and nasopharynx and for evaluating nasal obstruction. At each time point, there were 2 acoustic rhinometry measurements taken, one for each nostril. Mean of the left and right nostril measurements was taken as measurement at each time point. Minimum Cross-Sectional Area (Amin) at Baseline was defined as mean of 3, 'post-diluent, pre-allergen challenge' measures for each intervention period at 2 hours (hrs) 10 minutes (min), 2 hrs 25 min and 2 hrs 40 min post PF-03654746/placebo dose. Amin 'post-allergen challenge' measures recorded at 2 hrs 55 min, 3 hrs 10 min and 3 hrs 25 min post PF-03654746/placebo dose for each intervention period was averaged to derive single 'post-allergen challenge' value. Amin proportion was defined as ratio of 'post-allergen challenge' value and 'Baseline/pre-allergen challenge value'. Diluent used was saline and allergen was short ragweed extract. (NCT00562120)
Timeframe: 2 hrs 10 min, 2 hrs 25 min, 2 hrs 40 min post dose (Baseline); 2 hrs 55 min, 3 hrs 10 min, 3 hrs 25 min post dose on Day 1 of each intervention period

Interventionratio (Mean)
PF-03654746 10 mg0.760
PF-03654746 1 mg0.742
Allegra-D0.717
Placebo0.795

[back to top]

Nasal Volume Maximum Fall Measured Using Acoustic Rhinometry

Acoustic rhinometry: a technique intended for assessment of the geometry of the nasal cavity and nasopharynx and for evaluating nasal obstruction. At each time point, there were 2 acoustic rhinometry measurements taken, one for each nostril. The mean of the left and right nostril measurements was taken as the measurement at each time point. Nasal volume at Baseline was defined as mean of the 3, 'post-diluent, pre-allergen challenge' measures for each intervention period at 2 hrs 10 min, 2 hrs 25 min and 2 hrs 40 min post PF-03654746/placebo dose. Nasal volume 'post-allergen challenge' measures were recorded at 2 hrs 55 min, 3 hrs 10 min and 3 hrs 25 min post PF-03654746/placebo dose for each intervention period. The maximum fall for nasal volume was calculated as baseline measure minus smallest 'post-allergen challenge' nasal volume measurement among the 3 measures. (NCT00562120)
Timeframe: 2 hrs 10 min, 2 hrs 25 min, 2 hrs 40 min post dose (Baseline); 2 hrs 55 min, 3 hrs 10 min, 3 hrs 25 min post dose on Day 1 of each intervention period

Interventioncubic centimeter (cm^3) (Mean)
PF-03654746 10 mg3.132
PF-03654746 1 mg3.244
Allegra-D4.443
Placebo3.275

[back to top]

Nasal Volume Proportion Measured Using Acoustic Rhinometry

Acoustic rhinometry: a technique intended for assessment of the geometry of nasal cavity and nasopharynx and for evaluating nasal obstruction. At each time point, there were 2 acoustic rhinometry measurements taken, one for each nostril. Mean of the left and right nostril measurements was taken as measurement at each time point. Nasal volume at Baseline was defined as mean of 3, 'post-diluent, pre-allergen challenge' measures for each intervention period at 2 hrs 10 min, 2 hrs 25 min and 2 hrs 40 min post PF-03654746/placebo dose. Nasal volume 'post-allergen challenge' measures recorded at 2 hrs 55 min, 3 hrs 10 min and 3 hrs 25 min post PF-03654746/placebo dose for each intervention period was averaged to derive single 'post-allergen challenge' value. Nasal volume proportion was defined as ratio of 'post-allergen challenge' value and 'Baseline/pre-allergen challenge value'. Diluent used was saline and allergen was short ragweed extract. (NCT00562120)
Timeframe: 2 hrs 10 min, 2 hrs 25 min, 2 hrs 40 min post dose (Baseline); 2 hrs 55 min, 3 hrs 10 min, 3 hrs 25 min post dose on Day 1 of each intervention period

Interventionratio (Mean)
PF-03654746 10 mg0.800
PF-03654746 1 mg0.796
Allegra-D0.744
Placebo0.856

[back to top]

Serum PF-03654746 Concentration

Only participants receiving PF-03654746 were analyzed for this outcome measure. Mean serum concentration of PF-03654746 was calculated of each intervention period. (NCT00562120)
Timeframe: 1 hr 30 min post dose on Day 1 of each intervention period

Interventionnanogram per milliliter (ng/mL) (Mean)
PF-03654746 10 mg34.16
PF-03654746 1 mg2.78

[back to top]

Nasal Symptom Scores: Nasal Congestion, Nasal Itching, Rhinorrhea

Nasal symptoms included; nasal congestion: participants rated sensation of nasal blockage on 0 (no blockage) to 5 (total blockage) scale, nasal itching: participants rated sensation of nasal itch on 0 (no itch) to 5 (very itchy) scale, rhinorrhea: participants rated sensation of runny nose on 0 (no running) to 5 (very runny) scale. Symptom scores were assessed as mean of each intervention period at specified time-points for 'post-diluent, pre-allergen challenge' measure and 'post-challenge' measure. Post-diluent, pre-allergen challenge (for congestion, itching, rhinorrhea) included 2 hrs 10 min, 2 hrs 25 min and 2 hrs 40 min post PF-03654746/placebo dose at each intervention period and post-allergen challenge (for congestion, itching, rhinorrhea) included 2 hrs 55 min, 3 hrs 10 min and 3 hrs 25 min post PF-03654746/placebo dose at each intervention period and (for congestion only) 3 hrs 40 min post PF-03654746/placebo dose (Post-oxymetazoline) at each intervention period. (NCT00562120)
Timeframe: 2 hrs 10 min, 2 hrs 25 min, 2 hrs 40 min post dose (Pre-allergen challenge); 2 hrs 55 min, 3 hrs 10 min, 3 hrs 25 min post dose (Post-allergen challenge); 3 hrs 40 min post dose (Post-oxymetazoline) on Day 1 of each intervention period

,,,
Interventionunits on a scale (Mean)
Nasal congestion: Pre-allergen challengeNasal congestion: Post-allergen challengeNasal congestion: Post-oxymetazolineNasal Itching: Pre-allergen challengeNasal Itching: Post-allergen challengeRhinorrhea: Pre-allergen challengeRhinorrhea: Post-allergen challenge
Allegra-D0.41.90.90.00.90.21.3
PF-03654746 1 mg0.41.80.80.10.80.11.1
PF-03654746 10 mg0.21.50.80.00.40.10.6
Placebo0.42.20.90.11.40.11.9

[back to top]

Nasal Symptom Scores: Sneezing

The absolute number of sneezes was recorded by the participants under supervision of study personnel. Nasal symptom score for sneezing was assessed as the total number of sneezes of each intervention period at specified time-points for the post-diluent and post-challenge and post where 'post-diluent, pre-allergen challenge' included 2 hrs 10 min, 2 hrs 25 min and 2 hrs 40 min post PF-03654746/placebo dose at each intervention period and 'post-allergen challenge' included 2 hrs 55 min, 3 hrs 10 min and 3 hrs 25 min post PF-03654746/placebo dose at each intervention period. (NCT00562120)
Timeframe: 2 hrs 10 min, 2 hrs 25 min, 2 hrs 40 min post dose (Baseline); 2 hrs 55 min, 3 hrs 10 min, 3 hrs 25 min post dose on Day 1 of each intervention period

,,,
Interventionsneezes (Mean)
Sneezing: Pre-allergen challengeSneezing: Post-allergen challenge
Allegra-D0.11.2
PF-03654746 1 mg0.10.6
PF-03654746 10 mg0.00.7
Placebo0.13.6

[back to top]

Number of Participants Who Showed Improvement in Under Eye Swelling and Dark Circles Relative to Baseline Per Intervention

Efficacy was measured per intervention by assessing number of participants with improvement in under eye dark circles and swelling. Criteria used to assess under eye improvement and swelling was by a 5 point scale comparing each week's photographic appearance to the appearance at baseline: 1) fexofenadine right and placebo left, and 2) fexofenadine left and placebo right. The split face comparison was noted in efficacy measured changes in under eye swelling and dark circles relative to baseline. Participants were graded by 2 blinded dermatologists who reviewed photographs of all participants at entry and weekly until end of study plus one week, day 37. Total number of participants: 30. Placebo right and fexofenadine left 15 participants. Placebo left and fexofenadine right 15 participants. (NCT01172522)
Timeframe: Baseline, weekly, and end of study +7 days

Interventionparticipants (Number)
Fexofenadine0
Placebo0

[back to top]

Mean Individual Symptom Score for Itchy Nose by Post-Treatment Evaluation Time Point

"The individual symptom score for Itchy Nose was rated on a 5-point~scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Itchy Nose symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity." (NCT01469234)
Timeframe: From time of sensitization (time 0) to end of visit (~8 hours)

,,
Interventionunits on a scale (Mean)
0 minutes15 minutes30 minutes45 minutes60 minutes75 minutes90 minutes105 minutes120 minutes135 minutes150 minutes165 minutes180 minutes195 minutes210 minutes225 minutes240 minutes255 minutes270 minutes285 minutes300 minutes315 minutes330 minutes345 minutes360 minutes
Fexofenadine3.33.22.82.62.42.32.12.11.81.81.81.71.81.71.71.71.71.71.71.81.81.81.71.71.8
Loratadine3.33.12.82.72.62.42.32.21.92.02.12.02.01.92.01.91.91.81.91.91.81.81.81.91.8
Placebo3.43.12.82.82.62.52.42.42.12.22.22.22.22.22.22.22.22.22.12.22.12.22.12.22.2

[back to top]

Mean Individual Symptom Score for Runny Nose by Post-Treatment Evaluation Time Point

"The individual symptom score for Runny Nose was rated on a 5-point~scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Runny Nose symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity." (NCT01469234)
Timeframe: From time of sensitization (time 0) to end of visit (~8 hours)

,,
Interventionunits on a scale (Mean)
0 minutes15 minutes30 minutes45 minutes60 minutes75 minutes90 minutes105 minutes120 minutes135 minutes150 minutes165 minutes180 minutes195 minutes210 minutes225 minutes240 minutes255 minutes270 minutes285 minutes300 minutes315 minutes330 minutes345 minutes360 minutes
Fexofenadine3.23.02.92.62.32.22.12.12.02.02.01.81.91.91.81.81.81.71.81.91.81.81.81.81.9
Loratadine3.43.13.02.82.72.62.42.42.12.22.32.22.12.12.02.12.02.01.92.12.02.12.22.12.1
Placebo3.33.02.92.82.72.62.42.52.32.42.42.32.32.42.32.32.22.32.32.32.32.42.32.42.3

[back to top]

Mean Individual Symptom Scores for Itchy Eyes by Post-Treatment Evaluation Time Point

"The individual symptom score for Itchy Eyes was rated on a 5-point~scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Itchy Eyes symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity." (NCT01469234)
Timeframe: From time of sensitization (time 0) to end of visit (~8 hours)

,,
Interventionunits on a scale (Mean)
0 minutes (n=85, n=85, n=85)15 minutes (n=85, n=85, n=84)30 minutes (n=85, n=85, n=85)45 minutes (n=85, n=85, n=85)60 minutes (n=85, n=85, n=85)75 minutes (n=85, n=85, n=85)90 minutes (n=85, n=85, n=85)105 minutes (n=85, n=85, n=85)120 minutes (n=85, n=85, n=85)135 minutes (n=85, n=85, n=85)150 minutes (n=85, n=85, n=85)165 minutes (n=85, n=85, n=85)180 minutes (n=85, n=85, n=85)195 minutes (n=85, n=85, n=85)210 minutes (n=85, n=85, n=85)225 minutes (n=85, n=85, n=85)240 minutes (n=84, n=85, n=85)255 minutes (n=85, n=85, n=85)270 minutes (n=85, n=85, n=85)285 minutes (n=85, n=85, n=85)300 minutes (n=85, n=85, n=85)315 minutes (n=85, n=85, n=85)330 minutes (n=85, n=85, n=85)345 minutes (n=85, n=85, n=85)360 minutes (n=85, n=85, n=85)
Fexofenadine3.23.02.72.32.12.01.81.81.61.51.41.41.41.41.41.41.41.41.41.41.41.41.41.41.4
Loratadine3.02.62.42.21.91.91.81.81.61.51.51.51.41.51.41.51.61.41.41.31.41.41.51.41.5
Placebo3.12.82.42.42.21.91.91.81.71.71.61.71.71.81.71.71.71.61.61.71.71.71.61.81.7

[back to top]

Mean Individual Symptom Scores for Itchy Mouth/Throat/Ears by Post-Treatment Evaluation Time Point

"The individual symptom score for Itchy Mouth/Throat/Ears was rated on a 5-point~scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Itchy Mouth/Throat/Ears symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity." (NCT01469234)
Timeframe: From time of sensitization (time 0) to end of visit (~8 hours)

,,
Interventionunits on a scale (Mean)
0 minutes (n=85, n=85, n=85)15 minutes (n=85, n=85, n=85)30 minutes (n=85, n=85, n=85)45 minutes (n=85, n=85, n=85)60 minutes (n=85, n=85, n=85)75 minutes (n=85, n=85, n=85)90 minutes (n=85, n=85, n=85)105 minutes (n=85, n=85, n=85)120 minutes (n=85, n=85, n=85)135 minutes (n=85, n=85, n=85)150 minutes (n=85, n=85, n=85)165 minutes (n=85, n=85, n=85)180 minutes (n=85, n=85, n=85)195 minutes (n=85, n=85, n=85)210 minutes (n=85, n=85, n=85)225 minutes (n=85, n=85, n=85)240 minutes (n=85, n=85, n=85)255 minutes (n=85, n=85, n=84)270 minutes (n=85, n=85, n=85)285 minutes (n=85, n=85, n=85)300 minutes (n=85, n=85, n=85)315 minutes (n=85, n=85, n=85)330 minutes (n=85, n=85, n=85)345 minutes (n=85, n=85, n=85)360 minutes (n=85, n=85, n=85)
Fexofenadine3.03.02.82.82.62.62.32.42.02.31.82.21.72.11.72.01.52.01.62.01.42.01.42.01.3
Loratadine3.03.22.63.02.32.82.02.71.92.61.82.51.72.41.62.31.52.31.52.41.52.41.42.31.4
Placebo2.93.02.62.82.42.82.32.62.12.51.92.41.82.41.92.31.72.41.72.41.82.41.72.51.7

[back to top]

Mean Individual Symptom Scores for Nasal Congestion by Post-Treatment Evaluation Time Point

"The individual symptom score for Nasal Congestion was rated on a 5-point~scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Nasal Congestion symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity." (NCT01469234)
Timeframe: From time of sensitization (time 0) to end of visit (~8 hours)

,,
Interventionunits on a scale (Mean)
0 minutes (n=85, n=85, n=85)15 minutes (n=85, n=85, n=85)30 minutes (n=85, n=85, n=85)45 minutes (n=85, n=85, n=85)60 minutes (n=85, n=85, n=85)75 minutes (n=85, n=85, n=85)90 minutes (n=85, n=85, n=85)105 minutes (n=85, n=85, n=85)120 minutes (n=85, n=85, n=85)135 minutes (n=85, n=85, n=85)150 minutes (n=85, n=85, n=85)165 minutes (n=85, n=85, n=85)180 minutes (n=85, n=85, n=85)195 minutes (n=85, n=85, n=85)210 minutes (n=85, n=85, n=85)225 minutes (n=85, n=85, n=85)240 minutes (n=85, n=85, n=85)255 minutes (n=85, n=85, n=84)270 minutes (n=85, n=85, n=84)285 minutes (n=85, n=85, n=85)300 minutes (n=85, n=85, n=85)315 minutes (n=85, n=85, n=85)330 minutes (n=85, n=85, n=85)345 minutes (n=85, n=85, n=85)360 minutes (n=85, n=85, n=85)
Fexofenadine3.22.21.52.11.42.11.32.11.42.11.32.01.32.01.32.01.42.01.32.11.32.11.32.01.4
Loratadine3.42.51.62.51.62.41.62.41.52.41.52.41.42.51.52.41.52.41.62.41.52.41.52.41.5
Placebo3.42.72.02.61.82.61.82.61.82.61.82.51.82.61.82.61.82.61.82.61.82.51.82.51.9

[back to top]

Mean Individual Symptom Scores for Sneezing by Post-Treatment Evaluation Time Point

"The individual symptom score for Sneezing was rated on a 5-point~scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Sneezing symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity." (NCT01469234)
Timeframe: From time of sensitization (time 0) to end of visit (~8 hours)

,,
Interventionunits on a scale (Mean)
0 minutes (n=85, n=85, n=85)15 minutes (n=85, n=85, n=85)30 minutes (n=85, n=85, n=85)45 minutes (n=85, n=85, n=85)60 minutes (n=85, n=85, n=85)75 minutes (n=85, n=85, n=85)90 minutes (n=85, n=85, n=85)105 minutes (n=85, n=85, n=85)120 minutes (n=85, n=85, n=85)135 minutes (n=85, n=85, n=85)150 minutes (n=85, n=85, n=85)165 minutes (n=85, n=85, n=85)180 minutes (n=85, n=85, n=85)195 minutes (n=85, n=85, n=85)210 minutes (n=85, n=85, n=85)225 minutes (n=85, n=85, n=85)240 minutes (n=85, n=85, n=85)255 minutes (n=85, n=85, n=85)270 minutes (n=85, n=85, n=85)285 minutes (n=85, n=85, n=85)300 minutes (n=84, n=85, n=85)315 minutes (n=84, n=85, n=85)330 minutes (n=85, n=85, n=85)345 minutes (n=84, n=85, n=85)360 minutes (n=85, n=85, n=85)
Fexofenadine1.21.21.10.90.70.80.60.60.50.70.60.50.60.60.50.60.50.40.50.60.50.40.60.60.6
Loratadine1.31.21.21.01.11.00.70.80.50.80.90.80.70.80.70.70.70.60.60.80.70.70.70.70.6
Placebo1.51.31.21.31.21.11.01.10.91.21.10.90.91.01.00.90.91.01.01.10.91.11.01.01.0

[back to top]

Mean Individual Symptom Scores for Watery Eyes by Post-Treatment Evaluation Time Point

"The individual symptom score for Water Eyes was rated on a 5-point~scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Watery Eyes symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity." (NCT01469234)
Timeframe: From time of sensitization (time 0) to end of visit (~8 hours)

,,
Interventionunits on a scale (Mean)
0 minutes15 minutes30 minutes45 minutes60 minutes75 minutes90 minutes105 minutes120 minutes135 minutes150 minutes165 minutes180 minutes195 minutes210 minutes225 minutes240 minutes255 minutes270 minutes285 minutes300 minutes315 minutes330 minutes345 minutes360 minutes
Fexofenadine2.82.62.32.01.91.81.61.61.31.31.21.21.11.21.11.11.11.11.11.21.11.21.21.21.3
Loratadine2.72.42.21.91.81.71.51.51.31.21.21.21.21.21.21.21.21.21.21.21.21.21.31.21.2
Placebo2.72.42.12.01.91.61.51.51.41.41.41.41.31.51.41.41.41.41.41.41.31.41.41.41.4

[back to top]

Mean Major Symptom Complex (MSC) Score by Post-Treatment Evaluation Time Point (From 180 Minutes to 300 Minutes)

The MSC Score is calculated as the sum of 5 individual symptom scores for Runny Nose, Itchy Nose, Sneezing, Watery Eyes, and Itchy Eyes. Each individual symptom is rated on a 5-point scale of severity: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The total MSC score ranges from 0 - 25. Increasing scores are associated with increasing severity. (NCT01469234)
Timeframe: From time of sensitization (time 0) to end of visit (~8 hours)

,,
Interventionunits on a scale (Mean)
180 minutes (n=85, n=85, n=85)195 minutes (n=85, n=85, n=85)210 minutes (n=85, n=85, n=85)225 minutes (n=85, n=85, n=85)240 minutes (n=84, n=85, n=85)255 minutes (n=85, n=85, n=85)270 minutes (n=85, n=85, n=85)285 minutes (n=85, n=85, n=85)300 minutes (n=84, n=85, n=85)
Fexofenadine6.76.76.56.56.56.36.46.96.5
Loratadine7.47.57.37.47.47.17.07.37.1
Placebo8.58.98.78.58.38.48.48.78.4

[back to top]